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ABSTRACT 
The aim of this work was to gain information about 
the nature of the active site of human brain dihydro-
pteridine reductase. This included the determination of i) 
the amino acid composition, ii) the stoichiometry of the 
nucleotide cofactor and the enzyme, iii) the predominant 
tautomeric structure of the active substrate, iv) the 
effect of platinum(II) complexes on enzyme activity, and 
v) the nature of thiol groups of the protein. 
Amino acid analysis revealed that the amino acid 
composition of human brain DHPR was the same as the human 
liver enzyme within experimental error. The protein 
concentration which was obtained from the amino acid 
analysis gave the same value as the one from the Bio-Rad 
microassay, whereas the Lowry method gave almost twice the 
value of the above two methods for human brain DHPR. So in 
this thesis the protein concentration was measured by the 
Bio-Rad microassay. By using this method, the extinction 
coefficient of this protein was found to be 92,800 M-•.crn.-' 
at 200nm. The stoichiometry of NADH to enzyme (from 
various mammalian sources) has been reported during t..h.e las:t few 
years by many laboratories. This work revealed that the 
ratio of NADH to the enzyme from human brain was 1 : 1. 
The predominant enzyme active tautomer of the 
substrate was shown to have the ortho quinonoid structure 
[1] in this work, because the 2-unsubstituted pteridin-
4( 3H)-one derivatives, 2-methyl, 2-methylthio and 2-methyl-
viii 
0 
[ 1] 
amino derivatives were good substrates of human brain DHPR, 
while tetrahydrolumazine or 2-thiolumazine derivatives were 
not. This also indicates that DHPR can tolerate various 
subs tit uents in the pterid ine ring, and that the 2-amino 
group of the natural substrate, quinonoid dihydrobiopterin 
[2], is not totally essential for substrate activity. It 
H 
0 H 
0 
N 
N 5 6 CH3 
H 2N)l N 
8 7 
N 
H 
[2] 
may, however, have an important role 1n binding to the 
active site of the enzyme. Although attempts were made, it 
was not possible to obtain information about the charges at 
the amino acid residues which were essential for enzyme 
catalysis because of the instability of the quinonoid 
species and NADH cofactor at non-neutral pH. 
A brief study of the inhibition of DHPR by 
platin~m complexes was made, but none of the compounds, 
e.g. H2 PtC1 6 [Iso 360 µM (4 h incubation)], trans-platin 
[Is o 1 rnM ( 15 min)], were particularly strong inhibitors. 
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Potassium tetrachloroplatinate, on the other hand, was 
shown to be an irreversible inhibitor. This inactivation 
was studied in some detail. The enzyme was protected by 
NADH and by the quinonoid dihydro(6H)pterin cofactor from 
this inactivation. 
The nature of the thiol groups of this enzyme were 
revealed by . using thiol specific reagents and potassium 
' tetrachloroplatinate. Each DHPR subunit ( the enzyme has 
two identical subunits) has 3 or 4 cysteine residues. One 
of them 1s located at the outer surf ace of the subunit 
and two of them seem to be located at or near the active 
site of the enzyme. If the subunit has a further (i.e. 
the fourth) cysteine residue, it should be located deep 
inside the protein structure or is unreactive, because the 
reactions with thiol specific reagents revealed only three 
cysteine residues even with denatured proteins. Amino acid 
analysis showed that four residues may possibly be 
present. 
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GENERAL INTRODUCTION 
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1-1 History of the discovery of Dihydropteridine reductase 
The conversion of phenylalanine into tyrosine was 
especially interesting because this oxidation was at least 
partially blocked 1n the disease, oligophrenia 
1 
phenylpyruvica, and had been demonstrated in cell free 
2 
extracts in 1913. In 1952, Udenfriend and Cooper reported 
that rat liver extracts had the ability to catalyze this 
+ reaction and that NAD and an alcohol or aldehyde were 
3 
required for enzyme activity. Kaufman found that this 
system required two enzymes (i.e. a rat liver and a sheep 
liver enzyme) and that NADPH and oxygen were also 
4 
necessary. He found later that the rat liver enzyme was 
phenylalanine hydroxylase which catalyzed the oxidation of 
phenylalanine to tyrosine and the sheep liver enzyme 
catalyzed the reaction involving NADPH which served to 
maintain the cofactor in the active, reduced form (Scheme 
5 b 
1 ) . ' 
Tetrahydrooteridine 
Phe 
+ 
02 
NADPH+H+ 
'Oxidized pteridine' 
Tyr 
+ 
H20 
--- Oihydropteridine 
E 1: sheep liver extracts 
E2 : rat l iver extracts 
Scheme 1 
- 3 -
At that stage, the structure of the pteridine 
cofactor for the rat liver enzyme was not yet known, but in 
1963 Kaufman found that the cofactor was L-erythro-5,6,7,8-
7 
tetrahydrobiopterin [ 1] . 
0 
In his preparations, the rat 
(1] 
H 
N 
5 6 
8 7 
N 
H 
H 
0 
1 i ver enzyme was freshly extracted but the sheep 1 i ver 
enzyme was kept at -20 ° C after death and thawed before 
extraction. Phenylalanine hydroxy lase activity decreased 
rapidly after death but loss of activity on storage was 
slower at -20°c. In 1972, Craine et al. found that the 
NADPH dependency for the reductase was due to dihydrofolate 
8 
reductase which contaminated the liver enzyme preparation. 
Later the sheep liver reductase, now called dihydro-
pteridine reductase (DHPR) was found to be more active with 
NADH than NADPH (15 - 45 times) as nucleotide cofactor (EC 
+ 1.6.99.7, NADH + 6,7-dihydropteridine = NAD + 5,6,7,8-
8 9 1 0 
tetrahydropteridine). ' ' The kinetic parameters of DHPR 
with NADH and NADPH are listed in Table 1. However, other 
dihydropteridine reductases have been isolated from several 
sources, and they exhibited higher enzyme activity 
with NADPH than with NADH as cofactor. The same Enzyme 
Commission number, E. C. 
enzymes. 
(1.6.99.7.) was given for these 
- 4 -
Table 1. 
NADPH. 
Kinetic parameters of DHPR with NADH and 
Enzyme 
app.ISnl 
h.b. 4.7 
h .1. 8.0 
h. 1. 29 
h.p. 12 
s.b. 20 
s. 1. 30 
b .1. 9. 1 
r. 1 . 2. 2 
1 µM; 2 
protein; 
NADH NADPH 
app · vmax 2 s app.ISnl app · vmax 2 s 
336 90 --
1. 8 12 110 0.59 12 
468 75 770 316 75 
0.09 10 --
-- --
92 75 300 2. 3 75 
167 ? -- --
2.45 12 100 0.88 12 
µmol NAD(P)H oxidized/min per mg of 
S concentration of quinonoid pteridine used, µM. 
ref. 
15 
8 
10 
16 
17 
17 
18 
8 
h.b. human brain; h.l. human liver; h.p. human 
platelets; s.b. sheep brain; s.l. sheep liver; 
b.l. bovine liver; r.l. rat liver. 
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DHPR usefully recycles the pteridine cofactor for 
aromatic amino acid hydroxylases, 1 .e. phenylalanine 
1 9 
hydroxylase (phenylalanine to tyrosine), tyrosine 
2 0 
hydroxylase (tyrosine to dopa), and tryptophan 
2 1 
hydroxylase (tryptophan to 5-hydroxytryptophan). 
1-2 Occurrence and distribution 
Dihydropteridine reductase is widely distributed 
in mammalian tissues in which it plays an important role in 
metabolism (Table 2, cf. reference 22). The aromatic amino 
acid hydroxy lases with which DHPR . lS associated are of 
importance especially for the synthesis of neurotransmitters , 
and lack of these enzymes or of the pteridine cofactor can 
cause serious neurological problems. The relationship 
between the aromatic amino acid hydroxylases, their 
cofactor, substrates and some metabolites are shown in 
2 3 
Scheme 2. Phenylalanine is an essential amino acid for 
protein synthesis in mammalian tissues. Physiologically, 
its most significant degradation pathway involves its 
hydroxylation to tyrosine. 
restricted mainly to the liver, 
This hydroxylation 
kidney and pancreas 
. 
lS 
. 1n 
mammals. Tyrosine, the product of hydroxylation is also an 
essential amino acid for protein synthesis, and 1n the 
central nervous system it is the precursor of the neuro-
transmitters, dopamine, norepinephrine and epinephrine. 
Tryptophan . lS also one of the essential amino acid for 
mammals and is the precursor of another neurotransmitter, 
' 
'.' 
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Table 2. Sources from which DHPR has been isolated (cf. 
reference 22). 
Human 
Monkey 
Bovine 
Sheep 
Rabbit 
Cat 
Rat 
Mouse 
Hamster 
Fish 
Protozoan 
Bacteria 
brain, liver, lung, breast (normal and neo-
plastic cells), fetal tissues, placenta, 
amniotic cells, peripheral blood, platelets, 
lymphocytes, continuous lymphoid cells, skin 
fibroblasts 
brain, liver 
brain, pineal gland, liver, kidney, adrenal 
medulla 
brain, liver, adrenal medulla 
liver 
liver 
brain, liver, heart, lung, kidney, adrenal 
medulla, spleen, muscle, uremic tissues, 
erythrocytes, pheochromocytoma 
RAG cells, C-6 Glioblastoma, C-1300 Neuro-
blastoma 
Chinese WOR cells, Syrian TG2 cells 
Cheirodon axelrodi, Salmo irideus 
Tetrahymena, Crithidia fasciculata 
Pseudomonas species (ATCC 11299a) 
Phenylacetyl-
glut amine 
7 
NAD(P)H 
V Qu inonoid 7 , 8-Dihydro- 5, 6, 7 , 8-Tetrahydro-biopterin b iopterin (THB) 
( 
>< NADPH+H• 
Phenylpyruvic acid Phe 
/ 
co-Tyrosine 
~ 
co-Hydroxyphenylacetic acid 
!'-Hydroxyphenylpyruvate 
H,0.l 
Homogentisic acid 
I 
I 
+ 
Acetyl CoA 
l 
oc-Ketoadipate 
1 
Glutamate 
dihydrobiopter in (Q 
01 H,O ~ Ty,)>t<(opo 
THB Q DHB 
~ 
~ 
o<-Ketoglutamate 
DHB) 
O, 
Dopaauinone 
• Pheomelanin • Eume lan in 
Dopamine 
I 
I 
I 
/ 
" 3 , 4-Dihydroxy-
mandelic acid 
~,O 
Norep inephrine 
l 
Ep inephrine 
Pyruvate•-· ··· - ).la- -·· - - Trp ----J> lndolepyruv i c acid ~ lndoleacetic acid 
C THB Q!ie.E Q DHB Cll-i=R 
5-Hydrox ytryptophan 2 Phenylalanine Hydroxylase 
~ cei 3 Tyroslnase 
Serotonin 4 Tyrosine Hydroxylase 
l 5 Tyrosine Transaminase 
5-Hydroxyindoleacetic acid 6 Tryptophan Hydroxylase 
l - normal pathway 
5-Hydroxyindolealdehyde -+ abnormal pathway 
Scheme 2 
It, 
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serotonin. 
8 
Craine et al. reported that DHPR was 1n 
relatively high concentrations compared with the aromatic 
amino acid hydroxylases in tissues and may suggest that the 
formation of the cofactor for these hydroxylases is not the 
rate limiting step for the synthesis of neurotransmitters , . 
There are other possible functions for DHPR. It 
may also recycle the pteridine cofactor for other 
hydroxylases, e.g. 
2 4 2 5 
glycerol etherases, ' steroid 
2 6 
hydroxy lases, yet unkown tetrahydropterins requiring 
27 
hydroxylases and in prostaglandin synthesis, 
28 
involved in electron transport. 
and may be 
The distribution of DHPR in rat tissues was found 
to be in the order, kidney > liver >> brain > adrenal 
8 
medulla> heart> muscle= spleen> lung. The regional 
distribution in the rat brain was also studied, e.g. brain 
2 9....., 3 l 
stem> cerebellum> cortex. Several workers found 
that fetal tissues had lesser DHPR levels than adult 
3 2....., 3 4 
tissues and these DHPR levels increased in gestation, 
but each tissue showed a different degree of increase. In 
some human tumours, the levels of DHPR were lower than in 
32 34 
normal tissues, e.g. human pulmonary tumours. ' Similar 
results were found in transplantable rat ascites 
3 5 
hepatoma. On the other hand, in the case of breast 
3 6 3 7 
cancer, and neoplastic clonic tissue, the DHPR levels 
were higher than in normal cells. Cultures from C-6 mouse 
glioblastoma also possessed high DHPR activity compared 
with those from C-1300 mouse neuroblastoma which had 
- 9 -
3 l 
negligible activity. DHPR levels 1n human peripheral 
leucocytes, erythrocytes, lymphocytes and granulocytes are 
good indicators for diagnosis purposes, i.e. a rapid method 
38,....41 
.for checking malignancy. The enzyme was also isolated 
l 7 4 2 
from human platelets ' and the activity was found to 
42 
decrease with aging. Human continuous lymphoid and 
amniotic cells also contain DHPR and they have been used 
for the purpose of early diagnosis of variant forms of 
41 43 44 
hyperphenylalaninemia ' ' (cf. Section 1-3, p 10). 
Other sources of DHPR are shown in Table 2. Some 
mutants of Tetra hymen a are DH PR or p hen y 1 a 1 an in e 
hydroxylase deficient and can be used as models for 
45 
conditions similar to Phenylketonuria in humans. DHPR 
was also isolated from Crithidia fasciculata which had some 
46 
form of biopterin reduction system in the cell. 
Among these sources of DHPR (Table 2), quinonoid 
L-erythro-7,8-dihydro(6H)biopterin [ 2] 
0 
[2] 
N 
5 6 
8 7 
N 
H 
H H 
0 H O H 
H '~ 
was the natural 
substrate and was found to be a superior substrate than 
other quinonoid pteridines which are derived from synthetic 
pteridines ( e • g • 6,7-dimethyl-7,8-dihydro(6H)pterin 
- 10 -
8 10 47 ...... 49 [ 3 ] ) • ' ' This was not the case in Pseudomonas 
species (ATCC 11299a), which was found to have no biopterin 
or its reduced forms in the cells. Quinonoid L-threo-7,8-
d i h y-<l r o ( 6 H ) n e op t e r i n [ 4 ] w a s f o u n d t o b e a s u p e r 1 o r 
0 H 0 I ' 
N N 
N CH3 N CH~OH 
H 2N~ N 
CH3 
H2N)l N N H H H 
[3] [4] 
cofactor for the enzyme and L-threo-neopterin was present 
5 0 
in the cells of this bacterium. The Pseudomonas DHPR 
required NADH as the nucleotide cofactor and was inactive 
5 1 
when the cofactor was replaced by NADPH. 
DHPR was also detected . 1n 
52 
Cheirodon axelrodi and Salmo irideus. 
the fish . species 
The reductase has always been isolated from the 
soluble fractions of tissues, i.e. DHPR 1s a soluble 
cytoplasmic enzyme. 
1-3 Clinical aspects 
1-3-1 Phenylketonuria and Hyperphenylalaninemia 
Phenylketonuria (PKU) and Hyperphe nylalaninemia 
belong to a group of inborn errors of metabolism of 
phenylalanine which shows impaired phenylalanine oxidation, 
5 3 
and results in elevated tissue and serum phenylalanine. 
- 11 -
The classification of Hyperphenylalaninemia and related 
defects is summarized in Table 3 (cf. reference 53). PKU 
54 
affects 1 in ca 22,000 births, but can be as high as 1 in 
5 5 
10,000 in certain populations. PKU is an autosomal 
5 6 
recessive inherited disease. Because of the serious 
neurological consequences of this disease, it 1s ess.ential 
that it is diagnosed as early as possible. Most developed 
I 
countries screen new born babies for this defect 
immediately after birth. 
The biochemical aspects of PKU are now well 
characterized. In the more common classical form (type I 
and II in Table 3) the patients have low or no 
phenylalanine hydroxylase in their tissues. They are 
unable to convert phenylalanine to tyrosine and other 
metabolic pathways became activated (cf. Scheme 2). The 
neurological problems are usually corrected by using low 
phenylalanine diets. 
1-3-2 Hyperphenylalaninemia due to DHPR deficiency 
DHPR deficiency (type IV in Table 3) was confirmed 
57 
by Kaufman et al. in 1975. The patients had no DHPR in 
the liver, brain and skin fibroblasts. The phenylalanine 
hydroxylase activity was 20% of the average normal adult 
value and the urine and blood contained almost no reduced 
biopterin with very high xanthopterin and dihydrobiopterin, 
5 8 
as well as traces of biopterin and neopterin. This 
deficiency causes a decrease in the amounts of neurotrans-
- 12 -
Table 3. Classification of Hyperphenylalaninemia. 
Type Condition 
I Phenylketonuria 
II Persistent hyper-
phenylalaninemia 
III 
IV 
V 
Transient mild 
hyperphenyl-
alaninemia 
DHPR deficiency 
Abnormal 
dihydrobiopterin 
function 
Defect 
Phenylalanine 
hydroxy lase 
absent 
Decreased 
Phenylalanine 
hydroxy lase 
Maturational 
delay of 
Phenylalanine 
hydroxy lase 
DHPR deficient 
or absent 
Dihydrobiopterin 
synthesis defect 
Clinical aspects 
Mental 
retardation 
and associated 
symptoms if 
untreated 
Normal; may show 
retardation if 
untreated in 
more severe 
cases 
Normal 
Initially 
normal; 
seizures, 
abnormal 
development 
evident within 
first year of 
life; death 
before age of 
10 years 
Myoclonus, 
uncontrolled 
movements, 
tetraplegia, 
greasy skin, 
recurrent 
hyperthermia 
- 13 -
mitter precursors 1n the brain because the biopter1n 
cofactor for the hydroxylases cannot be recycled. Also the 
levels of the metabolites of dopamine and serotonin, 1.e. 
homovanillic acid and 5-hydroxyindoleacetic acid are 
decreased in the brain and the cerebrospinal fluid. 
This deficiency can be detected by assaying for 
5 7 5 9 
DHPR activity 
4 4 6 0 
cultures ' 
in liver biopsies, ' skin fibroblast 
38 39 44 
and/or blood cells, ' ' 
antigen-antibody reactions (e.g. reference 41). 
or by using 
The clinical treatment involves administration of 
L-dopa, 5-hydroxytryptophan and carbidopa, and sustaining a 
low phenylalanine diet. Tetrahydrobiopterin has also been 
used as a drug in these cases. Moreover, the analogue of 
tetrahydrobiopterin, 6-methyl-5,6,7,8-tetrahydropterin [5] 
has been used . on occasions, but apparently unlike 
6 1 
natural cofactor, it is hepato toxic. 
0 
[5] 
the 
- 14 -
1-3-3 Genetic aspects 
PKU . lS rare among Negroes and Orientals but . is 
common in Caucasians. It is more prevalent among Celtic 
62 
people and Central Europeans. 
4 l 
Firgaira et al. found more than one DHPR protein 
in the same patients and suggested that one DHPR protein 
species was derived from the other, implying that the same 
structural gene(s) encodes for DHPR in human liver, 
lymphocytes, and fibroblasts. They also demonstrated the 
. possibility of DHPR gene mutations by comparing the 
immunoreactivity of cultured cell extracts from DHPR 
deficient children and their parents. It should be noted 
6 3 
that recently Webber et al. have shown three NADH-
dependent DHPR . species from rat liver by isoelectric 
focusing and demonstrated that the protein species differed 
probably by minor structure changes, e.g. glutamic acid to 
g 1 u tamine, which occurred in the ce 11, because their N-
termi nal and amino acid analyses showed no significant 
differences. 
1-4 Purification and assay of DHPR activity 
1-4-1 Purification 
DHPR has been purified by . using classical 
techniques ( e . g . pro t e i n pre c i p i tat ion , adsorption and i on -
exchange chromatography); and affinity chromatography. In 
most procedures, the enzyme was precipitated from the crude 
- 15 -
extract by ammonium sulphate at 40 - 70% salt saturation. 
8 
When Craine et al. purified DHPR from sheep liver, they 
used several steps to obtain pure enzyme, i.e. ammonium 
sulphate precipitation, zinc ethanol fractionation, 
alkaline ammonium sulphate precipitation, elution from 
calcium phosphate gel, DEAE-cellulose chromatography, and 
Sephadex G-100 gel filtration (9% yield and 160-fold 
purification). In most cases now affinity column 
chromatography followed by ion-exchange chromatography is 
used routinely directly after ammonium sulphate 
fractionation. 
1 0 
Human liver DHPR was purified by Firgaira et al. 
by using a naphthoquinone-AH-Sepharose affinity column (26% 
yield, 1000-fold purification). 4 2 Shen et al. purified 
human platelet DHPR using a Matrex Gel Blue column as an 
affinity adsorbant (46% yield, 1500-fold purification). As 
above, affinity column chromatography shortened the 
purification procedure because of the greater specificity 
of the column material, although in all the cases at least 
three steps were still required. 
specificity . i S far from complete. 
This is because the 
6 4 
Nakanishi et al. 
reported the purification of human liver DHPR using only a 
two step procedure, 1.e. passage of the extract through a 
Matrex Gel Blue column followed by a phenyl Sepharose 
column (30% yield and 700-fold purification). 
Several different affinity columns were used by 
different laboratories (cf. reference 22). Some columns 
function by binding to the nucleotide binding site of the 
- 16 -
enzyme, e.g. Matrex Gel Blue, 5'-AMP Sepharose, and others 
to the pteridine binding site, e.g. naphthoquinone, phenyl 
Sepharose, of the enzyme. The human brain enzyme does not 
bind to the naphthoquinone column unless the solutions 
contain NADH and the column is in the oxidized form. The 
enzyme 1s released from this column by buffer free from 
NADH and containing a reducing agent, dithiothreitol 
( DTT) . 
1-4-2 Substrate specificity 
6 5 
Kaufman reported that the second natural 
cofactor in addition to NADPH for sheep liver DHPR ( see 
Scheme 1, p 1) was a pteridine derivative. It first had to 
be reduced by this enzyme with a pyridine nucleotide 
cofactor before it was an effective cofactor for the 
hydroxy lases (e.g. phenylalanine hydroxylase). In a 
detailed study he showed that a synthetic pterin, 6, 7-
dimethyl-5,6,7,8-tetrahydropterin [ 6] could replace the 
boiled liver extract as cofactor and using synthetic models 
he showed that the pterin cofactor was a double bond 
tautomer of 7,8-dihydropterin, probably the 5,6-dihydro 
6 6 
isomer (7). The natural cofactor for DHPR was isolated 
H 
0 0 0 H 
H H H 
N CH3 
N 
HN HN 5 
H2NA CH3 H2NA 8 N N N N 
H H 
[ 6] [7] 
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by Kaufman in an oxidized form and shown to be L-erythro-
7,8-dihydro(3H)-biopterin [8]. This was a substrate for 
dihydrofolate reductase which reduced it to the tetrahydro 
67 
derivative_ using NADPH as a cofactor. Further identity 
of the cofactor was obtained by oxidation to biopterin and 
characterized by the Crithidia bioassay which was very 
sensitive for the L-erythro isomer of biopterin. He 
suggested, however, 
0 
[ 8] 
N 
N 
H 
later that there were several 
H 
0 0 
[9] 
t au tome r i c po s s i b i 1 i t i es , e . g • [ 9 ] , [ 1 0 ] , [ 11 ] , a n d [ 1 2 ] , 
in addition to structure [7] for the active pterin 
cofactor. 
[10] [11] [ 12] 
Several investigations excluded structures [7] and 
[9], and of the three possible tautomers, [10], [11], and 
[12], tautomer [10] was supported by UV spectral studies of 
quinonoid 6,7-dimethyl-7,8-dihydro(6H)pterin which showed 
that there was a bathochromic shift of 15 - 20 nm 1 n 
- 18 -
the 2-alkylamino derivatives whereas no such shift was 
6 8 
observed in 8-alkylated derivatives. But in this study 
3-alkylated derivatives were not examined, so that 
structure [11] was not strictly excluded. Viscontini and 
6 9 
Bobst suggested that structure [10] was a possible 
tautomer by comparing the oxidation of several N-methyl-
tetrahydro derivatives. Also Bobst supported structure 
7 0 [10] by molecular orbital calculation. Gready later 
proposed the ortho-quinonoid structure [12] as a possible 
active substrate by comparing the energies of each tautomer 
} l. 
using theoretical methods. The exact tautomeric 
structure of the pyrimidine ring has been questioned and 
72 
kinetic evidence was presented by Armarego and Waring 
which showed that tautomer [11] was the reactive tautomer. 
They compared the rates of aerobic oxidation of 2-
dimethylamino- [13], 8-methyl- [14], and 3-methyl-5,6,7,8-
tetrahydropterin [15] derivatives and found that the rates 
HN\~) 
0 0 
~H ~H HN N H3C, N HC-N~ N N HN.,b:N NJ H N1N NJ 3 
I H 2 I 2 H 
CH3 CH3 
(13] (14] (15] 
of oxidation of compounds [ 13] and [ 14] were faster than 
compound [ 15] . This was explained by stabilization of the 
i n i t i a 1 rad i ca 1 cat ion i n termed i ate [ 1 6 ] 1 ea d i n g to the 
cation [17]. Such stabilization does not occur in the 3-
unsubstituted pterins, (13] and (14], because the radical 
. 
j 
I 
' 
I' 
ii 
:, 
" 
I 
' 
i 
Ii 
11 
! 
I 
I 
I 
Ii 
11 
11 
Ii 
Ii 
I 
r 
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cation would be deprotonated at the neutral pH of the 
oxidation buffer + by loss of H from N-3. In the 3-methyl 
0 0 0 
H3C,N~~J H~,N~~J H~, 0N) 
... 
• H NrN N H2NAN N H2N.Jl N N H 2 H H 
(15] [16] [17] 
compound [15], a positive charge will be generated at N-3 
to give the quinonoid pterin [17] which should rearrange to 
the corresponding 7,8-dihydro(3H)pterin [18] much faster 
than the corresponding quinonoid pterins derived from 
0 
H3C, N:rH N 
H2N.A -N N 
H 
[18] 
[ 13] and [ 14] • This has been observed . 1n 
7 3 
compounds 
practice. 1 H NMR studies of the oxidation of 6-methyl-
5,6,7,8-tetrahydropterin also excluded the presence of 
structure [12], because the signal from H-6 moved downfield 
by 1. 08 ppm whereas the signals from H-7 axial and 
equatorial were shifted downf ield by only O. 27 and O .18 
ppm, respectively. Moreover, oxidation of 6-rnethyl-2-
methylamino-5,6,7,8-tetrahydropterin [ 19] did not show 
large chemical shift changes of the 2-methylamino protons 
which implied that structure [20] was formed. This result 
could not be extrapolated to the 2-unsubstituted pterins 
- 20 -
0 
H CH3 HN Nf H 
HN~N N 
tH H ' 3 0 
(19] ~ CH3 
HN NfH 
HC-N~ N N 
3 H 
[21] 
because methyla tion of the C-2 amino group might perturb 
the tautomeric equl ibrium to form the exocycl ic tautomer 
74 [21]. Benkovic et al. later used 15N NMR spectroscopy to 
demonstrate clearly that tautomer [11] was the maJor 
species in the buffer solution. The downfield chemical 
shift of the 15N resonance of the 2-amino group when 6,7-
dimethyl-5,6,7,8-tetrahydropterin [ 6 ] was oxidized to 
quinonoid 6,7-dimethyl-7,8-dihydro(6H)pterin [3] 1s too 
0 0 
H H H 
~iCH, Ni NJ 5 6 CH H2N~ ~ 1 CH3 • HN~ 8 1 CH: 8 1 ~ H N ~ H 2 
[ 6] [ 3] 
small (-41 ppm) to be consistent with an sp3 + sp2 change 
(i.e. C-NH 2 + C=NH); compare the chemical shift of N-5 upon 
oxidation which undergoes a 320 ppm downfield shift. 
1-4-3 Assay methods 
The true pteridine subsrates for DHPR are the 
quinonoid species. These are relatively unstable and 
- 21 -
therefore have to be generated 1n the assay. This should 
not be a rate limiting step for the DHPR enzyme reaction. 
Generally they are stable enough for the assay period and 
this does not interfere with the assay. 
In the assay solution, the quinonoid species are 
generated almost spontaneously by oxidants (e.g. potassium 
ferricyanide, hydrogen peroxide or peroxidase 1n the 
presence of hydrogen peroxide). The solution, in general, 
contains an oxidant, tetrahydropteridine, NADH, buffer and 
the reaction is initiated by the additon of DHPR. The rate 
of the reduction of quinonoid pteridine to tetrahydro-
pteridine is observed by the absorbance changes at 340 nm 
due to the concurrent oxidation of NADH to NAD+ using 
double beam spectrometer. 
1-4-4 Physical properties 
The molecular weights of the native NADH-dependent 
DHPRs which consist of two identical subunits range from 
41,000 to 55,000 and vary depending on the enzyme sources 
and the methods of estimation. For example, on PAGE, huma n 
liver DHPR showed very high ~r values (e.g. 100,000 ) 
1 0 
because of its relatively low charge to size ratio. On 
gel chromatography, on the other hand, it showed an Mr 
value of 47,500, and sedimentation-equilibrium analysis 
gave a value of 50,000. 
The molecular weight of the subunit is between 
25,000,..,, 27,000. For example, in the above human 1 i ver 
- 22 -
Table 4. Physical properties of Dihydropteridine Reductase 
Optimum* E:280 
Enzyme Isoelectric Optimum* temperature ref. 
point pH 
( o C) ( M- 1 • cm- 1) 
h.l. 7.0 7.2 37 10 
b.l. 5.7 90.000 75 
83,000 76 
b.a.m. 5.7 75 
b.b. 5.7 77 
s .1. 5.4 78 
6.8-7.0 17,78 
88,500 78 
r.l. 6.4 6.3-6.8 105,000 78 
5. 7, 5.9 63 
and 6. 5 
P. 7.2 51 
-
* for enzyme activity 
h.l. human liver; b.l. beef liver; b.a.m. beef 
adrenal medulla; b.b. beef brain; s.l. sheep liver; 
r.l. rat liver; P. Pseudomonas. 
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1 0 
DHPR, SOS-PAGE revealed a subunit ~r value of 26,000. 
The measured isoelectric points are listed . 1n 
Table 4. 
high (7.0) 
Among these, human liver DHPR has a relatively 
1 0 
isoelectric point compared with others (5.4 -
6.4) (cf. reference 22). The optimum pH and temperature 
for DHPR activity and also the extinction coefficients for 
DHPR are listed in Table 4. 
The amino acid compositions of DHPR from different 
8 
sources are shown in Figure 1. Craine et al. reported 
that the sheep liver enzyme contained one cysteine residue 
per subunit, which was not exposed in the native enzyme. 
1 7 
On the other hand, Cheema et al. reported that the sheep 
1 iver reductase contained one free cysteine and one 
cystine. The N-terminal residue of DHPR . lS blocked by 
<:3-cetylation in all the enzymes that were examined for N-
terminal amino acids. In the beef and sheep liver DHPRs 
acetylisoleucine is probably the N-terminal amino acid 
l } 
residue for both enzymes. The human brain reductase is 
79 
also blocked at the N-terminal. 
1-5 Active site and mechanism of action 
Dihydropteridine reductase forms a stable complex 
with NADH and multiple forms due to bound NADH have been 
reported by several authors (e.g. references 10, 11, and 
7 6) • These include unbound enzyme, NADH-bound enzyme 
sub uni t ( 1 : 1 ) and NA DH - bound enzyme sub uni ts ( 1 : 2 ) . The 
stoichiometry of binding of this enzyme and cofactor was 
- : •. l. (ref.8) 
- : •. 1. (ref. 17) 
: •• b. (ref. 17) 
- : b.l. (ref. 75) 
44 - : b.l. (ref. 76) 
- : b.l. (ref. 81) 
42 - : b ••••. (ref. 75) 
- : b ••••• (ref. 17) 
40 - : r.l. (ref. 80) 
- : h.l. (ref. 10) 
- : h.b. (present work) 38 b.l. RADPH-dependent 
36 
DHPR (ref. 14) 
"t:S • ... 34 (.J 
n:s 32 • 
• 0 30 
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... 28 8 26 ca 
..c 24 
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Amino acids 
Figure 1. Amino acid compositions of DHPR 
from various sources. s.l. sheep liver , s.b. sheep 
brain , r .l. rat liver , b.l bov ine liver , b.a.m. bov ine 
adrenal medulla, h.l. human liver , h.b. human brain . 
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reported as being 1 . . 2 NADA-enzyme subunits complex by 
8 2 
Webber and Whiteley for rat liver DAPR, and as being 
75 
1 : 1 NADA-enzyme subunit complex by Aksnes et al. 
76 
Hasegawa for bovine liver DAPR. 
and by 
The dissociation constants for the nucleotide 
cofactor are listed in Table , 5. These show the variety of 
v a 1 u e s ob ta i n e d de p e n d i rrg on the e n z ym e source s and 
probably also on the experimental conditions. 
8 3 
The enzyme reaction mechanism proposed by Wong 
involves a rapid equilibrium random mechanism, i.e. either 
substrate may be added first, followed by the second 
substrate, to form a ternary complex, and either product 
may be released first. On the other hand, the affinity 
column work suggests an ordered binding of substrates to 
8 l 
the reductase with NADA binding first. By studying the 
l 8 
kinetics of bovine liver DAPR, Aksnes and Ljones 
suggested a sequential ordered mechamism, with NADA binding 
first and NAD+ dissociating last. In more recent detailed 
studies using isotope, pulse-chase, stopped-flow, and rapid 
84 
quench techniques, Poddar and Henkin concluded that in 
the kinetic mechanism of the reduction of quinonoid 6, 7-
dimethyl-7,8-dihydro(6H)pterin [ 3 ] catalyzed by bovine 
1 i ver DAPR, NADH bound first to the enzyme followed by 
quinonoid substrate, i.e. ordered mechanism. This ternary 
complex undergoes isomerization which is the rate 
determining step, followed by hydride transfer, and release 
8 5 
of products. Randles also proposed an ordered bi-bi 
mechanism for human brain DAPR by studying the temperature 
- 26 -
Table 5. Dissociation constants for NADH and for quinonid 
6-methyl-7,8-dihydro(6H)pterin. 
Enzyme NADH Quinonoid 6-MeDHP ref. 
( µM) ( µM) 
r.l. 0.07 2 86 
0.08* 
5.71 82 
0.17* 
b.l. 0.04 75 
(at pH 7. 8) 
0.01 75 
(at pH 6 . 8) 
' 
b.a.m. 0.01 75 
(at pH 6 . 8) 
r.l. rat liver; b.l. b0vine liver; b.a.m. 
bovine adrenal medulla. 
* values which were re-calculated by using a 
computer programme (reference 22). 
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dependency of the enzyme activity. 
4 7 
Armarego et al. suggested that the ethylene 
bridge j o i n i n g N - 5 to N - 8 i n the no rm a 1 p t e r i n subs tr ate 
was not necessary for substrate activity, but this bridge 
did assist in binding at the enzyme active site. 
8 7 8 8 
Armarego ' also investigated the stereochemistry of 
quinonoid . species at the active site by assaying the 
activity of quinonoid 6,6-dimethyl-7,8-dihydro(6H)pterin 
0 
axial 
~8 
~ 
H 
0 
§Sllatorial 
6-S-ENANTIOMER 
and the activities of the two optical isomers of 6-methyl-
5,6,7,8-tetrahydropterin. He concluded that an axial 
substituent at C-6 is not readily accepted by the reductase 
and that steric requirements at the active site around the 
C-7 position of the pterin are not as strict as those 
2 2 
around C-6. The pteridine substrate sits at the active 
site with the 6-alkyl substituent in the quasi equatorial 
8 8 
conformation. 
lH NMR revealed that the reduced pyrazine ring of 
the quinonoid species was in the half chair conformation and 
substituents at C-6 and C-7 could exist in axial or in 
equatorial conformations (cf. reference 73-b). 
- 28 -
From the data available the chemical mechanism of 
the enzyme react ion can be summarized as fallows: NADH 
binds to the enzyme followed by the pteridine cofactor with 
the 6- substituent in the equatorial conformation. Then a 
conformational change of the enzyme ternary complex at the 
active site occurs. This is followed by hydride transfer 
from the B face of NADH with transfer of the pro-S 
8 9 
hydrogen to N-5 of the quinonoid dihydropteridine, and 
then protonation of N-3 by some amino acid residue, which 
has not yet been identified, at the active site. Finally 
+ 84 
the reduced pteridine is released followed by NAD. 
1-6 Inhibitors 
1-6-1 Pteridine analogues 
The inhibition constants of DHPR by pteridine 
analogues are listed in Table 6. The inhibition appears to 
depend not only on the structure of the compound but also 
on the source of the enzyme. The assay conditions may also 
affect the inhibition (cf. Chapter 4, p 192). 
inhibition ( i . e • quinonoid dihydrobiopterin) 
Substrate 
had been 
reported by Firgaira et al., and it occurred at substrate 
.L 0 
concentrations above 50 µM. 
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Table 6. Inhibitions of DHPR by pteridine analogues. 
Inhibitor 
Aminopterin 
Amethopterin 
(Methotrexate) 
p-Aminobenzoylglutamate 
2,4-Diamino-6-methyl-
pteridine 
2,4-Diaminopteroic acid 
2,4-Diamino-7,8-dihydro-
pteroylglutamic acid 
Quinonoid 2,4-diamino-
dihydropteroylglutamic 
acid 
Folic acid 
6,7-Dimethylpterin 
2,4-Diamino-6,7-
dimethylpterin 
2-Amino-6,7-dimethyl-
pteridin-4(3H)-one 
Enzyme Type 
h.l. non-comp.* 
h.l. non-comp.# 
P. comp.* 
s.l. non-comp.* 
r.l. comp.* 
s .1. 
b.k. 
b.k. 
b.k. 
r.l. 
comp.* 
mixed non-
comp.* 
uncomp.# 
comp.# 
r.l. comp.* 
r.l. comp.* 
r.l. comp.* 
s.l. non-comp.* 
s .1. non-comp.* 
s.l. non-comp.* 
s.l. non-comp.* 
Ki (µM) ref. 
10 
11 
210 
20 
24.0 
40 
3 0, 50 
or 180 
40 or 70 
10,000 
or 
4,000 
inert 
29.5 
23.0 
22.0 
240 
300 
80 
50 
90 
90 
51 
17 
91 
8 
92 
92 
92 
91 
91 
91 
91 
17 
17 
17 
17 
s.l. sheep liver; h.l. human liver; R_:_ 
Pseudomonas; b.k. bovine kidney; r.l. rat liver; 
comp. competitive; non-comp. non-competitive; 
* for substrate; # for NADH. 
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1-6-2 Thiol specific reagents 
The inhibition constants of DHPR from various 
sources by thiol specific reagents and heavy metals are 
1 isted in Table 7. The table also shows the different 
degrees of inhibition (in percent) by reductase from 
different sources. 
These data do not distinguish any one particular 
cysteine residue as necessary for enzyme activity, but 
indicate that thiol groups may be involved in the binding 
of the NADH cofactor to enzyme because of the protective 
effect of NADH against those inhibitions. 
Table 7. Inhibition constants of DHPR by thiol specific 
reagents and metal complexes. 
Inhibitor Enzyme 
Pb-acetate r.b. SOµM( -50%) 
Al 3 + r.b. 100µM(40%) 
cis-Pt(NH 3 ) 2 Cl 2 rat 170µM(28%) 
PCMB s .1. lmM(>80%) 
h.l. 10µM(70%) 
r.l. 6molecule(l00%) 
DTNB h .1. 100µM(60%) 
P. 570µM(-100%) 
r:T. 4 cysteine (80%) 
NEM h.l. lmM 
P. 10mM(57%) 
r.l. inert 
IA h .1. lOmM 
IAA r.l. inert 
HgC1 2 s. 1 . 10µM(>80%) 
h.l. O.lµM(60%) 
P. 400µM(50%) 
-
r.b. rat brain; c.l. chicken liver; s.l. 
liver; h.l. human liver; P. Pseudomonas; 
rat liver. 
ref. 
93 
94 
95 
17 
10 
80 
10 
51 
80 
10 
51 
80 
10 
80 
17 
10 
51 
sheep 
r.l. 
IA iodoacetamide; IAA iodoacetic acid. 
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1-6-3 NADH analogues 
The inhibition constants of beef DHPR by NADH 
analogues are listed in Table 8. 
Table 8. Inhibition constants of DHPR by NADH analogues. 
Inhibitor enzyme Type Ki(µM) ref. 
AMP b.l. comp. 1,000 81 
b.k. comp. 1,000 92 
NAD+ b.k. comp. 300 92 
Cibacron Blue b.k. comp. 0.3 92 
Blue dextran b.k. comp. 0.3 92 
b.l. bovine liver; b.k. bovine kidney. 
1-6-4 Metabolites 
Some of the reported inhibition constants of DHPR 
by amino acid metabolites and especially the catecholamine 
derivatives are listed in Table 9. 
1-6-5 Quinone inhibitors 
The reported inhibition constants of DHPR by 
compounds which possess quinone structures, and especially 
some drug metabolites, which are interesting from the 
pharmaceutical point of view, are listed in Table 10. 
1-6-6 Antibodies 
Antibodies which inhibit the activity of DHPR have 
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Table 9. Inhibition constants of DBPR by amino acid 
metabolites and their derivatives. Enzyme activities 
were assayed in the presence of peroxidase and hydrogen 
peroxide unless otherwise stated. 
Inhibitor Enzyme Type Isa Ki ref. 
( µM) ( µM ) 
L-Phenylalanine h.l. non-comp. >10,000 96 
L-Tyrosine h.l. 440 97 
h.l. non-comp. 440 250 96 
a-Methyl tyrosine h.l. 1,100 97 
3-Iodotyrosine h.l. >2,000 97 
Phenylpyruvic acid h.l. uncomp. * 6,500 90 
h.l. non-comp. 4,700 96 
r.l. mixed 50 98 
L-Phenylacetic acid h.l. non-comp. 7,600 96 
p-Hydroxyphenyl-
. 
acid h.l. 3.3 3.7 96 pyruvic non-comp. 
p-Hydroxyphenyl-
acetic acid h.l. 58 74 96 
Tyramine h.l. non-comp. * 50 97 
h.l. non-comp.# 24 97 
h.l. non-comp. 40 50 96 
Dopamine r.l. 110 99 
h.l. non-comp. * 6. 5 90 
h .1. non-comp.# 6.0 90 
h.l. non-comp. * 14 97 
h.l. non-comp.# 7 97 
h.b. inertcp 15 
N-Methyldopamine h.l. 27 97 
3-0-methyldopamine h.l. 60 97 
4-0-Methyldopamine h.l. 69 97 
Homoveratrylamine h .1. 10,000 97 
5-Hydroxydopamine h .1. 42 97 
6-Hydroxydopamine h.l. non-comp. * 24 97 
h.l. non-comp.# 24 97 
(±)Octopamine h.l. 190 97 
Dopa chrome h.b. 600 15 
Adrenochrome h.b. mixed* 29.8 15 
& 89 15 
h.b. comp.# 4.9 15 
L-Dopa h.l. non-comp. 230 260 96 
Norepinephrine r.l. non-comp. 490 98 
(-)-Norepinephrine h .1. non-comp. * 190 97 
h.l. non-comp.# 160 97 
(-)-Epinephrine h.l. uncomp. * 110 97 
h.l. uncomp.# 140 97 
3-0-methyl-
epinephrine h.l. 180 97 
* for substrate; # for NADH: h.l. human liver; h.b. 
human brain; r.l. rat liver; cf> enzyme activity was 
assayed in the absence of hydrogen peroxide. 
- 33 -
Table 10. Inhibition constants of human liver DBPR by 
inhibitors which possess quinone structures. Enzyme 
activities were assayed in the presence of peroxidase and 
hydrogen peroxide after incubation of the inhibitor and the 
reductase. 
Inhibitor Type Is~ Ki ref. (µM ( µM) 
17-S-Estradiol non-comp. * 3. 5 101 
17-a-Estradiol non-comp. 5.4 
Estriol uncomp. * 3. 3 
16-Epiestriol non-comp. 0.9 
17-Epiestriol non-comp. 1.9 
16,17-Epiestriol non-comp. 1 . 1 
Estrone non-comp. 8.0 
2-Hydroxyestradiol non-comp. * 2. 8 
2-Hydroxyestriol non-comp. * 2.6 
2-Hydroxyestrone non-comp. * 4. 6 
2-Methoxyestradiol non-comp. 5.4 
2-Methoxyestrone non-comp. 7.9 
d-Equilenin non-comp. 6.6 
Equilin non-comp. 7.5 
4-Phenyl- 1 non-comp. 12,000 102 
l-Methyl-4-phenyl-l non-comp. 3,000 
1-Methyl-
4-(4'-chlorophenyl)-l non-comp. 2,700 
4-(4'-Hydroxyphenyl)-l non-comp. 5.9 
4-(3'-Methoxy-4'-
hydroxyphenyl)-l non-comp. 7.2 
4-(3' ,4'-Dihydroxyphenyl)-l non-comp. 3.6 
l-Methyl-4-(3' ,4'-
dihydroxyphenyl)-l non-comp. 3.4 
8-Amino-2-meth~l- 103 
4-phenyl- non-comp. 150 
4-(4'-hydroxyphenyl)-2 non-comp. 45 35 
4-(3'-hydroxy-4'-
methoxyphenyl)-2 non-comp. 241 
Maleic acid inert 
R-(-)-Apomorphine non-comp. 2.0 2. 2 104 
R-(-)-Norapomorphine non-comp. 2.8 
R-(-)-N-n-Propyl-3 non-comp. 1. 8 2.2* 
S-(+)-N-n-Propyl-3 non-comp. 2.2 
R-(-)-N-Chloroethyl-
apomorphine non-comp. 2.9 
R-(-)-N-Hydroxyethyl-3 non-comp. 1.0 
R-(-)-2,10,11-Trihydroxy-
aporphine non-comp. 1. 6 1.9* 
R-(-)-2,10,11-Trihydroxy-
N-n-propylnoraporphine non-comp. 1.7 
R-(-)-Apocodeine non-comp. 79 
* for substrate7 # for NADH; 1 1,2,3,6-tetrahydro-
pyridine derivatives; 2 1,2,3,4-tetrahydroisoquinoline 
derivatives; 3 norapomorphine derivatives. 
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been prepared for DHPR from different sources. The bovine 
brain antibody crossreacts with the enzyme from rat brain, 
7 1 
rat kidney, and rat liver. On the other hand, sheep 
liver antibody crossreacts with the enzyme from human, rat, 
.1. 0 0 
and bovine tissues. 
The antibodies which are prepared for NADPH-
dependent DHPR do not react with NADH-dependent DHPR and 
this method is used for the identification of the presence 
.I. 1 
of NADPH-dependent DHPR in tissues. 
1-7 Aims 
The . aims of the work which is described in this 
thesis are directed to obtain information about the nature 
of the active site of human brain DHPR. 
The amino acid residues that are essential for 
enzyme catalysis have not yet been identified. To obtain 
details of the chemistry of catalysis of DHPR, it is 
necessary to probe the active site. To achieve this it is 
at first important to obtain the amino acid composition of 
this enzyme. By . using the results from the . amino acid 
analysis, proper estimations of enzyme concentration are 
obtained; these are necessary for the study of the 
stoichiometry of NADH and the reductase. 
The correct tautomer of quinonoid dihydropteridine 
species which is enzymically active is still not completely 
known. This has been studied in detail using the pteridine 
analogues where changes at C-2, C-4, C-6, N-8, and at the 
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2-amino group have been made, and 1s reported in this 
thesis. The results of such a study should be useful for 
structure-activity relationship which can give some idea of 
the space requirements and perhaps binding at the active 
site. 
More information can be obtained about the . . 1on1c 
nature of the reactive amino acid residues at the active 
I 
site by pH rate profile studies, and about the effect of 
the chemical structures of inhibitors. Such studies have 
been attempted. In the present work, platinum complexes 
have been examined as inhibitors which, with the aid of 
several thiol specific reagents, provided information 
regarding the reactivity of the cysteine residues in this 
enzyme. This study was carried out because it was known 
that several reductases have essential cysteine residues at 
the active site. These are apparently involved in the 
chemical mechanism of the enzyme reaction. 
CHAPTER 2 
AMINO ACID COMPOSITION, PROTEIN CONCENTRATION, 
SPECTROSCOPIC PROPERTIES AND REACTIVITY OF THIOL GROUPS 
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2-1 Introduction 
Dihydropteridine reductases from various mammalian 
sources were isolated and their amino acid compositions 
were compared by several authors (see Chapter 1, Section 1-
2 2 
2, p 5). In the case of the human reductase, Firgaira 
4 l 
et al. demonstrated that the enzym~ from human liver, 
cultured fibroblasts and continuous lymphoid cells were 
immunologically identical, and concluded that these were 
encoded by the same structural gene(s). Several 
l 7 J 5 7 6 8 1 
authors ' ' ' reported that reductases from bovine 
liver and adrenal medulla had similar . amino acid 
compositions but were not exactly the same. This might 
well be due to the differences in experimental methodology. 
7 5 
Aksnes et al. compared the enzyme from bovine liver and 
adrenal medulla under the same conditions and obtained the 
same amino acid composition for these two proteins. Sheep 
8 l J l J 
liver ' and brain DHPR were also compared and their 
amino acid compositions were the same. The human brain 
DHPR is most probably the same as the liver enzyme, because 
hyperphenylalaninemia patients which lack DHPR in liver and 
fibroblast tissues exhibit mental disturbance 
characteristic of DHPR deficiency. In an endeavour to 
obtain further data to establish the similarity of the 
human brain and liver enzymes the amino acid composition of 
the brain reductase has been determined and reported 
this chapter. 
. in 
In the previous publications, various authors used 
different methods for estimating protein concentration, 
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and this seriously affected studies of the stoichiometry of 
NADH and DHPR. In this work, the methods for estimating 
DHPR concentration were compared and then the stoichiometry 
of NADH binding was calculated using the correct protein 
concentration. 
The spectroscopic properties of the enzyme are 
reported in the following sections. The reactivities of 
several thiol reagents towards human brain DHPR have also 
been investigated. 
2-2 Enzyme purification 
The isolation of DHPR from human brain was 
l 5 
performed as described by Armarego and Waring who used 
the naphthoquinone affinity chromatography technique of 
l O 5 
Cotton and Jennings. The enzyme, dissolved in 50 mM 
Tris/HCl buffer containing 2 mM DTT, was stored in frozen 
aliquots at -200c and thawed when required. The enzyme 
used for the work described in this chapter, and in Chapter 
4 was a partially purified fraction from human brain (after 
naphthoquinone affinity chromatography) kindly provided by 
Dr Armarego. It showed seven bands on SDS-PAGE in which 
the band at molecular weight ca 25,000 was the most intense 
(>90%). 
The active fraction was purified further by 
passing through a DEAE-Sephadex A-50 column and eluting 
with a O - 250 mM KCl gradient in 50 mM Tris/HCl buffer. 
The active fractions eluted at 100 - 150 mM KCl and showed 
67,000 
43,000 
30,000 
20,100 
14,400 
A 
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B C D E 
Figure 1. SDS-polyacrylamide gel electrophoresis of DEAE-
Sephadex purified DHPR. Electrophoresis was performed 
on 15% of gel concentration at pH 9.4, 40c. 
A: Low molecular weight standard (Pharmacia). 
B: DHPR (4.3 i.ig, 1.2 n!"1ol) with 1.2% SDS and 5.9% 
glycerol (no incubation). 
C: OHPR (4.3 i.ig) was incubated with O.n% SOS, 3% glycerol 
and 1.2% 8-mer~aptoethanol for 30 min at 1000c. 
0: OHPR (4.3 i.ig) was incubated as above for 5 min. 
E: OHPR (4.3 i.ig) with 0.6~ SOS, 3% glycerol and l.2i 8-
mercaptoethanol (no incubation). 
The gel was stained by Serva blau R-250. 
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monomer and dimer molecular weight bands on SDS-PAGE and 
PAGE respectively. On SDS-PAGE, 1n the absence of 
mercaptoethanol or when heated in O .1% SDS and 1% 
mercaptoethanol at 100°c, for 30 min, this enzyme showed 
two close bands around Mr 26,000 + 1,000. With 
mercaptoethanol, on the other hand, only one band close to 
the slower . moving band of the . previous two bands was 
observed (Figure 1). It appears that the formation of two 
bands may be associated in some oxidation of cysteine 
residues. 
The purified DHPR was stored in 50 mM Tris/HCl 
buffer (pH 7.3) or in 50 mM potassium phosphate buffer (pH 
7.2) with 2 mM DTT and kept in glass vials in 1 ml 
aliquots. When DTT and NADH free enzyme was required it 
~as subjected to prolonged dialysis. However, the thawed 
enzyme (stock enzyme), which apparently contained only one 
protein, gave a small amount of white precipitate on 
dialysis against the above respective buffers at 4°c. The 
amount of precipitate was ca 30% of the total protein, but 
the total enzyme activity of stock DHPR was the same as the 
one of the dialysate, implying that the precipitated 
protein was essentially inactive enzyme. 
This dialyzed enzyme was used for most of the work 
in the present chapter and in Chapter 4 unless otherwise 
stated. 
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2-3 Amino acid composition 
l O 6 
A standard procedure was used to determine the 
amino acid composition of the proteins. The proteins were 
carboxymethylated with iodoacetic acid and hydrolyzed with 
6 M HCl. The amino acid compositions were determined 
( duplicated runs) using a Beckman Systems 6300 HPLC 
analyser. No trace of cystine residues was observed in the 
resulting chromatography, i.e. alkylation was complete. 
Cysteine was also alternatively determined by oxidation of 
the pro t e in with perform i c a c id and est i mated as cyst e i c 
acid using the same analyser. Bovine 8-lactoglobulin B, 
l O 7 
kindly supplied by Dr D.C. Shaw was used as standard in 
order to check the techniques and equipment used. Tyrosine 
residues could be obtained by these methods but tryptophan 
residues were destroyed. The tryptophan residues were 
determined using Goodwin and Morton's and also Edelhoch's 
l O 8 
UV methods (modified) (see below). 
The amino acid compositions were calculated using 
a monomer molecular weight of 25,000 Daltons for DHPR, and 
18,000 Daltons for 8-lactoglobulin Band are shown in Table 
1 . 
The amino acid ratios in Table 1 were based on 
the assumption that the determined concentration of 
alanine was correct, because this is one of the most stable 
amino acids 1n the analytical procedures used. The UV 
estimation of the tryptophan to tyrosine ratio in human 
brain DHPR was 1.8 ± 0.2. The number of tyrosine residues 
Table 1. 
Ala 
Cys 
Asp 
Thr 
Ser 
Glu 
Pro 
Gly 
Val 
Met 
Ile 
Leu 
Tyr 
Phe 
His 
Lys 
Arg 
Trp 
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Amino acid compositions. 
a 
Human 
brain 
DHPR 
24 
f 
-4 ( 3 ) 
16 
g 
12(13) 
13 
21 
8 ( 9) 
22 
13 
4 
8 
18 
3 
7 ( 8) 
3 
13 
9 
5 ( 6) 
Human 
liver 
DHPR 
31 
h 
3 
16 
17 
18 
22 
9 
26 
17 
4 
8 
21 
3 
7 
5 
14 
9 
5 
b C 
Human 
liver 
DHPR 
27 
3 
14 
17 
18 
22 
9 
26 
17 
4 
8 
19 
3 
7 
4 
14 
8 
5 
d 
B-LG 
15 
5 
15 
8 
7 
25(26) 
8 
6 
7 
4 
8 ( 9) 
22 
3 ( 4) 
4 
2 
15 
3 
2 
e 
B-LG 
15 
5 
15 
8 
7 
25 
8 
4 
9 
4 
10 
22 
4 
4 
2 
15 
3 
2 
calculated 
Mol. Wt. 
25,400 
(25,800) 
29,000 25,600 20,800 21,200 
(21,200) 
a : compositions based on Mr values of 25,000 (present work) 
b : reference 10 
c : recalculated from reference 3 on the basis of Mr 25,000 
as a monomer molecular weight 
d : this work, 8-LG = bovine B-lactoglobulin B 
e : reference 107 
f : determined as cysteic acid 
g : determined by the reaction with PCMB or DTNB 
h : determined as S-carboxymethylcysteine 
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per subunit was three from the amino acid analysis, so the 
number of tryptophan residues were 5 - 6. The analysis for 
S-lactoglobulin B showed that the amino acid recovery from 
the analyzed data was . 1n a very good agreement with the 
amount of protein used ( 95 - 10 2%). From this recovery, 
the DHPR concentration of this dialyzed enzyme solution was 
estimated to be 247.6 (± 1.6) µg/ml from two estimates. 
Al though there were small discrepancies between 
amino acid compositions of human brain and liver 
reductases, these were within the experimental error of the 
method. The true amino acid composition will be revealed 
when the complete sequence has been detennined. 
2-4 Estimation of the protein concentration 
Protein concentrations have been measured . 1n 
several ways by different workers. The general methods for 
this purpose are summarized in Table 2 (cf. reference 109). 
A reliable method was required for obtaining 
the concentration of DHPR in the present study and it was 
necessary to find out which rapid method (e.g. Bio-Rad, 
Lowry) gave correct protein concentrations. In this work 
the protein concentration from the amino acid analysis 
method (which is the most reliable) has been compared with 
those from the Bio-Rad and Lowry assays in order to find 
out if they gave reliable values. Also, once the protein 
concentration was established for the pure enzyme then the 
extinction coefficient of DHPR at 280 nm can be determined 
Table 2. General methods for determining protein 
concentration. 
methods 
Dry 
weight 
Kjeldahl 
Biuret 
Lowry 
Pigme·nt 
binding 
Amino 
acid 
analysis 
UV 
(280nm) 
Fluo-
rescence 
principle 
Dry weight of 
purified 
protein 
Measures NH 3 
derived from 
nitrogen in 
the protein 
Reaction 
between cu2+ 
and peptide 
bonding in 
alk. solution 
Reaction be-
tween phenol 
reagent and 
Tyr, Trp, 
and Cys and 
the Biuret 
reaction 
were mixed 
In acidic 
solution, the 
complex from 
protein and 
Coommassie 
blue G-250 
gives blue 
colour 
Acid hydroly-
sis and amino 
acid analysis 
by HPLC 
Measurement 
of absorption 
at ca 280 nm 
fromTrp and 
Tyr residues 
Titration by 
specific 
reagents to 
give fluores-
cence after 
binding 
limit(mg) interference comments 
1 variable 
1.sx10-3 
1 
50 pmol 
0.1 
nitrogen 
compounds 
e.g. 
(NH 4 ) 2 S0 4 
EDTA, 
Tris, 
Amide, 
(NH 4 ) 2S0 4 
reducing 
reagents, 
EDTA, 
phenol, 
Triton X-
100, 
amino acids, 
glycerol 
Triton X-
100(>0.1%), 
SDS(>0.1%), 
DNA ( > 0 • 1 % ) , 
etc. 
amines 
nucleic 
acids, 
aromatic 
compounds, 
etc. 
peptides, 
amino acids 
content of 
water 
several 
methods can 
be used for 
determina-
tion of NH3 
low sensi-
tivity, 
requires 
arbitrary 
standards 
large 
differences 
between 
protein 
molecules, 
. 
requires 
arbitrary 
standards 
as above 
requires 
prior 
knowledge 
of approx. 
Mr 
large 
differences 
between 
proteins, 
requires 
pure 
protein and 
E: values 
sensitive, 
. 
requires 
pure 
protein and 
Mol. Wt. 
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accurately and later used to estimate DHPR concentrations 
of pure enzyme preparations. 
The pigment binding method using the Bio-Rad 
110 111 
micro assay and the Lowry method are commonly used. 
The Bio-Rad method is reasonably sensitive, easy to 
perform, and gives results in the shortest time. Like the 
Lowry method, calibration with a standard protein is 
neccessary and bovine serum albumin is the most popularly 
used standard. This method . can give incorrect 
concentrations because of impurities or the nature of 
protein itself (see Table 2). The Lowry method was 
developed by Lowry et al. in 1951 and has been used in many 
laboratories, although like the Bio-Rad method, it can give 
quite large differences in values -depending on the protein 
and can be out by a large factor, e.g. of two or three. 
If the recovery from the amino acid analysis is 
higher than 90%, this method gives results that are 
almost as reliable as the dry-weight method, and requires 
much less protein. The protein concentrations of DHPR (DTT 
free or in 2 mM DTT) determined by the various methods are 
compared in Table 3. 
The results from the amino acid analysis and the 
Bio-Rad micro assay are in quite good agreement for human 
brain DHPR. The Lowry method gave almost twice the value 
obtained by the above methods for human brain DHPR. It can 
be concluded that for routine protein determinations the 
Bio-Rad assay will give more reliable values for human 
brain DHPR. 
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Table 3. Protein concentrations by the different 
estimations. 
method 
a 
b 
C 
d 
protein 
DHPR (DTT free) 
DHPR ( DTT free) 
DHPR (2mM DTT) 
DHPR (DTT free) 
DHPR (DTT free) 
a: Bio-Rad micro assay 
b: Lowry method 
c: Amino acid analysis 
protein 
concentration 
(µg/ml) 
262 
500 
583 
248 
255 
d: UV absorption using E2so = 90,000 
M-1.cm-l in buffer (pH 7.2) 
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2-5 0V and fluorescence spectra 
Dihydropteridine reductase from human brain has 
strong UV absorption like DHPR from other sources, i.e. it 
possesses a wavelength . maximum around 280 nm with a 
shoulder at 290 nm (see Figure 2). The extinction 
coefficient of 92,800 M- 1 .cm- 1 at 280 nm, pH 7.20 (0.1 M 
potassium phosphate buffer) determined in this work 1s 
based on the protein concentration obtained from the Bio-
Rad assay. This value is in good agreement with the s 280 
values of DHPR from other sources. For very pure 
preparations of enzyme, the UV method is quite sensitive 
for determining protein concentrations. Thus for an £2 80 
value of 92,800, 54 µg/ml of DHPR will give 0.1 absorbance 
units for a 1 cm cell. 
The fluorescence emission spectra of dialyzed DHPR 
(DTT free) were measured at 200c. The excitation 
wavelength of 280 nm affected both the tyrosine and the 
tryptophan residues and gave much stronger emission spectra 
than when excitation was at 290 nm. In proteins containing 
all three aromatic amino acids, phenylalanine, tyrosine and 
tryptophan, the observed emission spectrum is due mainly to 
the tryptophan residues (in neutral aqueous solutions, the 
emission maxima of tyrosine and tryptophan residues are at 
l l 2 
about 308 nm and 348 nm respectively). When the 
emission spectrum (excitation at 280 nm) of human brain 
DHPR was scanned from 310 nm to 550 nm (Figure 3), the 
emission maximum was at 351 nm (compare with the emission 
<V 1.0 
(.) 
C: 
ct, 
.0 
'-
0 
<n 
.0 
<C 0.5 
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250 300 350 
Wavelength (nm) 
Figure 2. UV spectrum of DHPR (2 mM DTT in 50 mM potassium 
phosphate buffer, pH 7.2). 
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Figure 3. Fluorescence erniss ion spectrum of DHPR. DHPR 
(OTT free, 10 µl, 68 pmol) was dissolved in . 0.1 M potassium 
phosphate buffer (pH 7. 2) ( 490 µl) and excited at 280 nm 
(slit 5 nm) at 200c. 
- 49 -
8 6 82 
maxima at 350 nm and 3 35 nm for rat liver DHPR). The 
exc'itation slit was opened only before scanning and was 
closed immediately after completion of the scan to avoid 
deterioration of the enzyme by the UV light. If this slit 
was kept open, human brain DHPR lost 11% of its 
fluorescence . in 50 min, whereas when the slit was opened 
o cc as ion a 11 y the e n z yme/ was s tab 1 e for at 1 east 5 . 5 h at 
When NADH or quinonoid dihydropteridine substrate 
was bound to DHPR, the enzyme fluorescence was very 
strongly quenched ( see Figures 4 and 5). The decreasing 
fluorescence with time in Figure 5 was due to the 
rearrangement of the quinonoid pterin. 
In general, fluorescence emission spectra of 
proteins in which the tryptophan residues are buried in the 
protein molecule show emission maxima at ca 330 nm, whereas 
when they are immob i 1 i zed by bonding (e.g. hydrophobic, 
hydrogen) at the protein surface the maxima are shifted to 
about 340 nm, and are at ca 350 nm when they are completely 
1 1 3 
exposed to water. 
Dihydropteridine reductases from other sources 
also have emission . at about 350 nm (except for maxima 
reference 10 6) , and we may conclude that most of the 
tryptophan residues . DHPR highly exposed to the in are 
solvent. possibility . that DHPR used 
. 
Another lS lS 
partially denatured where 
exposed to the solvent. 
work was not denatured. 
On denaturation 
all the tryptophan residues are 
However, the DHPR used in this 
the emission wavelength . maximum 
Figure 4. 
DBPR at pH 
7.2); B: 
NADH ( 0. 8 
7 • 2) • 
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enzyme ( 0 • 1 4 µ M ) + NA DH ( 0 • 8 ii M ) i n bu f f e r ; C : 
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Figure 5. Effect of quinonoid 6-methyl-7, 8-dihydro ( 6B)-
pterin on the fluorescence spectrum of DHPR at 200c. 
A: DHPR (0.14 uM) in 0.1 M phosphate buffer; B: enzyme+ 
quinonoid 6-MeDHP [generated by mixing of 6-MeTHP ( in 4 mM 
HCl, 43 uM) and K3Fe(CN)6 (100 µM)]; C: K3Fe(CN)6 (100 uM) 
with 4 mM HCl in buffer; D: K4 Fe(CN) 6 (100 µM) with 4 mM 
HCl in buffer; E: 0.1 M potassium phosphate buffer (pH 
7 . 2 ) . 
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should be shifted to longer wavelength. When human brain 
DHPR was denatured with 8 M guanidine.HCl, the wavelength 
maximum was shifted from 350 nm to 374 nm without decrease 
in intensity (Figure 6) . Unfortunately, the 8 M 
guanidine.HCl in 0.1 M potassium phosphate buffer (pH 7.2) 
itself had a maximum at 384 nm and its intensity at 370 nm 
was 78% of that of DHPR at the same wavelength. In weaker 
guanidine.HCl solution (e.g. 4 M), the emission maximum w~s 
also shifted, but to 362 nm and this smaller bathochromic 
shift is probably due to denaturation of the enzyme . 
When DHPR was denatured . using strong thermal 
conditions (in air at 37°c for 24 hand at 4s 0 c for 21 h), 
the maximum wavelength was shifted only to 362 nm with 
decreased intensity (90%) ( Figure 7) . Although this 
bathochromic shift is consistent with exposure of 
tryptophan residues to the sol vent, it is not as large as 
expected. 
Incubation of DHPR with 4 M urea in phosphate 
buffer (as above) caused the emission maximum to shift with 
time to longer wavelengths but with decreasing fluorescence 
intensity ( 0 h, 3 5 2 nm, 10 0 % ; 2 . 5 h, 3 5 7 nm, 7 8 % ; 13 h , 
357 nm, 59%) ( Figure 8). (Either an increase or decrease 
had been observed previously upon urea denaturation 
l l 4 
depending on the protein. ) 4 M Urea itself had an 
emission maximum at 437 nm due to impurities but this was 
too weak to interfere in the previous experiment. 
Theoretically the fluorescence intensity of the protein 
should increase on denaturation and the observed decrease 
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Figure 6. Fluorescence spectra of guanidine hydrochloride-
denatured DHPR at 200c. A: DHPR (0.07 ).lM ) in 4 M 
guanidine.HCl in 0.1 M phosphate buffer (pH 7.0); B: NADH 
( 0 • 8 J.l M ) was added to above so 1 u t ion ; C : after 1 5 m i n 
from NADH addition; D: NADH (0.8 ).lM ) in 4 M guanidine.HCl 
solution (pH 7.0). 
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Figure 7. Fluorescence spectra of thermally denatured-DHPR 
at 200c, pH 7.2. A: Thermally denatured by heating (at 
370c for 24 h and 450c for 21 h) DHPR (0.14 µM) in 0.1 M 
phosphate buffer (pH 7.2); B: NADH (0.8 µ~) was added to 
above enzyme solution: C: NADH (0.8 µM) in 0.1 M phosphate 
buffer (pH 7.2); D: 0.1 M phosphate buffer (pH 7.2) 
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buffer (pH 7.2); B: DHPR (0.07 µM) in 4 M urea 
times after mixing (h); C: 4 M urea in 0.1 M 
buffer (pH 7. 6). 
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in intensity on thermal denaturation can be explained by 
preferential adsorption of the denatured protein onto the 
wall of the cuvette. No turbidity was observed in the 
cuvette but this probably is because the protein 
concentration was very low, 7.7 µg/ml. 
2-6 Cysteine estimation using thiol specific reagents 
A number of dehydrogenases are known to contain 
few cysteine residues, some of which are essential for 
l l 5 
catalytic activity. Dihydropteridine reductases from 
various sources are also known to contain cysteine residues 
but no cystine residues except as reported for the sheep 
1 iv er enzyme ( re f . 1 7 ) • It was therefore of interest to 
obtain more information about the cysteine residues 
. 1n 
human brain DHPR. 
A few thiol specific reagents have been used to 
estimate the number of cysteine residues in proteins 
( natured or denatured). Of these 5, 5' -di thiobis ( 2-ni tro-
benzoate) ( DTNB), 2-ni tro-5-thiocyanobenzoate ( NTCB), and 
p-chloromercuribenzoate (PCMB) have been used in the 
present work in order to obtain some information about the 
nature of the thiol groups in human brain DHPR. It 
. 
lS 
possible to titrate thiol groups spectroscopically by using 
those reagents. 
DTNB interacts primarily with the more reactive 
thiol groups, 1.e. highly exposed free cysteine residues, 
probably because of its molecular size. PCMB and NTCB, on 
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the other hand, react with further cysteine residues which 
are located inside of molecule. 
2-6-1 Reaction with S,S'-dithiobis(2-nitrobenzoic acid) 
(DTNB) 
1 1 6 
Although DTNB can react only with highly active 
cysteine residues under non-denaturing conditions, it does 
react with more cysteine residues in the denatured 
protein. 
When the protein solution . is incubated with an 
excess of DTNB, thionitrobenzoate . anion (thiolate . anion, 
TNB) . is liberated, and the reaction . is followed by 
measuring the absorbance at 412 nm of the thiolate anion. 
Excess of DTNB . is 
reaction (Scheme 1). 
necessary to minimize the reverse 
The blank experiment is carried out 
Scheme 1 
with the corresponding buffer solution and a typical result 
is shown in Figure 9. 
The concentration of cysteine residues which react 
with DTNB is the same as the concentration of TNB formed 
and is calculated from following equation (1), 
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Figure 9. The incubation of DHPR with DTNB at 21°c in 0.1 M 
potassium phosphate buffer, pH 7.2. 
A : enzyme ( OTT f re e , 1 5 0 µ 1 , 9 • 9 6 µ M ) was i n cub a t e d 
with 10 mM DTNB (30 µl, 1.07 mM) in 0.1 M phosphate 
buffer (pH 7.2) (100 µl) for 6 h. 
B: Blank [0.1 M Phosphate buffer (pH 7.2) (250 µl) was 
incubated with 10 mM DTNB (30 µl, 1.07 mM) .] 
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C = A X D ( 1 ) --
e: 
where C is cysteine concentration in the original solution, 
A is absorbance change, e: is extinction coefficient of TNB 
anion at 412 nm (i.e. 13,600 M-1 .cm- 1 ) and D 1s the 
dilution factor. Incubation of DHPR with high 
concentrations of DTNB for a long time period (4.5 h) 
revealed that 1. 0 cysteine residue per subunit was 
estimated under non-denaturing conditions without any loss 
of enzyme activity. 
When DHPR (4.2 µM) was incubated with DTNB (0.24 
mM) as above in 8 M guanidine.HCl (in 0.1 M phosphate 
buffer, pH 7.0), i.e. denaturing conditions, the absorbance 
at 412 nm decreased with time (due to the reverse reaction 
by TNB) ( Scheme 1 ) . With much higher concentrations of 
DTNB (e.g. 5 mM) and lower concentrations of DHPR (e.g. 2.1 
µM), this phenomenon was much slower and gave values 
consistent with 3.5 cysteine residues per subunit. 
When DHPR ( 5 .1 µM) was pre-incubated with NADH 
(286 µM) for 10 min prior to titration with DTNB, 1.4 -SH 
per subunit (i.e. one -SH group per subunit) reacted with 
DTNB with ca 34% enhancement of enzyme activity. This 
enhancement of enzyme activity may be explained by a 
conformational change at the active site due to the 
reaction of DTNB at a remote site which affects the binding 
of substrates and/or release of products. From the above 
observations, human brain DHPR seems to have one free 
cyst e in e res id u e on the outer face of the enzyme and the 
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resulting partial conformational changes after reacting 
with DTNB do not decrease the enzyme activity. 
2-6-2 Reaction with £-Chloromercuribenzoic acid (PCMB) 
117 118 
p-Chloromercuribenzoic acid (PCMB) ' is the 
most widely used . organo-mercur1c compound for the 
estimation of cysteine residues in proteins. It is not as 
l l 7 
toxic as the previously used inorganic mercury and the 
format ion of p-carboxyphenylmercaptide can be detected at 
255 nm (pH 4.6) or 250 nm (pH 7.0) (Scheme 2). In acidic 
coo9 
R-SH + • R-S-Hg-Q-coo8 
Hg 
I 
Cl 
Scheme 2 
solution ( pH 4. 6) , PCMB reacts with exposed and internal 
-SH groups in the protein. PCMB 1n neutral buffer (pH 
7.0), on the other hand, reacts with the more exposed -SH 
groups as in the case of DTNB and also with some of 
internal -SH groups which are not so deeply buried 
protein structure. 
in the 
The stock solution of PCMB was made by dissolving 
the acid into 1.6 mM NaOH and aliquots were re-mixed with 
50 mM phosphate buffer ( pH 7. 0) or O. 33 M sodium acetate 
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buffer (pH 4.6). In this stock solution, p-hydroxymercuri-
benzoate was formed, because of the higher affinity of 
hydroxide 
times). 
. ions for the mercury than chloride . ions (1,000 
The proportion of these two components in the 
solutions depended on the concentration of chloride ions 
and pH. Because precipitation of white solids occurred on 
standing, solutions (of pH 7.0 and 4.6) were centrifuged 
and the concentrations of PCMB in the supernatants were 
estimated with glutathione before use. The titration was 
fallowed using a double beam UV spectrometer at 2 50 C for 
both the acidic and neutral conditions. 
The protein solution (DTT and NADH free) was 
placed in the experimental cuvette and the same volume of 
0.1 M potassium phosphate buffer (pH 7.2) was in the blank 
cuvette. Solutions in both cuvettes were diluted with 
0. 33 M sodium acetate buffer (pH 4. 6) or 50 mM potassium 
phosphate buffer (pH 7.0) and each titrated with aliquots 
of the respective standardized PCMB solutions. A typical 
curve is shown in Figure 10. The concentration of -SH 
groups was estimated from the concentration of PCMB at the 
intersection of the two lines. The number of -SH groups 
per subunit estimated in sodium acetate buffer (pH 4.6) was 
2 • 7. Titration in 2% SDS solution in the same buffer gave 
2.8 -SH per subunit value. 
The reaction was much slower at pH 7.0, because 
it depended on the reactivity of each -SH group in the 
protein. The DHPR enzyme activity was also measured at the 
same time by assaying aliquots from the cuvettes ( Figure 
11) . 
- 62 -
PCMB concentration 
Figure 10. 
117) • 
Typical PCMB titration curve (cf. reference 
X 1 o-z ~ 6i 
• ~ ·-·-·-· \ / .---- . 
.- 4 I 
~ a • 
• • • • 
0,) 
u 
C 
~ 
.rJ 
-0 (J) 
.rJ 
<t: 
2 
• 
I 
• 
0 2 
·~ 
·----
4 6 8 
·--· 
--... 
10 12 
PCMB (nmoles) 
::0 
~ 
100 3 Q) 
-· :, 
-· :, 
tQ 
Q) 
n 
50 ,-+, 
-· ~ 
-· ,..,. 
'<: 
-~ 
-
0 
Figure 11. Titration of DHPR with PCMB (pH 7.0) at 2s 0 c. 
-•- : OHPR (OTT free, 50 µl, 840 pmol) in 50 mM potassium 
phosphate buffer (pH 7.0) (250 ml) was titrated with 74.5 
µM PCMB (pH 7.0). The blank cuvette contained 0.1 M 
phosphate buffer (pH 7.2) (50 µl) and 50 mM phosphate 
buffer (pH 7.0) (250 µl). -•- The enzyme activity was 
monito:::-ed in duplicate. 3 µl of enzyme samples were 
removed after equilibration with each aliquot of PCMB and 
assayed. 
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The titration curve at pH 7.0 (Figure 11) was not 
as sharp as at pH 4.6. The curved portion was at about 3.2 
to 3. 3 -SH equivalent of PCMB ( 3 -SH by extrapolation). 
This curvature is probably due to the slower reactivity of 
the second and third -SH groups. By assaying the aliquots 
for enzyme activity during the titration it was found that 
the activity decreased after the second -SH group was 
titrated (Figure 11). This is in a good agreement with the 
result from DTNB estimation. Protection by NADH from the 
inhibition caused by PCMB was observed when DHPR was pre-
incubated with NADH (45.5 µM) (no -SH group reacted with 
PCMB). This protection by NADH against PCMB inhibition was 
l 0 
also observed in the case of human liver DHPR. In the 
l 0 
latter report, however, 100 µM DTNB and 10 µM PCMB 
inhibited the enzyme activity by 60 and 70% respectively, 
whereas no inhibition of human brain DHPR by DTNB was 
observed in this work. The higher inhibitor activity with 
DTNB which was observed in human liver DHPR may be due to 
prior oxidation of the enzyme itself, because the enzyme 
and inhibitor were pre-incubated for 5 min in the assay 
mixture (which presumably included peroxidase and hydrogen 
44 
peroxide). 
2-6-3 Reaction with 2-nitro-5-thiocyanobenzoic acid (NTCB) 
The 2-ni tro-5-thiocyanobenzoic acid ( NTCB) assay 
was developed to introduce a small and neutral group for 
reaction with thiol residues in the native protein and for 
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1 1 9 
comparison with other thiol specific reagents. Both 
DTNB and PCMB are bulky by comparison and it is difficult 
to ignore the effects from their size on their reactions 
with proteins. In the case of PCMB, there was still doubt 
as to whether the inhibition was caused by the reaction 
between PCMB and the catalytic cysteine residues in the 
enzyme or the bulkiness of PCMB molecule which bound to 
non-catalytic cysteine residues close to the active site. 
1 l 9 
NTCB was incubated in the same way as DTNB. In 
both non-denatured and denatured conditions the colour 
development at 412 nm was very poor even with reasonably 
high NTCB concentrations. Only O. 5 -- 0. 9 -SH per subunit 
(ca one -SH) was titrated. (All solutions were freed from 
oxygen by bubbling nitrogen gas.) The proposed react ion 
l l 9 
is shown in Scheme 3. It was carried out in 0.1 M 
SCN se 
pH 7•8 
+ H<t> R-SH + • R-SCN + coo9 
coo9 
N02 N02 
Scheme 3 
phosphate buffer {pH 7.2), so it was unlikely that the pH 
of the solution dropped after the release of protons. 
Theoretically NTCB should react wi~h most of the 
-SH groups. The poor affinity of NTCB for the -SH groups 
of this protein cannot be readily explained. It lS 
possible that some -SH groups are less readily ionized at 
pH 7.2 and therefore less nucleophilic. 
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2-7 Stoichiometry of DHPR and NADH 
Now, as the concentration of DHPR has been 
determined accurately, it 1s possible to obtain good 
estimations of the stoichiometry of the reaction with NADH. 
Stoichiometric studies of the binding of NADH to the DHPR 
molecule from other sources have given two different 
results; (a) one molecule of NADH binds to one subunit ( * 
the active form of DHPR from all sources has two identical 
subunits), and (b) one molecule of NADH binds to two 
subunits. The different results may be due to incorrect 
protein concentration estimation (seep 43) or may depend 
on the sources of DHPR. 
In this work, the determination of the 
stoichiometry was carried out by fluoriometric titration. 
Fluorescence titration 
When NADH was bound to human brain DHPR, the 
enzyme fluorescence was quenched very strongly; excitation 
wavelength was 280 nm and emission spectra were scanned 
from 310 to 550 nm (Figure 4~ p 50). Similar behaviour was 
8 2 8 6 
observed with rat liver DHPR. ' The fluorescence 
intensity of DHPR at 350 nm decreases concurrently as NADH 
. 
lS binding is 
. 
remains complete and then until the added 
steady as more NADH is added. Under the same conditions, 
free NADH has almost no fluorescence, whereas NADH bound to 
DHPR causes an increase in the fluorescence at the 
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wavelength maximum 469 nm. After saturation of the DHPR 
active site with NADH, the fluorescence at 469 nm does not 
increase further. 
In this work, the reaction between NADH and human 
brain DHPR was followed by observing the changes in the 
. 
fluorescence of NADH at 
depicted in Figure 12. 
4 70 nm. The titration curve lS 
NADH did not bind to human brain DHPR which was 
denatured thermally or with 4 M guanidine.HCl. After 
incubating the enzyme at 370c for 24 hand 450c for 21 h, 
this enzyme was titrated with NADH but no fluorescence 
changes at 350 nm (for protein) and at 470 nm (NADH) were 
observed (Figure 7, p 54). In this experiment, the 
temperature used might be too high and may have caused 
complete unfolding of the protein molecule. In 4 M 
guanidine.HCl solution, the wavelength maximum of protein 
fluorescence was shifted to 362 nm due to denaturation and 
the fluorescence at this wavelength slowly decreased after 
addition of NADH, although no increase of the fluorescence 
due to bound NADH was observed at 470 nm (Figure 6, p 53). 
This decrease may be due to slow denaturation of the enzyme 
in the weak guanidine.HCl solution. 
When human brain DHPR (DTT free) (408 pmoles) was 
titrated with aliquots of 13. 9 µM stock NADH solution in 
0.1 M potassium phosphate buffer (pH 7.2), the titration 
curve indicated that one molecule of NADH was bound to 1.3 
molecules of the active subunit. (The active enzyme 
seems to be 50% of the total protein concentration, because 
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Figure 12. Titration of DHPR with NADH at 230c. 
-•- : DHPR (OTT free, 30 µl, 204 pmol) in 0.1 M phosphate 
buffer (pH 7.2) (470 µl) was titrated with 13.9 l-lM NADH at 
230c. -•- : Titration curve of blank contained 0.1 M 
phosphate buffer (pH 7.2) (500 µl). The excitation and 
emission wavelengths were 280 nm (slit 5 nm) and 470 nm 
(slit 10 nm) respectively. 
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the specific enzyme activity had decreased to half of the 
original value, whereas the total protein concentration of 
DHPR did not change.) This result is in a good agreement 
1 0 8 1 
with the results obtained for bovine liver DHPR. ' 
82 
Webber and Whiteley reported a different stoichiometry (1 
NADH : 2 subunits) with rat liver DHPR in the presence of 1 
mM S-mercaptoethanol by the equilibrium dialysis experiment 
and by the UV spectroscopic method. When human brain DHPR 
was titrated in 1 mM S-mercaptoethanol in the present 
study, the result was still one mole of NADH to 1.3 moles 
of the active subunit. These differences may be due to 
differences in the amino acid compositions of rat DHPR and 
human and bovine DHPR ( see Figure 1 in Chapter 1, p 2 4) • 
82 
Another possibility is that Webber and Whiteley had not 
determined their protein concentrations correctly (they 
used the Lowry method whereas the UV method was used 1n 
1 0 8 1 
other cases, ' ) or had not completely removed naturally 
bound NADH from their protein. 
The dissociation constant of the binding of NADH 
to human brain DHPR was calculated from the titration by 
observing the changes of the protein fluorescence at 470 nm 
(Figure 12, p 67). 
The Kd value was determined using a computer 
1 2 0 
programme kindly supplied from Dr J.F. Morrison and 
found to be 13.8 ± 3.2 nM. This corresponded to a total 
protein concentration of 74.1 ± 1.6 nM. This total enzyme 
concentration was almost half the value of that obtained 
from the Bio-Rad estimation (160 nM). However, the enzyme 
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used in this experiment had lost about half its enzyme 
activity, so the true active protein concentration was ca 
80 nM which was in a good agreement with the value from 
the computer evaluation. The Kd value for human brain DHPR 
of 13.8 is to be compared, considering the errors involved, 
8 6 8 2 
with the Kd values of 78 ± 24 nM and 166 ± 74 nM 
reported by different authors for rat liver DHPR (see 
reference 22). 
2-8 Conclusion 
The Bio-Rad assay and UV method (s 92,800 M-1.cm-1 
at 280 nm) were found to be the most reliable methods for 
estimation of the protein concentration of human brain DHPR 
The Lowry method gave high protein values. 
The amino acid composition of human brain DHPR 
(Table 1, p 42) was similar, within the error of the method 
used, to the reported composition for human liver DHPR. 
Human brain DHPR has 5 or 6 tryptophan residues per subunit 
and most of those residues are highly exposed to the 
solvent. 
from the 
Three or four cysteine residues were estimated 
. 
amino acid analysis whereas only three residues 
were obtained from the reaction with thiol specific 
reagents. This difference could be due to experimental 
errc~ but another possibility was that the fourth cysteine 
residue was located at a highly hydrophobic region of the 
protein and was not readily accessible to thiol reagents 
even under the denaturing conditions. Experiments revealed 
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that human brain DHPR had one free cysteine residue per 
subunit on· the outside of the molecule which did not affect 
enzyme activity. The second and third cysteine residues 
may be of significance for enzyme activity, al though the 
inactivation of the enzyme was slow after the first thiol 
group was reacted (cf. Chapter 4 on DHPR inactivation by 
platinum(II) complexes). 1 
One mole of NADH cofactor binds to one mole of the 
DHPR subunit with a Kd value of 13.2 nM. 
For the definitive amino acid composition, we have 
to wait for the results from amino acid sequence studies 
and from X-ray crystallographic analysis. 
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2-9 Experimental 
2-9-1 General Methods 
A: Chemicals 
All commercial chemicals were of the highest 
commercially available purity. 
DEAE-Sephadex A-50 was from Pharmacia, Uppsala, 
Sweden. 6-Methyl-5,6,7,8-tetrahydropterin hydrochloride 
was supplied by Dr W.L.F. Armarego. Visking dialysis 
tubing (Scientific Instrument Centre Ltd., London) was 
stored at 4°c in 50% ethanol and hydrated before use by 
soaking overnight in distilled water. 
All concentrations in parentheses are the final 
concentrations. 
B: Methods 
.I. 2 .I. 
Polyacrylamide gel electrophoresis was carried 
.I. 2 .I. 
out according to the method of Ornstein and Davis (60 x 
80 x 1 mm running gel was used). Pharmacia low molecular 
weight standards ( Uppsala, Sweden) were used as molecular 
weight markers. 
The gels were stained with Serva Blau R-250 
.1. 2 2 (Serva, Heidelberg, WG) or with silver staining. 
.I. 2 .I. 
SDS-polyacrylamide gel electrophoresis was 
carried out according to the method of Laemmli (60 x 80 x 1 
mm gel was used). 
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Amino acid an a 1 y sis was carried out us 1 n g a 
Beckman Systems 6300 HPLC analyser in the Department of 
Biochemistry by Mr L.B. James. 
A Perkin-Elmer Lambda 1 single beam UV 
spectrometer was used for the determination of protein 
concentrations and the thiol group estimation with DTNB or 
NTCB. Ultraviolet spectra and kinetic assays were 
performed on a double beam Unicam SP 1800 connected to a 
Rikadenki B-281 H recorder with 5 mV across the slide wire 
to produce a maximum pen movement corresponding to O .1 
absorbance units. For higher sensitivity a Cary 219 
spectrometer adjusted to produce maximum pen movement for 
0.01 absorbance uni ts was used. The cell holders were 
thermostated at the desired temperatures with re-
circulating water from a Coolnics thermostat unit (model 
CTE-18, Komatsu-Yamato, Japan). 
Fluorescence spectra were measured with a Perkin-
Elmer LS-5 Luminescence spectrometer . using 280 nm as 
excitation wavelength (slit 5 nm) and the fluorescence 
emission was measured at 350 or 470 nm (slit 10 nm) or was 
scanned (slit 5 nm). A 4 mm thermostated quartz cuvette 
was used at the desired temperature and the excitation beam 
was given only when fluorescence readings were noted. 
The assays were performed as described by 
9 
Nielsen except that potassium ferricyanide was used as 
4 9 
oxidant. The experiment and blank cuvettes had the same 
ingredients except for the experimental cuvette into which 
the enzyme solution was injected. Both cuvettes contained 
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distilled water ( 805 µl; or 755 to 785 µl for enzyme 
purification) and 1 M Tris/HCl buffer (pH 7.4) (100 µl, 0.1 
M), and were kept at 25°c prior to the assay. The enzyme 
solution (1 µl; or 20 to 50 µl for enzyme purification) was 
added to the experimental cuvette and then 6-MeTHP 
( 20 µl dissolved in 4 mM HCl, 30. 2 µM), and NADH ( 25 ul 
dissolved in 50 mM Tris/HCl buffer, pH 7.3, 119.1 µM) were 
added to both cuvettes simultaneously. The react ion was 
initiated by addition of 2 mM potassium ferricyanide ( 50 
µl, 100 µM). The oxidation of NADH to NAD+ was observed at 
340 nm, 25°c, and the rate of reaction was obtained from 
the concentration of oxidized NADH ( absorbance change at 
340 nm) per minute by . using 6. 2 X as the 
extinction coefficient of NADH. 
Kinetic assays were run in duplicate. 
Small volumes of enzyme used in kinetic runs were 
dispensed with a Hamilton Whittier-cal PB 600 dispenser and 
a 50 µl Hamilton syringe which can deliver 1 µlat a time. 
2-9-2 Enzyme purification 
The active fractions from the naphthoquinone 
affinity chromatography (see Section 2-2, p 38) were 
collected and dialyzed against 50 mM Tris/HCl buffer (pH 
7.4) for 24 h at 4°c. This dialysate was concentrated to 
small volumes ( 10 ,.., 15 ml) in an Amicon PM-10 membrane 
filter (Amicon Co., Danvers, USA.), and applied to a DEAE-
Sephadex A-50 column (2 x 35 cm) with 50 mM Tris/HCl buffer 
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(pH 7.8). The column was eluted with a gradient of O to 
250 mM KCl 1n the same buffer at 40c. The protein 
concentrations of the fractions were measured by UV 
absorption (at 280 nm) and by the Bio-Rad micro assay. The 
enzyme activity was also measured for these fractions. The 
active fractions eluted at about 100 - 150 mM KCl. These 
were collected and 1 ml portions were stored in glass vials 
at -20°c (these were designated as stock DHPR). When 
required, these solutions were thawed and dialyzed against 
the above buffer or the buffer which contained 2 mM OTT at 
Some protein precipitated on dialysis and was 
removed. Because the enzyme gave the same band (one band) 
on SDS-PAGE before and after dialysis it appeared that the 
protein that had precipitated on dialysis was inactivated 
DHPR (see Table 4). 
J. 0 6 
2-9-3 Amino acid analysis 
A: The protein was alkylated with iodoacetic acid prior 
to . amino acid analysis. Dialyzed DHPR solution (OTT free, 
100 µl) in 0.1 M potassium phosphate buffer was lyophilized 
in screw-cap glass vials. The residue was re-dissolved in 
buffer solution (50 µl; 6 M guanidine.HCl, 0.1 M Tris and 1 
mM EDTA solution, pH 8.3) and 3.9 mM B-mercaptoethanol (129 
µl) was added. The air in the vials was displaced by 
blowing nitrogen gas through them and the solution was 
incubated for ca 10 h at 37°c. Iodoacetic acid 
( recrystallized from chloroform and then petroleum ether) 
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Table 4 Enzyme purification on DEAE-Sephadex A-50 
a 
Total protein Total activity 
b 
(mg) ( u) 
DEAE-Sephadex A-50 
stock DHPR 12.2 1928 
dialyzed DHPR 8.4 1932 
a) Protein concentration was obtained by the Bio-Rad 
. 
m1croassay. 
b) unit (µmoles NADH oxidized per min) 
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1n water (50 mM, neutralized with NaOH) (12 ul) was added 
to the previous solution and again flushed with nitrogen 
gas and capped. The mixture was incubated at room 
temperature for 30 min. This reaction mixture was passed 
through a Sep-pak column (Waters Associates, Ma., USA.; 
which was pre-equilibrated with 80% acetonitrile in O .1 % 
aqueous trifluoroacetic acid and then with O .1% aqueous 
trifluoroacetic acid), to remove non-protein materials, and 
the column was washed with O .1% aqueous trifluoroacetic 
acid (2 ml) and then with 20% acetonitrile in 0.1% aqueous 
trifluoroacetic acid (2 ml). Protein was eluted from the 
column with 80% acetoni trile in O .1% aqueous trifluoro-
acetic acid (4 ml) and the eluate was evaporated in vacuo 
over KOH pellets. This protein residue was hydrolyzed with 
6 M HCl at 110°c for 22 hand the amino acid composition 
was determined. 
B: The performic acid oxidation of protein was performed 
as follows. The buffer in the protein solution (50 ul) was 
removed by passing the solution through the Sep-pak column 
(see above) and dried. Performic acid [1 ml, prepared from 
90% formic acid ( 9. 5 ml) and 30% hydrogen peroxide ( 0. 5 
ml)] was added to the protein residue in an ice-bath. The 
oxidation was allowed to proceed at o0 c for 6.5 hand the 
solution was evaporated to dryness. The dried ( in vacuo 
over KOH) residue was hydrolyzed with 6 M HCl at 110°c for 
22 h 1n a sealed tube. Bovine 8-lactoglobulin B (Mr 
18,400) was used as the standard protein. It was dissolved 
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1n the same buffer as used for DHPR and then treated as 
above for DHPR. 
The estimated error for pipetting was obtained by 
weighing and was ± 1.1%. This value was applied for the 
calculation of total protein concentration. 
2-9-4 Spectrophotometric determination of the numbers of 
tryptophan and tyrosine residues 
Solution A: 8 M guanidine.hydrochloride in 25 mM 
phosphate buffer (pH 6.33). 
Solution B: 8 M guanidine.hydrochloride in 0.13 
M NaOH (pH 11.8). 
i O 8 
The method of Goodwin and Morton made use of 
the UV absorptions of tyrosine and tryptophan in alkaline 
( 295 nm) and neutral ( 280 nm) pH. The experiment was 
carried out using a single beam UV spectrometer at 250c. 
The dialyzed DHPR solution (containg 2 mM DTT, 50 µl, 92 
pmol) in 50 mM potassium phosphate buffer (pH 7 .2) was 
mixed with solution A (150 µl, final concentration of 
guanidine.HCl was 6 M) in a cuvette and the optical density 
was read at 280, 288 and 295 nm. The corresponding blank 
experiment contained 50 mM phosphate buffer (50 µl) instead 
of enzyme solution. The optical density of DHPR . 1n 
alkaline pH was read at 295 nm after mixing the dialyzed 
DHPR solution ( 2 mM DTT, 50 µl) and solution B ( 150 µl). 
The blank value was measured by using the corresponding 
buffer solution. 
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If the absorbance of the protein in alkaline and 
neutral pH can be measured then an estimate of the number 
of tryptophan residues can be made · from a knowledge of the 
number of tyrosine residues (obtained from equation 2 and 
general amino acid analysis). According to Goodwin and 
1 0 8 
Morton's method, the ratio can be obtained from the 
following equation (3); 
A 280.neutral = 5690 X Nt + 1280 X Nt rp yr 
A295.alkaline= 2480 x Ntyr + A295.neutral 
N /N = 
, trp - tyr 
A - A 295.alk 295.neut 
--- (1) 
--- (2) 
X 0.44 
--- (3) 
where A is absorbance observed, N is number of amino acids, 
5690 is the extinction coefficient of tryptophan at 280 nm 
in neutral pH, 1280 is the extinction coefficient of 
tyrosine at 280 nm in neutral pH, and 2480 is the 
extinction coefficient of tyrosine at 295 nm in alkaline 
pH. 
On the other hand, Edelhoch proposed the 
determination of the number of moles of tyrosine and 
tryptophan per mole of protein 1n neutral solution by 
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measuring the UV absorption at 280 and 288 nm. When this 
method was applied to DHPR, it gave negative values for the 
ratio, so Ntrp was obtained from the neutral pH values 
which were derived from equation (4), and Nt was obtained yr 
from equation (2) and the ratio from equation (5). 
Nt = (0.322 X A288 t - 0.0969 X A280 t) X 10-3 --(4) rp .neu .neu 
N /N = trp tyr 
(0.322 x A288.neut - 0.0969 x A280.neut) 
0
·
4032 (A295.alk - A295.neut) 
---(5) 
The results obtained were applied to equations (3) 
and (5), and both results should give the same value within 
experimental error (see Table 5). 
2-9-5 The Bio-Rad micro assay 
DHPR solution (DTT free, 10µ1) in 0.1 M potassium 
phosphate buffer (pH 7.2) was dissolved into water (790 µl) 
and the Bio-Rad reagent ( 200 µ 1) was added to it, mixed 
well, and then set aside at room temperature for 10 . min. 
The optical density was measured at 595 nm. The 
corresponding buffer solution ( 50 µl) was used as blank. 
The protein ccncentration was evaluated from the standard 
curve using BSA. 
duplicate. 
The determinations were carried out in 
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Table 5. The ratio of N trp to N tyr· 
A 
neut Aalk N /N trp tyr 
280 288 295 nm 295 nm a b C 
DHPR 
human 
brain 
(dialyzed) 0.171 0.156 0.114 0.155 1. 6 2.0 
S-lacto-
grobulin 0.177 0.140 0.081 -- - 0.5 o.sd 
DHPR 
human 
liver --
-- -- -- - - l.67e 
a . calculated from equation ( 3) . 
b . calculated from equation ( 5 ) . 
C . calculated from known amino acid composition . 
d . cf. reference 107 . 
e . cf. reference 10 . 
- 81 -
2-9-6 Lowry method 
Solution A: Na 2 C0 3 (20 g) + NaOH (4 g) /L of H2 0 
Solution B : Sodium tartrate (1 g) was dissolved 
in water (100 ml) and then CuS04 .SH 2 0 (0.44 g) was 
added to it. The supernatant was used. 
Solution C : Prior to use, solution A and solution 
B were mixed in the ratio of 50 : 1. 
Polin solution : Folin-Ciocalteau's phenol reagent 
(BDH, Poole, England) : H2 0 = 2 : 3 
DHPR solution ( DTT free or 2 mM DTT, 20 µl) was 
dissolved in H2 0 (180 µl) and solution C (1 ml) was added 
to it and then left at room temperature for 10 min. The 
Fol in solution ( 0. 5 ml) was added and after 30 min the 
absorbance at 650 nm was measured. The blank was carried 
out with H2 0. The protein concentration was deduced from a 
curve using BSA as a standard protein. 
2-9-7 The fluorescence spectra of DHPR 
A: Non-denatured DHPR 
i) DHPR (DTT free) (10 µl, 0.14 µM) was dissolved in 0.1 
M potassium phosphate buffer (pH 7.2) (490 µl) and the 
emission spectra were scanned at 200c (Figure 3, p 48). 
ii) DHPR (DTT free) (10 µl, 0.14 µM) was mixed with NADH 
( 10 µl, 0. 8 µM) in O .1 M potassium phosphate buffer ( pH 
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7. 2) (490 µ 1) • The fluorescence . . em1ss1on spectra were 
scanned at 20°c (Figure 4, p 50). 
iii) DHPR (DTT free) (10 µl, 0.14 µM) was mixed with 6-
MeTHP (10 µl in 4 mM HCl, 43 µM) in 0.1 M potassium 
phosphate buffer (pH 7.2) (490 µl), and potassium 
ferricyanide (10 µl, 100 µM) was added to it. The emission 
spectra were scanned at 20 ° C ( Fig·ure 5, p 51) . 
B: Denatured DHPR 
i) DHPR ( DTT free) ( 10 µl, 0 .14 µM) was denatured in 8 M 
guanidine.HCl in 0.1 M potassium phosphate buffer (pH 7.0) 
( 490 µl) and the emission spectra were scanned at 200c. 
Al though the f 1 uorescence maximum of DHPR shifted to 3 7 4 
nm, this 8 M guanidine.HCl in buffer itself had a maximum 
at 384 nm and its intensity was 78% of that of DHPR at the 
same wavelength. This bathochromic shift of enzyme 
fluorescence seems to be due to guanidine.HCl. 
i i ) DH PR ( DTT free ) ( 5 µ 1 , 0 . 0 7 µ M ) was denatured i n 4 M 
guanidine.HCl in 0.1 M phosphate buffer (pH 7.0) (495 µl), 
and then NADH (10 µl, 0.8 µM) was added. The fluorescence 
emission spectra showed no quenching due to NADH-(denatured 
DHPR) binding (Figure 6, p 53). 
iii) Thermally denatured DHPR (at 37°c for 24 hand 45°c 
for 21 h~ 10 µl, 0.14 µM) was dissolved in 0.1 M phosphate 
buffer (pH 7.2) (490 µl) and then incubated with NADH (10 
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µl, 0.8 µM). The fluorescence spectra showed no quenching 
based on NADH binding to DHPR (Figure 7, p 54). 
iv) DHPR (DTT free) (5 µl) was denatured in 4 M. urea in 
0.1 M phosphate buffer (pH 7.6) (595 µl) at 200c and the 
fluorescence spectra were scanned. The emission maximum 
shifted with time to longer wavelength and with decreasing 
fluorescence (Figure 8, p 55). 
2-9-8 Cysteine estimation 
A: DTNB 
DTNB solution for the estimation of -SH groups in 
non-denatured enzyme was made from DTNB (40.68 mg) in 0.1 M 
potassium phosphate buffer (pH 7.0, 10 ml). Dialyzed DHPR 
(DTT free) (150 µl, 9.96 µM) was dissolved in 0.1 M 
potassium phosphate buffer (pH 7.2) (100 µl) and the above 
10 mM DTNB solution (pH 6 .8) ( 30 µl, final concentration 
1.07 mM) was added and then this mixture was incubated at 
The absorbance changes at 412 nm were measured with 
a single beam spectrometer and the reaction was complete 
after 4.5 h. Blank incubations were carried out with 0.1 M 
potassium phosphate buffer ( pH 7. 2) instead of DHPR 
solution. The change of absorbance due to the protein-DTNB 
reaction was 0~135 O.D. and this was calculated as 1.0 
cysteine residue by using 13,600 M- 1 .cm- 1 as the extinction 
coefficient for the released TNB anion. 
Concurrently, the enzyme activity was measured at 
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intervals of time by assaying aliquots ( 1 µl) from the 
incubation cuvette. No change ,in enzyme activity was 
observed during the first 5.3 h of incubation. 
The estimation of total -SH groups . 1n DHPR was 
carried out by incubating DHPR (DTT free, 50 µl, 4.2 µM) 
with 10.3 mM DTNB (pH 7.0) (5 µl, final concentration 0.24 
mM) in 8 M guanidine.HCl in 0.1 M phosphate buffer (pH 7.0) 
(150 µl) at 210c. The blank experiment was carried out 
with 0.1 M potassium phosphate buffer (pH 7.2) (50µ1) 
instead of enzyme solution. The absorbance at 412 nm 
started to decrease soon after mixing, because of the 
released TNB anion. Under the same conditions, 10.3 mM 
DTNB (pH 7.0) (200 µl, final concentration 5 mM) was 
incubated with DHPR (DTT free, 50 µl, 2.2 µM) in the above 
buffer (pH 7.0) (150 µl) and this revealed the presence of 
. 
3.5 cysteine residues per DHPR subunit. 
DHPR (DTT free, 75 µl, 5.1 µM) was pre-incubated 
with 4 mM NADH in 50 mM phosphate buffer (pH 7.2) (10 µl, 
140 µM) and 0.1 M potassiumm phosphate buffer (pH 7.2) (180 
µl) for 5 min at 210c and then mixed with 10 mM DTNB (pH 
6. 8) ( 15 µl, final concentration 536 µM'). This was 
incubated for 4.4 h and gave a value of 1.4 cysteine 
residues per subunit. The enzyme activity was examined 
from time to time by taking aliquots (1 µl) from the 
incubation cuvette and ca 34% enhancement of DHPR activity 
was observed (no time dependent loss of enzyme activity was 
not iced) . The blank incubation was carried out by using 
0.1 M potassium phosphate buffer (pH 7.2) (255 µl) and the 
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corresponding NADH solution (10 ul). 
B: PCMB 
Stock solution : PCMB (9.1 mg) and 0.04 M NaOH (1 
ml) were diluted to 25 ml with water and this was 
kept in dark at room temperature. 
Solution A : The above stock solution ( 2. O ml) 
was diluted to 25 ml with 50 mM potassium phosphate 
buffer (pH 7.0). The solution was centrifuged prior 
to use to remove any precipitate formed. 
Solution B : The stock solution (2.0 ml) was 
diluted to 25 ml with 0.33 M sodium acetate buffer 
(pH 4. 6) • The solution was centrifuged . prior 
to use to remove any precipitate formed. 
i) Standardization with glutathione 
Glutathione stock solution was freshly prepared by 
dissolving glutathione ( 20. 3 mg) in water ( 10 ml). PCMB 
solution (1 ml of the solution A or B) was placed in the 
cuvette and corresponding buffer ( 1. 0 ml) in the blank 
cuvette. The titration was carried out by delivering 
stock glutathione solution to both cuvettes and mixing with 
a glass rod. The absorption was measured at 250 nm for the 
pH 7 . 0 buffer or a t 2 5 5 nm for the pH 4 . 6 buffer . The 
observed absorbanc8s were corrected for dilution and 
plotted against the concentration of glutathione added. 
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ii} Determination of total thiol groups 
DHPR (DTT free, 50 µl, 840 pmol) in 0.33 M sodium 
acetate buffer (pH 4.60) (250 µl) was placed in one cuvette 
with 0.1 M potassium phosphate buffer (pH 7.2) (50 µl) in 
0.33 M sodium acetate buffer (pH 4.60) (250 µl) in the 
blank cuvette at 250c. These two cuvettes were titrated 
with solution B, 36.3 µM PCMB, (10 µl aliquots) and the 
changes at 255 nm were observed. This estimated 2.8 -SH 
groups per enzyme subunit. Moreover, the same experiment 
was carried out in the O. 33 M sodium acetate buff er ( pH 
4. 6) which contained 2% of SDS. In this case 2. 9 -SH 
groups were estimated per DHPR subunit. 
iii) Determination of active thiol groups 
DHPR (DTT free, 50 µl, 840 pmol) in 50 mM 
potassium phosphate buffer (pH 7.0) (250 µl) was placed 1n 
a cuvette, and 0.1 M potassium phosphate buffer (pH 7.2) 
( 5 0 µ 1 ) i n 5 0 mM p hosp hate buffer ( pH 7 • 0 ) ( 2 5 0 µ 1 ) was i n 
the blank cuvette at 250c. The titration was carried out 
with solution A, 74.5 µM PCMB, (3 µl aliquots) (Figure 11, 
p 62). This revealed ca 3.2 to 3.3 -SH per enzyme subunit. 
The enzyme activity was assayed at the same time by taking 
aliquots (3 µl) of solution from the cuvettes; the activity 
decreased after the second -SH group was titrated. The 
enzyme activity was not restored after dialyzing this 
incubation solution against 50 mM phosphate buffer (200 ml 
x 3) for 18 hat 4°c. 
When DHPR (DTT free, 50 µl, 3.2 µM), NADH (100 µl, 
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4 5 . 5 JJ M ) and 5 0 mM p hosp hate buffer ( pH 7 . 0 ) ( 15 0 µ 1 ) were 
placed 1n the experimental cu vet te, and O .1 M phosphate 
buffer (pH 7.2) (50 µl), NADH (100 µl, 45.5 µM) and 50 mM 
phosphate buffer (pH 7.0) (150 JJl) were in the blank 
cuvette, and those were titrated with solution A (using 4 
µl aliquots), no PCMB reacted with DHPR. This absence of 
colour change might be due to the low protein concentration 
(3.2 µM). Because in the case of DTNB one -SH was titrated 
under NADH protection, so also 1n the case of PCMB 
reaction, at least one -SH should be titrated. The enzyme 
activity was unaltered at the end of the PCMB titration. 
C: NTCB 
The buffer and reagent solutions were flushed with 
nitrogen gas prior to use. 
i) Non-denatured enzyme 
DHPR (DTT free, 50 µl, 840 pmol) was incubated 
with 10 mM NTCB solution ( in O .1 M phosphate buffer, pH 
7.2) (100 µ1) and ().1 M phosphate buffer (pH 7.2) (150 µl). 
The blank cuvette contained 10 mM NTCB solution ( 100 µl) 
and 0.1 M phosophate buffer (pH 7.2) (200 µ1). The 
absorbance changes at 412 nm were measured with a single 
beam spectrometer at 23°c. The total absorbance change was 
0.038 O.D. which indicated 0.9 -SH per subunit when using 
13,600 M-1.cm- 1 as the extinction coefficient for the TNB 
anion. 
When the incubation was carried out with DHPR 
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(DTT free, 200 JJl, 6.6 JJM), NTCB (40 JJl, 1.4 mM) and 0.1 M 
potassium phosphate buffer (pH 7.2) (50 JJl), ca 0.5 -SH per 
subunit was estimated. The enzyme activity was measured at 
the same time, but no inactivation by NTCB was observed. 
ii) Denatured enzyme 
DHPR (DTT free, 25 JJl, 0.96 JJM) was incubated with 
10 mM NTCB solution (25 JJl) and 8 M guanidine.HCl (in 1.3 
mM EDTA and 0.1 M phosphate buffer, pH 7.2; 200 JJl) and the 
blank experiment was carried out with the corresponding 
phosphate buffer in place of enzyme. This experiment also 
rev ea 1 e d ca one - SH per subunit but the enzyme was s t i 11 
active (80%). 
conditions. 
DHPR was only partly denatured under these 
2-9-9 Stoichiometry of NADH and DHPR 
A: Fluorescence titration 
i) DHPR (DTT free, 30 JJl, 204 pmoles of active subunit) 
was diluted with 0.1 M potassium phosphate buffer (pH 7.2) 
(470 JJl) and titrated with 13.9 JJM NADH (2 JJl aliquots) at 
23 °c. The changes [excitation at 280 nm (slit 5 nm) J were 
observed at 470 nm (slit 10 nm). The blank titration was 
carried out using O .1 M phosphate buffer (pH 7. 2) ( 500 JJl) 
instead of the DHPR solution. The changes in fluorescence 
were plotted against NADH concentration. At the sharp 
change in slope 155.7 pmoles of NADH were consumed. From 
11 1 
IU 
' 
II 
!I 
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this result, the stoichiometry of the DHPR subunit and NADH 
was 1.3 : 1, i.e. -1 : 1. 
ii) DHPR (DTT free, 10 111, 68 pmol of active subunit) 
was diluted with 0.1 M potassium phosphate buffer (pH 7.2) 
(490 111) and mixed with S-mercaptoethanol (35 µl, 1 mM) and 
then titrated with 40 µM NADH (1 µl aliquots) at 200c. The 
relative fluorescence changes were observed at 470 nm (slit 
10 nm) with excitation wavelength at 280 nm (slit 5 nm). 
The blank was carried out with corresponding buffer. At 
the sharp change in slope, 54 pmoles of NADH were consumed. 
From this, the stoichiometry of DHPR subunit and NADH was 
1.3: 1. 
B: Dissociation constant of the DHPR - NADH complex 
DHPR (DTT free, 10 µl, 80 pmoles) was diluted with 
0.1 M potassium phosphate buffer (pH 7.2) (500 µl) and 
titrated with 48 µM NADH at 230c. The fluorescence 
(excitation at 280 nm, slit 5 nm) was observed at 470 nm 
( s 1 it 1 0 nm ) • The observed fluorescence changes at the 
various volumes of added NADH solutions were computed using 
a programme which was kindly supplied by Dr J.F. Morrison. 
The calculated Kd value obtained was 13.8 ± 3.2 nM. From 
this Kd value the protein concentration was re-calculated 
as 74.1 ± 1.6 nM by using the following equation; 
11 
I 
II 
I! 
ii 
b 
' 
l 
II 
i: 
·, 
I 
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q>(<p + 1) 
where Et is total protein concentration, Lt is total ligand 
concentration, Kd is dissociation constant and cp = (Fa - F) 
/ ( Fa F ) (cf. reference 120). 00 Where Fa is the 
fluorescence of the free NADH, F is observed fluorescence 
and F is the fluorescence of the enzyme-NADH complex. 00 
The protein concentration which was estimated from 
the Bio-Rad microassay was 160 nM, but at the time of the 
present experiment the enzyme activity had decreased by ca 
50%. From a previous experiment [ 2-9-9 (A), p 88], it is 
known that NADH can bind only to the active DHPR and 
produce a change in fluorescence. Thus the real active 
enzyme concentration . 1s ca 80 nM · ( 160/2 nM) which is in 
good agreement with the value obtained from the above 
estimation. 
CHAPTER 3 
NEW PTERIDINE SUBSTRATES FOR -DIHYDROPTERIDINE REDUCTASE 
- 92 -
3-1 Introduction 
The natural cofactor of dihydropteridine 
reductase, quinonoid L-erythro-7,8-dihydro(6H)biopterin 
[lJ, can be replaced by simple alkylpterins, e.g. quinonoid 
6-methyl-7,8-dihydro(6H)pterin [ 2 ] and quinonoid 6,7-
dimethyl-7,8-dihydro(6H)pterin [3J and still exhibit enzyme 
2 2 
activity. These synthetic cofactors are formed 
0 H O H 
N~N'f-CHOHCHOHCH3 N~:t CH, 
H,N.llNJ:...N..+H H N.(N~wJ.f-·H 
H H 2 H H 
[ 1] [2] [3] 
quantitatively from the respective 5,6,7,8-tetrahydro-
·pterins at physiological pH by oxidation. The most 
commonly used method for generating quinonoid dihydro-
pterins for assaying dihydropteridine reductase is that of 
9 
Nielsen et al. which involves oxidation with peroxidase 
and hydrogen peroxide. 
The structures of the quinonoid dihydropter ins 
produced by the different oxidants and by the aromatic 
7 3 
amino acid hydroxylases are the same, and have been the 
subject of several studies. Quinonoid dihydropterins can 
exist in three tautomeric forms [4J, [SJ and [6J in aqueous 
6 8 
solution at near neutral pH. Kaufman proposed the para-
1 2 3 
quinonoid structure [SJ after a suggestion by Hemmerich, 
and presented good evidence for the structure of the 
- 93 -
pyrazine moiety [ 5 J • He reported that quinonoid 2-
alkylamino-6,7-dimethyl-7,8-dihydro(6H)pterins exhibited 
N~Ni-R H NJl.N~ N~ R' 2 H H 
[4] [5] 
HN~NtHR HN~N.hN R' 
2 H 
[6] 
pronounced bathochromic shifts of 15 ,.., 20 nm, whereas no 
such shifts were observed in an 8-alkylated derivative. 
However, no 3-alkylated derivatives were included in the 
7 l 
studies. Gready proposed the ortho quinonoid structure 
[ 6] as a possible active substrate by . comparing the 
energies of each tautomer using theoretical methods. The 
kinetic evidence showed that the tautomer with the endo-
cyclic double bond, i.e. tautomer [4] was the reactive 
tautomer. 72 For example, Armarego and Waring found that 
the rates of aerobic oxidation of compounds [7] and [8) 
HN:.r~) 0 H H,C,N:\~J H:t)::J HC-N~N N H2N.J::::: N N 
3 I H 2 I H CH 3 CH3 
[7] [8] [9] 
were faster compared with compound [9], because of 
s tabi 1 i zat ion of the initial radical cat ion intermediate 
[10] leading to cation [11]. Such stabilization does not 
occur in the 3-unsubstituted pterins [7] and [8] because 
the radical cation would be deprotonated at the neutral pH 
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(9] [10] 
HC"N~N) 
H
3 
N.ll N~N 
2 H 
[11] 
by loss of H+ from N3. 
mechanism should produce 
The authors proposed that such a 
the quinonoid . species with the 
ortho structure [ 4] and not [ 5] or [ 6] . In the 3-methyl 
compound [9], a positive charge will be generated at N-3 to 
give the quinonoid pterin [11] which should rearrange to 
the corresponding 7, 8-dihydro ( 3H) pterins much faster than 
the corresponding quinonoid pterins derived from the other 
pterins [7] and 
l 3 
1H NMR studies 
[ 8 ] • 72 This was observed experimentally. 
also excluded the presence of structure 
[6], although the smaller amounts (-30%) of exocyclic 
tautomer [5] could not be excluded in the tautomeric 
74 
equilibrium (see Chapter 1, p 19). Benkovic et al. later 
used isN NMR spectroscopy to demonstrate clearly that 
tautomer [4] was the major species, whereas tautomer [6] 
7 3 ( b) 
could not be detected 1n the 1 H NMR spectra (see 
Chapter 1, p 20). 
The present work shows that the predominant 
tautomer [4] in neutral aqueous medium is the enzyme active 
tautomer. For clarity the quinonoid pteridine structures 
in this chapter have been written in this tautomeric form, 
e.g. [1], [2] and [3]. 
Apart from the pterins, several oxidized 
pyrimidines have been reported as substrates of DHPR, for 
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47 124 125 
example 2,6-diamino-5-iminopyrimidin-4-one [12], ' ' 
1 0 
2,6-diamino-5-benzyliminopyrimidin-4-one [13] and 2,6-
1 0 4 7 d iaminopyrimidin-4, 5-dione [ 14]. Armarego et al. 
[12] (13] [14] 
concluded that the ethylene bridge joining N-5 to N-8 1n 
the normal pterin substrate is not absolutely necessary for 
substrate activity, but the saturated bridge between the 
two nitrogen atoms in pterins does aid binding to the 
active site of the enzyme. 
However, the predominant tautomer in solution is 
not necessarily the structure that is enzymically active. 
It was therefore argued that if the quinonoid substrate has 
the tautomeric structure [4], then the quinonoid dihydro-
pteridines [15] to [17], derived from the respective 
5,6,7,8-tetrahydropteridinone derivatives, which do not 
have the 2-amino group, should also be substrates for DHPR. 
[15] 
0 
N~N'f-cH, 
lJ.NJ..N~H 
H H 
(16] [17] 
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To deduce the tautomeric structure of the substrates at t h e 
active site, a study was made of the substrate activities 
of the quinonoid dihydro compounds obtained by oxidation 
of the 5,6,7,8-tetrahydropteridin-4(3H)-ones (18] to [25], 
-
and of the related thioxo and methylthio compounds (26] t o 
[ 2 9 J • 
0 
HN 
R~N 
s 
HN 
H 2N~N 
(26] 
0 
HN 
H,CS~N 
[28] 
H R2 
N R3 
N R4 
H Rs 
H H 
N CH 3 
N 
CH 3 
H H 
H _H 
N 'j'-CH 
N+CH: 
H H 
[ 18] H 
[ 19] H 
[20] H 
[ 21] H 
[ 2 2] H 
[23] H 
[24] Me 
[25] MeNH 
0 
HN 
S~N 
H 
0 
HN 
H,CS~N 
H H H H 
D D D D 
Me H H H 
Me D H D 
Me H Me H 
Me D Me D 
Me H Me H 
Me H Me H 
H H 
... 
NtCH, 
• CH 3 
N -H .... H 
(27] 
(29] 
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Most of the tetrahydro compounds used have been synthesized 
for this work. Also, the quinonoid oxidation products of 
6,8-dimethyl-5,6,7,8-tetrahydropterin [ 3 0] , 6,6,8-tri-
1 2 6 
methyl-5,6,7,8-tetrahydropterin [31], 6-methvl-5 6 7 8-
- ' ' ' 
0 0 
H CH3 H CH 3 N 
HN H HN NtCH, 
H2N~ N , HN~N N N I 2 I 
CH3 CH3 [30] [31] 
tetrahydrolumazine [32] and the related pyrimidinone 
derivative, 4,5-diaminopyrimidin-6(1H)-one 
examined as substrates for DHPR. 
[33] were 
0 0 H CH 3 
HN N NH 2 H 
O~N 
HN 
N 
~N NH2 H H 
[ 32] [33] 
3-2 Syntheses of pteridin-4(3H)-one derivatives 
3-2-1 Unsubstituted-, 6-methyl- and cis-6,7-dimethyl-
5,6,7,8-tetrahydropteridin-4(3H)-ones and their deuteriated 
derivatives [18] to [23] (Scheme 1) 
Pteridin-4(3H)-one [35] which was prepared by 
l. 2 7 
following the method of Albert et al. could not be 
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reduced catalytically with pre-reduced platinum oxide 1n 
trifluoroacetic acid, or with Raney nickel in ethanol; 
This was found not to be due to poisoning of the catalyst 
by traces of sulphur from the intermediates because the 
reduct ions were unsuccessful with rigorously purified 
pteridinone, and when large excesses of catalyst were used. 
No satisfactory explanation for this failure could be 
presented other than severe poisoning of the catalysts by 
traces of reduced intermediates. Reduct ion to the 
tetrahydro derivative with sodium borohydride was, however, 
successful (cf. reference 128). Similarly [6,6,7,7-D4 ]-
5,6,7,8-tetradeuteriopteridin-4(3H)-one [19] was prepared 
by . using [1,2-D 2 ]-glyoxal bis-(sodium bisulphite) to 
synthesize 6, 7-dideuteriopteridin-4 ( 3H) -one which was 
reduced with sodium borodeuteride in D2 0. 
l 2 9 
6-Methylpteridin-4(3H)-one [37], on the other 
hand, gave the reduced derivatives [20] and [ 21 J on 
hydrogenation with platinum oxide 1n methanol and by 
reduction with sodium borodeuteride in D2 0 respectively. 
In the former case, however, when the reduction was carried 
out in trifluoroacetic acid and stopped after two 
equivalents of hydrogen were absorbed, a mixture of tetra-, 
[ 2 0] , and hex a - , [ 38] , hydropteridi none was produced. 
0 
[38] 
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~N!..lN~H 
[35] 
l NaBH, 
HN~~l~ H 
~N~N =.H 
H H 
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O H D 
\)::1: 
H i5 
[19] 
[33] 
l 
[36] 
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HN 
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H H 
cis c22J 
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Scheme 1 
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The pure hexahydro derivative [38] was obtained by allowing 
reduction to proceed to completion. Alternative structures 
for the fully reduced product, such as the ring-opened 
cations of N-methyltetrahydropyrazines [39] or [40], or 
0 0 
H 2N ~tc:, 
HN N 
I H 
CH3 
H C-N 
3 H 
N 
H2 
[ 39) (40] 
the N-hydroxymethyltetrahydropyrazines 
~tc:, 
N 
H 
[41] or [42] 
derived from the bicyclic compound (38] by ring cleavage, 
0 0 
H 2N ~tc=, HOH 2C-N ~tc:, H 
N HN N N 
I H H2 H 
CH 20H 
(41) (42] 
were excluded on the grounds that the l H NMR spectra in 
acidic solution (Figure 1) had proton integrals consistent 
with two (cf. [38]) and not three protons for the singlet 
at 4. 99 ppm (excluding [39] and [40]); compare with the 
singlets of the two H-2 protons in the spectra of the 
neutral species of cis- and trans-l,2,4a,5,6,7,8,8a-
octahydroquinazolin-4 ( 3H) -one [ 43] which were at 4. 30 and 
l 3 0 
4.33 ppm. Moreover, the 1 3c NMR (Figure 2, C-4a which 
usually appears as very weak signal at ~98 ppm could not be 
seen after 4,600 transients) signal from C-2 was at 52 .1 
0 
HN H* H N H 
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H 
(43] 
H 
H 
ppm and is cons is tent with the -HNCH 2 NH- structure [ 38] 
rather than -HNCH 2 0H structures such as [41] and [42]. 
This deduction was made from the known 13 c chemical shifts 
of 6-aminohexan-1-ol where the signals from C-1 and C-6 
1 3 i 
were at 62.9 and 43.2 ppm respectively. The model shows 
that the oxygen atom adjacent to a methylene carbon atom 
deshields it much more strongly than an adjacent nitrogen 
atom. The value of 52.1 ppm observed cannot be reconciled 
·with a -HNCH 2 0H structure. 
cis-6,7-Dimethyl-5,6,7,8-tetrahydropteridin-4(3H)-
one [22] was prepared as the hydrochloride salt by 
catalytic hydrogenation of the respective pteridinone . 1n 
acidic medium and allowed to proceed to completion. The 
c1s stereochemistry at C-6 and C-7 was deduced from the 
small H-6, H-7 coupling constants (cf. reference 132) . 1n 
the 1 H NMR spectra (Figure 3). 6,7-Dimethyl-[6,7-D2 ]-
5,6,7,8-tetrahydropteridin-4(3H)-one [23] hydrochloride was 
similarly prepared by catalytic hydrogenation with D2 gas. 
0 
H-2 
H-6 
i 
5 4 
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8 7 
N 
H 
3 
6-CH3 
2 1 ppm 
Figure 1. l H NMR spectrum of 6-methyl-2, 3, 5, 6, 7, 8-hexa-
hydropteridin-4 ( 3H) -one (38] in 1 M DCl at 90 MHz. 
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C-2 
C-7 
ic-6 
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0 
6-CH3 
20 ppm 
H CH3 ~~H 
s) 
N 
H 
Figure 2. 13c NMR spectrum of 6-methyl-2,3,5,6,7,8-hexa-
hydropteridin-4(3H)-one (38] [A proton coupled (8,700 
transients); B proton decoupled (4,600 transients)] in D2 0 
at 90 MHz. 
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3-2-2 cis-2,6,7-Trimethyl-5,6,7,8-tetrahydropteridin-
4(3H}-one (24] 
2,6,7-Trimethylpteridin-4(3H)-one [45] was 
prepared from 4, 5-diamino-2-methylpyrimidin-6 ( lH) -one [ 44] 
l 3 3 
sulphate and diacetyl, and further reduced catalytically 
w it h p 1 at i nu m ox id e to form c i s - 2 , 6 , 7 -tr i met h y 1- 5 , 6 , 7 , 8 -
0 0 HN:x~1Me HNJNH2 HN~N:r• Pt02/H2 
Me~N I NH2 Me~N I N., Me 3M-HCI Me~N j N =- Me H H 
• [44] [45] CIS [24] 
Scheme 2 
tetrahydropteridin-4(3H)-one [24] hydrochloride (Scheme 2). 
This stereochemistry was deduced from the lH NMR 
spectrum (cf. reference 132) ( Figure 4). The spectrum did 
not contain signals of the trans isomer. 
3-2-3 cis-6,7-Dimethyl-2-thioxo-3,4,5,6,7,8-hexahydro-
pteridin-4(1H)-one [27] 
6,7-Dimethyl-2-thioxo-2,3-dihydropteridin-4(1H)-
l34 135 
one [46] ' (which was prepared by the condensation of 
4,5-diamino-2-thioxopyrimidin-6(1H)-one and diacetyl), was 
reduced to the cis-hexahydro derivative [27] (see 1H NMR 
spectrum, Figure 5) with excess sodium borohydride (Scheme 
0 
HN3 
~1 
N 
H 
H H N ..... 
s ).:. CH 3 
s 7 CH N ... 3 
H -H 
H-2 
I 
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Figure 3. 1H NMR spectrum of cis-6,7-dimethyl-5,6,7,8-
tetrahydropteridin-4{3H)-one (22] ~o.s M DC1 at 90 MHz. 
0 
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Figure 4. lg NMR spectrum of cis-2,6,7-trimethyl-5,6,7,8-
tetrahydropteridin-4(3H)-one [24]°"in D20 at 90 MHz. 
- 106 -
3). However, when it was reduced catalytically with 
~~~+Me 
S~N~NkMe 
H H H 
CIS 
[46] (27] 
Scheme 3 
platinum oxide in methanol, 3 M hydrochloric acid or 
trifluoroacetic acid, hydrogen uptake was not complete and 
the corresponding 6,7-dirnethyl-2-thioxo-3,4,7,8-tetra-
hydropteridin-4(1H)-one [47] was formed. This 7,8-dihydro 
0 CH3 
N 
HN 
S~N N CH 3 
H H H 
(47] 
structure [ 4 7] was deduced from the NMR spectrum (cf. p 
168) and by analogy with the incomplete catalytic reduction 
products of related pteridines which were known to form the 
more stable 7,8-dihydro derivatives compared with the 5,6-
or 5,8-dihydro derivatives. 
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6-, 7-CH3 
0 
HNJ 
~1 S N 
H 
H H N .... 
s ~- CH3 
s 7 CH N .. _ 3 
H ""'H 
H-6 7 
' J i TPS TPS 
3 2 1 ppm 
Figure 5. lg NMR spectrum of cis-6, 7-dimethyl-2-thioxo-
3, 4, 5, 6, 7 ,8-hexahydropteridin-4 ( 1H)-one [27] in 0.01 M NaOD 
at 90 MHz. 
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3-2-4 2-Amino-6,7-dimethyl-5,6,7,8-tetrahydropteridin-
4(3B)-thione [26] (Scheme 4) 
cis-trans 
(49] (48] [26a] 
CIS [26b] 
Scheme 4 
Unlike previous reactions where the cis-isomers 
were formed exclusively, the reduction of 2-amino-6,7-
dimethylpteridin-4( 3H)-thione [48] (which was synthesized 
by condensation of 2,5,6-triaminopyrimidin-4(3H)-thione 
[49] and diacetyl), with a large excess of sodium 
borohydride resulted in a 1. 6 
trans . isomers [26a] ( Figure 6) . 
• . 1. 0 mixture of . cis and 
These reduced pteridines 
could not be obtained completely free from borate and the 
stereo isomers were not separated. This mixture of cis and 
trans . isomers was used for the . enzym1c assays. In an 
attempt to obtain preparations free from borate the 2-
amino-6,7-dimethylpteridin-4(3H)-thione [48] was reduced 
catalytically with platinum oxide in methanol. This gave 
only the cis-5,6,7,8-tetrahydro derivative [26b] (by 1 H 
NMR) (Figure 7). Similar reduction in trifluoroacetic acid 
s 
H H 
N CH 3 
8 CH 3 N 
H H 
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Figure 6. LH NMR spectrum of the mixture of cis- and 
trans-2-amino-6,7-dimethyl-5,6,7,8-tetrahydropteridin-
4(3H)-thione [26a] in 2 M DCl at 270 MHz. 
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8 7 
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Figure 7. 1 H NMR spectrum of cis-2-amino-6,7-dimethyl-
5,6,7,8-tetrahydropteridin-4(3H)-th10ne [26b] hydrochloride 
in D2o at 90 MHz. 
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yielded a 2.3 : 1.0 mixture of cis and trans isomers. The 
sharp signals in the 1 H NMR spectra of these products were 
an indication that these compounds were free from platinum 
or platinum complexes. 
3-2-5 cis-6,7-Dimethyl-2-methylthio-5,6,7,8-tetrahydro-
pteridin-4(3H)-one (28] and the deuteriated derivative 
(29] 
6,7-Dimethyl-2-thioxo-2,3-dihydropteridin-4(1H)-
one [46] (see Section 3-2-3, p 104) reacted with methyl 
iodide and formed 6,7-dimethyl-2-methylthiopteridin-4(3H)-
one [50]. This preparation of the 2-methylthio derivative 
134 136 [50] was different from before. ' It had been 
previously prepared by the condensation of 2-methylthio-
pyrimidin-4(3H)-one and diacetyl. Catalytic hydrogenation 
of this 6,7-dimethyl-2-methylthiopteridin-4(3H)-one [50] 
with platinum oxide in trifluoroacetic acid gave 7,8-
dihydro derivative. When the solvent was methanol or (D4 )-
methanol (with deuterium gas) reduction was complete and 
the cis derivatives [28] (Figure 8) and [29] were obtained 
respectively. Also the reduction with sodium borohydride 
in iso-propanol gave the same cis-tetrahydro derivative 
[ 2 8] • These compounds were soluble in chloroform which is 
unusual for oxo-pteridines (Scheme 5). 
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Figure 8. Lg NMR spectrum of cis-6, 7-dimethyl-2-methyl-
thio-5, 6, 7, 8-tetrahydropteridin-4 ( 3H)-one [28] in CDC1 3 at 90 MHz. -
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3-3 The assay 
3-3-1 Rearrangement of quinonoid pteridines 
Prior to measuring the kinetic parameters, it is 
important to ascertain that these pteridines and 
pyrimidines form quinonoid tautomers at neutral pH, because 
only the quinonoid . species are substrates for DHPR (see 
Chapter 1, p 16). Normally, the UV spectra of the 
quinonoid species of pterins can be observed after treating 
the tetrahydropterin with peroxidase and hydrogen peroxide. 
These quinonoid species are not stable and rearrange to the 
respective 7,8-dihydro(3H) compounds (tautomers) which are 
22 
not substrates any more for DHPR (Figure 9). 
The 5,6,7,8-tetrahydropteridin-4(3H)-ones [ 18 J , 
l 2 8 [20] and [22] which have pKa values of ca 3.8 do not 
undergo aerobic oxidation in aqueous buffer at ca pH 7 as 
readily as the more strongly basic 5,6,7,8-tetrahydro-
137,.,,,140 
pterins which have pKa values of ca 5.5, even though 
they exist mainly as neutral species. In this solution the 
pteridinones [18), [20] and [22] show no changes in the UV 
spectra during 1 h. Addition of 50 - 70 molar equivalents 
of hydrogen peroxide causes changes in the spectra, but 
they are too slow ( less than 5% change in 10 min) for 
deriving kinetic parameters. However, when peroxidase and 
hydrogen peroxide were added together very rapid spectral 
changes occurred (Figure 10). The spectral changes for 
each compound were slightly different, but all 
Figure 9. UV 
tetrahydropterin 
200 
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Figure 10. UV spectra of 6-methyl-5,6,7,8-tetrahydro-
pteridin-4{38)-one (20] after treatment with peroxidase and 
hydrogen peroxide in 0.1 M Tris/BCl buffer, pH 7.4 at 2soc. 
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showed the same pattern. Finally after 24 h the main UV 
absorbing band disappeared leaving a very weak band at long 
wavelength (approx. 380 nm). These spectral changes are 
very similar to those observed with 4,5-diamino-pyrimidin-
6(1H)-one [33] and 2,4,5-triaminopyrimidin-6(1H)-one [54] 
under the same conditions. The latter is known to give the 
quinonoid pyrimidine [12], which is a good substrate for 
0 0 
NH 2 NH 
HN N 
HN~N 2 NH 2 H2NJlN NH 2 
[54] (12] 
l 4 l 
DHPR. The spectral changes of the quinonoid pteridin-
4(6H)-ones (rearrangement and decomposition, cf. Figure 10) 
were found to obey first-order kinetics for more than 85% 
of the reaction, and the half-lives are listed in Table 1. 
These first order rate constants were measured with a 
single beam spectrometer at a fixed wavelength. In the 
. pterin series, the rearrangement of quinonoid species 
occurs readily and is subject to general acid-base 
catalysis. It was also shown that when H-6 in alkylpterins 
(Scheme 6, p 116, for example) was replaced by deuterium 
then the rate of rearrangement of quinonoid species [55] to 
the 7 ,8-dihydro derivatives [56] in Tris/HCl buffer at ca 
pH 7 was subject to large deuterium isotope effects ( i . e . 
142 l 4 3 
kH/kD values as large as 10) . , The respective 6,7-
dideuteriated pteridinone derivatives of [ 18] , [ 2 0] and 
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Table 1. First order rate constants for the changes 
subsequent to oxidation of compounds, (18], [20], (22] and 
(33], at 2soc. 
Runs contained: buffer ( 100 µl), substrate ( 100 
µl), H2 0 2 (100 µl, 11 µmol) and water (600 µl), and the 
reaction was initiated with peroxidase (100 µl, cf. p 174). 
a: In 0.1 M Tris/HCl buffer, pH 7.4; b: In 0.1 M Bicine 
buffer, pH 7.0; c: In 0.3 M potassium phosphate buffer, pH 
7.1; d: In 0.1 M Bicine buffer, pH 6.7. 
5,6,7,8-tetra-
hydropteridin- buffer kobsxl03 
4(3H)-one t112 
cone. \analyt. 
- (sec- 1 ) (min) ( µM) (nm) 
Unsubstituted [ 18] a 5.0(±0.08) 2. 3 149 289 
6-Methyl- [20] a 2.1(±0.02) 5. 6 143 290 
b 1.9(±0.02) 6.0 117 290 
C 0.8(±0.01) 13.9 117 290 
6,7-Dimethyl- [ 2 2] a 2.1(±0.04) 5.5 172 292 
b 1.2(±0.01) 9.6 166 292 
C 0.4(±0.01) 29.4 166 292 
4,5-Diamino-
pyrimidin- a 6.1(±0.01) 1. 9 282 190 
6(1H)-one [ 3 3] d 
-
8.2(±0.01) 1.4 282 190 
C 7.1(±0.08) 1. 6 282 190 
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0 0 
H(D) CH3 N N N CH3 HN 
HNJlN 
... 
H2N~N 
D D N N 2 H H H H 
(55] [56] 
Scheme 6 
[ 2 2] , . 1 • e. [ 19] , (21] and (23] were synthesized and the UV 
spectral changes immediately after oxidation with 
peroxidase and hydrogen peroxide were examined. These were 
identical with those of the respective protio compounds 
(cf. Figure 10, p 113). Direct comparison revealed no 
deuterium isotope effects (Table 2), and the quinonoid 
d ihydro ( 6H) pteridinones formed clearly did not rearrange 
smoothly to the corresponding 7, 8-dihydro( 3H) derivatives 
as occurred in the respective pterins. The absence 
of isotope effects from the measurements of compounds [18] 
to (23] indicates that after oxidation to the quinonoid 
species these pteridinones are undergoing decomposition 
more rapidly than the usual rearrangement. The observed 
spectral changes for the pyrimidinone [33] were faster in 
comparison (cf. Table 1) . The spectral changes observed 
after oxidation of compounds [18], [20], (22] and [33] were 
faster in Tris/HCl buffer (pH 7 .3) than in Bicine buffer 
(pH 7.0) or in phosphate buffer (pH 7.0) (Table 1), whereas 
in general pterin derivatives rearranged faster 1n 
143 144 
phosphate buffer than in Tris buffer. ' These 
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Table 2. Deuterium isotope effects subsequent to oxidation 
of tetrahydropteridines in 0.1 M Tris/HCl buffer {pH 7.4) 
at 2s 0c. 
10 3 k8 /min- 1 10 3 k0/min- 1 ke/ko 
5,6,7,8-tetra-a 
hydropteridin-
4(3H)-ones 
Unsubstituted (18] 297 371 0.8 
6-Methyl- (20] 124 126 1.0 
6,7-Dimethyl- [ 2 2] 127 139 0.9 
2-Methylthio-
6,7-dimethyl- [28] 0.75 0.04 18.8 
5,6,7,8-tetra-b 
hydropterins 
2-Arnino- * 
6-methyl- 21.3 2.18 9. 8 
6,7-dimethyl- [ 5 2] 58.7 6.30 9. 3 
6,7,7-trimethyl- 38.9 3.35 11. 6 
* These values are from reference 22 
a Only traces of quinonoid 7,8-dihydropteridin-4 ( 6H) -
ones are formed in these cases. 
b 7,8-Dihydro(6H)pterins are formed almost exclusi ve ly . 
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differences could be expected because 1n the case of 
compounds [18], [20] and [22] the decompositions (in which 
cleavage of the C-H(D) bond at C-6 is not rate limiting) 
were the major contributors to the observed rates and not 
the rearrangements. 
When the experiment was extended to a variety of 
substituted pteridines, [24] to [ 3 2] , the respective 
quinonoid species were formed by oxidation with peroxidase 
and hydrogen peroxide or potassium ferricyanide ( 3 - 10 
equivalents). Potassium ferricyanide was used as oxidant 
for DHPR assays in these cases, because the oxidation of 
2,6,7-trimethyl-5,6,7,8-tetrahydropteridin-4(3H)-one [24] 
with peroxidase and hydrogen peroxide was relatively slow, 
whereas the oxidation with three molar, or more, 
equivalents of potassium ferricyanide was complete within 
five seconds. All of these compounds (24] to [32] behaved 
more or less like the pterins on oxidation. They 
rearranged to the 7,8-dihydro(3H) tautomers (as observed by 
UV spectroscopy, cf. Figure 9, p 113) which were then 
further oxidized to pterins. However, in some of them, 
e.g. compounds [24], [26], [27], [28] and [29] the 
rearrangements of the quinonoid species were accompanied by 
some slight decomposition (e.g. Figure 11 compare with 
Figure 9 and 10). The decompositions were not very serious 
for the enzyme assay in these examples, because they 
occurred after the formation of quinonoid species and were 
slower than in the above pteridin-4-ones. The quinonoid 
species from compounds [25], [28] and (31] had typical UV 
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Figure 11. UV spectral changes of cis-6, 7-dimethyl-2-
methylthio-5,6,7,8-tetrahydropteridin-4(3H)-one [28] wi th 
peroxidase and hydrogen - peroxide ( 11. 2 µM) at pH 7. 3, 
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spectra of quinonoid dihydropterins (as in Figure 9). 
72 
Armarego and Waring showed previously that the quinonoid 
species from the 2-methylamino derivative [25] rearranged 
to the 7,8-dihydro(3H) tautomer with a half life of 34.6 
min (pH 7.5, Tris/HCl buffer, kb 2.0 x 10-2 min- 1 ), and 
0 S 
when the rate was compared with the rate of the 6,7-
dideuteriated derivative the k8 /kD value was 9.0. In this 
study the 2-methylthio analogue [ 28] rearranged similarly, 
but with a half life of 0.9 . min (pH 7, Tris/HCl buffer, 
kobs 0.75 min- 1 ) and when compared with the rate of 
rearrangement of the deuteriated quinonoid dihydropterin 
derived from compound [29], i.e. compound [58], the kH/kD 
value was 18. This further confirms the quinonoid 
structures [57] and [58], because of this very large 
0 0 
H N N CH 3 N CH 3 N 
HCS)l CH 3 H,CS)lN 
CH 3 
N N 3 
H H H D 
(57] [58] 
deuterium isotope effect (cf. reference 22). The isotope 
effect, however, is much larger than the values usually 
observed with pterins, i.e. k8 /k 0 -10, suggesting that the 
protio compound was not undergoing exactly the same 
reactions at the same time as the deuterio compound. 
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3-3-2 Non-enzymic oxidation of NADH 
NADH 1s oxidized non-enzymically by quinonoid 
dihydropterins. The rate of this reaction must be excluded 
from the . enzym1c rate. When the quinonoid . species of 
compounds [18], [20], [22], and [24] to [32] were subjected 
to this study the rates of non-enzymic oxidation of NADH by 
these quinonoid species were only 1.4 - 6.8% of the enzymic 
rates (Table 3). It was shown that at the highest 
concentration of potassium ferricyanide the rate of 
oxidation of NADH by this iron complex was negligible 
(<0.05%) compared with the enzymic rate. The assay 
procedures, however, were such that the . non-enzym1c 
oxidation of NADH was compensated in the two cuvettes (in a 
double beam spectrometer), and only the enzymic rates were 
recorded (see below). 
3-3-3 Assay procedures 
In the first . enzym1c experiments the peroxidase 
and hydrogen peroxide oxidation products of compounds [18], 
[20], [22] and [33] were examined for inhibition of DHPR. 
It was found that no inhibition occurred at concentrations 
of 120 - 140 µM of the products when quinonoid 6-methyl-
7, 8-dihydro( 6H)pterin [2] (p 92) (at 49 µM) and NADH (at 58 
µM) were used. Preliminary studies showed that the 
oxidation products of each of the compounds [ 18], [ 20], 
[22] and [33] were substrates for DHPR. 
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Table 3. Non-enzymic oxidation of NADH at 2soc. 
A: 0.1 M Tris/HCl buffer (pH 7.4), peroxidase, 
hydrogen peroxide (11 µmol); B: 0.1 M Tris/HCl buffer (pH 
7.6), peroxidase; C: 0.1 M Tris/HCl buffer (pH 7.6), 
oxygen; D: 0.1 M Tris/HCl buffer (pH 7.4), potassium 
ferricyanide. 
Compound concn. buffer NADH ua l 10-3 ( µM) ( µM) ( u /ml) 
[ 18] # 149 A 77 >15.3 
[ 2 0] # 143 A 77 > 7.7 
[ 22] # 172 A 77 > 5. 9 
[ 3 3] # 190 A 77 >25.3 
[ 2 4] 61 D 68 16.0 
[ 2 5] ... 100 C 150 1. 3 
[ 2 6] ... 
- -
--
(27] 47 B 109 5.8 
(28] 70 D 126 63.0 
(29] 70 D 101 95.8 
[ 3 2] 75 B 109 0.9 
[ 5 2] 63 D 111 31.6 
The rates were measured with a single beam 
spectrometer at 340 nm. 
* µ moles NADH oxidized per min 
# Reaction was initiated after 1 min from 
the formation of quinonoid species. 
~ Values are from reference 72 
~ Values could not be measured because the 
spectral changes were not typical, i.e. the band at 
340 nm increased with time. 
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The instability of the quinonoid . species from 
compounds [18], [20], [22] and [33] made it difficult to 
use standard mixing procedures (see Chapter 1, p 20) 
because the decomposition of the initial quinonoid species 
formed can proceed to quite an extent in one cuvette before 
addition of an ingredient in the other cuvette. So the 
assay was performed by simultaneous addition of 
substrates and also simultaneous addition of NADH to both 
cuvettes in a double beam spectrophotometer. The order of 
addition of ingredients which gave best reproducibility of 
initial rate traces for a particular . series of runs was 
selected ( see Section 3-6-6, p 177). Because the initial 
products of peroxidase and hydrogen peroxide oxidation of 
the compounds [ 1 8 ] , [ 2 0 ] , [22] and [33] undergo 
?ecomposition readily, it was necessary to find out how the 
DHPR activity altered with time after allowing the 
decomposition to proceed before starting the assay for this 
enzyme. In this case the order of addition was Tris/HCl 
buffer, peroxidase, hydrogen peroxide, DHPR ( to one 
cuvette), substrate ( simultaneously to both cuvettes) and 
allowing a recorded time interval before initiating the 
reductase reaction by adding NADH ( simultaneously to both 
cuvettes). A typical curve is shown in Figure 12. Maximum 
activity was observed at the shortest time. [In Figure 12, 
the concentration of hydrogen peroxide was very weak ( 11 
µM) and any oxidation of DHPR by hydrogen peroxide should 
be mini ma l ( see later , p 14 2 ) . J This also suggests that 
the quinonoid . species are formed rapidly and then 
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300 
100 
0 5 10 
T I M E (min) 
Figure 12. Dihydropteridine reductase activity at 
various time intervals after initiation of the peroxidase 
and hydrogen peroxide oxidation of 6-methyl-5,6,7,8-tetra-
hydropteridin-4(3H)-one [20] and starting the reaction with 
NADH in 0.1 M Tris/HCl buffer (pH 7.4) at 2soc. 
X 1 o- 3 
• 
40 
------- . 
~· 
0 
~ 
20 
0 0.2 0.4 0.6 0.8 1.0 
DHPR (,ug) 
Figure 13. The effect of DHPR concentrations on the 
initial rates at pH 7.3, 2soc. 6-Methyl-5,6,7,8-tetra-
hydropteridin-4(3H)-one was used as a substrate precursor. 
uo µmoles NADH oxidized / min per total protein. 
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decompose, because the DHPR activity of the species formed 
from peroxidase and hydrogen peroxide oxidation is highest 
immediately after . . m1x1ng and then decreases. The rate 
constants in Table 1 (p 115) are therefore for the 
formation and degradation of the quinonoid species. So all 
assays were performed at the shortest possible time (ca 1 
min). For the measurements of the kinetic parameters for 
DHPR, the reactions were initiated by adding compounds 
( 18] , ( 2 0 J , ( 2 2 J and ( 3 3 J 1 as t . The rates of formation 
of quinonoid species were not rate limiting for these four 
compounds, because these quinonoid species were formed soon 
after oxidation. 
The concentrations of DHPR for the assays were 
selected from the plots of enzyme activity versus enzyme 
concentration. In the above cases the plots were linear up 
to enzyme concentrations of 0.4 - 0.6 µg/µl, i.e. the rate 
was doubled when the enzyme concentration was doubled, and 
then slowly levelled off (cf. Figure 13). This levelling 
off of enzyme activity at higher enzyme concentration does 
not appear to be caused by inefficient recycling of the 
pteridines by peroxidase and hydrogen peroxide and may be 
due to lower effective concentration of enzyme caused 
perhaps by association or polymerization of the prate in. 
This was not investigated further. The enzyme 
concentrations used were selected from the linear portions 
of the plots (Table 4). 
In the case of substituted pteridines, [24] to 
[32], the quinonoid substrates were generated by potassium 
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Table 4. DHPR assay conditions for each pteridine. 
Pteridines oxidants enzyme 
[µl(µg)] 
initiation by 
[ 3 3] A 1 (0.39) pyrimidine 
[18] A 1 (0.39) pteridine (20] A 7*(0.27) pteridine 
[ 2 2] A 8*(0.31) pteridine 
[24] B 8*(0.31) NADH 
[ 2 5] B 4*(0.16) NADH 
[26a] A 3 (1.17) NADH 
[ 2 7] B 1 (0.39) NADH 
(28] B 5*(0.19) pteridine 
[29] B 5*(0.19) pteridine 
[ 3 0] B 6*(0.24) NADH 
[ 31 J B 3*(0.12) pteridine 
[ 3 2 J B 3*(0.12) pteridine 
[ 5 2] B 3*(0.12) NADH 
oxidants: A; peroxidase and hydrogen peroxide 
B; potassium ferricyanide 
* The diluted enzyme solution was used to inject 
larger aliquots (i.e. smaller error). 
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ferricyanide oxidation and the reaction was initiated as in 
Table 4. The type of oxidant did not affect the kinetic 
parameters as long as the formation of the quinonoid 
species was fast, i.e. not rate limiting. 
3-3-4 Kinetic parameters with DHPR 
Kinetic parameters for the pteridinones (15], [16] and 
[ 17] • 
The parameters for the pteridinones [15], [16] and 
[17] (p 95) are listed in Table 5. Although it was found 
that the quinonoid species of the 4,5-diaminopyrimidin-
6 ( lH) -one [ 33] had substrate activity, it decomposed too 
rapidly and the reproducibility of the initial-rate plots 
was very poor. The substrate concentrations in Table 5 are 
not true values because of the fast degradation of the 
quinonoid . species. In the case of pterins the rates of 
rearrangement were reasonably slow, so one could use the 
concentration of tetrahydropterins as equal to the true 
concentrations of the quinonoid substrates. When app.K 
rn 
and app.V values were calculated in this experiment, the max 
concentrations of the tetrahydropteridinones were taken as 
being the same as the quinonoid substrate concentrations. 
The true quinonoid substrate concentrations could be much 
smaller, so the true K values for these substrates will be 
m 
smaller than the values in Table 5. The app.K values 
m 
. 
1n 
phosphate buffer are slightly less than in Tris buffer and 
could reflect the higher proportion of quinonoid species 
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Table 5. Kinetic parameters of 
pteridine reductase for compounds, 
2s 0c. 
human brain dihydro-
[ 15] , [ 16] and [ 1 7] at 
A 
B 
7,8-Dihydro(6H)- app.Km app.Vmax V/K 
pteridinones 
* ( µM) (u /mg) 
Unsubstituted [ 15] 669(±2) 234(±0.4) 0.35 
6-Methyl- [16] 366(±20) 131(±3) 0.36 
6,7-Dimethyl- [17] 754(±45) 76(±4) 0.10 
Unsubstituted [15] 597(±20) 318(±8) 0.53 
6-Methyl- [16) 276(±8) 444(±7) 1.61 
6,7-Dimethyl- [ 1 7 J 640(±52) 489(±27) 0.76 
In 0.1 M Tris/HCl buffer, pH 7.4 A 
B 
* 
In 0.3 M potassium phosphate buffer, pH 7.1 
µM NADH oxidized per min 
NADH 
( µM) 
117 
117 
117 
117 
80 
131 
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(slower decomposition) in the former buffer. The app.V 
max 
1n Tris/HCl buffer for the respective quinonoid species, 
which were derived from compounds [18], [20] and [22], were 
in the order, (15] > (16] > [17]. Since these are the 
velocities at saturating concentrations of the quinonoid 
substrates, they are more meaningful constants than the 
app.K values. 
m The values in phosphate buffer are higher 
than in Tris/HCl buffer but they are of the same order of 
magnitude. 
The reproducibility of the initial rates and the 
satisfactory spread of errors in the kinetic analyses 
confirm that the proportional concentrations of quinonoid 
species with respect to tetrahydropteridines used, at 
various concentrations of the latter, are the same within 
experimental error in each set of experiments. 
Some of the substrates contained small amounts of 
borate salts and there was some concern that borate might 
inhibit the activity of the enzyme. No inhibition of DHPR, 
however, was observed at borate concentrations up to 1 mM 
when 6-methyl-7,8-dihydro(6H)pterin and NADH weLe used. 
The highest concentration of borate from the substrates in 
the assays was 0.9 mM, and most of the solutions contained 
considerably less than this concentration. 
Kinetic parameters for compounds (24], (25], (28] and (30]. 
The kinetic parameters for the substituted 
pteridines are listed in Table 6. The quinonoid species 
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derived from compounds [24], [25], [26], [28], [29] and 
[30] were substrates for human brain DHPR. 6,6,8-Trimethyl 
7 ,8-dihydro( 6H)pterin [59] which is the oxidation product 
of compound [31] was not a substrate for human brain DHPR 
but was shown to be a weak inhibitor for the same enzyme by 
0 
N 
H,NJlN 
1 2 6 
Randles and Armarego. 
(59] 
The parameters of the known 
substrate 6,7-dimethyl-7,8-dihydro(6H)pterin [3] (p 92), 
were determined under identical conditions for comparison. 
In Tables 5 (p 128) and 6, the V/K values are a better 
indicators of the overall efficiency of the enzyme with a 
particular substrate than the separate app.K and app.V 
m max 
values, and the larger V/K value is an indication of better 
substrate efficiency. 
6 8 
Kaufman had previously demonstrated that the 
quinonoid pterin [60] derived from the methylamino compound 
[25] (p 96) was a substrate by measuring only one initial 
0 
H 
N 
N CH 3 
HC-NJl N N CH 3 
3 H H H 
(60] 
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Table 6. Kinetic parameters of human brain dihydro-
pteridine reductase for compounds ( 3] , [ 57] , [ 58] , [ 59] , 
[ 61] and ( 6 4] at 2 5 O C. 
7,8-dihydro- app.Km app.Vmax V/K NADH K3 Fe(CN) 6 pteridin-4(6H)-one 
* ( µM) (u /mg) ( µM) ( µM) 
2-Amino-
6,7-dimethyl- [ 3 J 24.7 199 8 95 200 
2-Amino-
6,8-dimethyl- [ 6 4 J 349 24.3 0.1 108 200 
2-Methylamino-
6,7-dimethyl- [ 6 0] 127 150 1 117 300 
2-Methylthio-
6,7-dirnethyl- [57] 119.7 437.4 3.7 106 200 
2-Methylthio-
[6,7-Dz_J-
6,7-dirnethyl- [58] 28.0 107.9 3. 9 106 200 
2,6,7-Trimethyl-[61] 38.8 10.1 0.3 111 360 
NADH# 17.3 91.8 
* µM NADH oxidized per min 
# The concentration of 6-MeTHP as a substrate precursor 
was 50 µM. 
0 
[ 61) 
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rate. This rate was 36% of the initial rate of the 
quinonoid species [3] (p 92) derived from 6,7-dimethyl-
5,6,7,8-tetrahydropterin [52] (p 113) when using the sheep 
liver DHPR. In the present work, the kinetic parameters 
for human brain DHPR were determined. The V/K values 
indicate that the enzyme activity with the pterin [60] as 
substrate was 12.5% of the activity when [3] was substrate. 
The thioxopteridinone [27] (p 96) was oxidized by 
peroxidase and hydrogen peroxide or potassium ferricyanide 
as observed by the UV spectral changes. However, no DHPR 
active species could be detected in the oxidation products, 
and the TLC and UV spectral properties of the final 
oxidation product were similar to those of the original 
6,7-dimethyl-2-thioxo-2,3-dihydropterin-4(1H)-one [ 4 6 J (p 
106) (see Section 3-6-8, p 182). This demonstrates that 
either the quinonoid species [62] were formed in very small 
0 0 
H Nf:' N -N tCH, HN 
HS)lN CH 3 O~N N :. N H H H 
[ 62] (63] 
( steady state) concentrations ( too small to show enzyme 
activity) or were not formed at all. Also 6-methyl-
5,6,7,8-tecrahydrolumazine [ 3 2] (p 97) which had been 
oxidized to 6-methyl-7,8-dihydropteridin-2(3H) ,4(6H)-dione 
7 3( b) 
[ 6 3] ( 1 H NMR ev i de nee) , was found in the present work 
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not to be a substrate or inhibitor of human brain DHPR. 
The oxidation product of 2-amino-6,7-dimethyl-
5,6,7,8-tetrahydropteridin-4(3H)-thione [26] (p 96) was 
found to be a substrate of human brain DHPR in this work, 
because this quinonoid . species showed that i ) . maximum 
e n z yme act iv it y ( i . e . i n i t i a 1 rates of ox id at ion of NA DH ) 
was observed at least immediately after addition of enzyme, 
i i ) at set con cent rat ions of substrate and NA DH , enzyme 
activity increased linearly with . . increase in enzyme 
concentration, i i i ) at constant enzyme and NADH 
concentrations but . varying substrate concentrations the 
initial rates were hyperbolic, . 1 • e • indicative of 
saturation kinetics. The kinetic parameters could not be 
obtained for this substrate, however, because it was not 
possible to reproduce the initial rate traces to within the 
accepted standard deviation. This is possibly due to 
oxidation of the 4-thio group to give the respective 
disulphide which may or may not be enzyme active; and/or 
dismutation between the quinonoid species and the unchanged 
4-thioxo [26] compound in the early stages of oxidation. 
The quinonoid . species [ 6 4] derived from 6,8-
dimethyl-5,6,7,8-tetrahydropteridin-4(3H)-one [ 3 0 J by 
0 
(64] 
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oxidation proved to have substrate activity, although it is 
among the poorest of the active pteridines that were 
studied, and satisfied the above three general criteria for 
substrate activity (see Table 6, p 131). 
The quinonoid species from the methylthio 
derivatives [28] and [29] showed higher efflciency as 
substrates than the quinonoid species from the methylamino 
derivative, although they decomposed more rapidly and the 
initial rates were more difficult to obtain experimentally 
because of the relative instability of the substrate. This 
indicates that the electrostatic effect of the substituent 
at the C-2 position (-SMe versus -NHMe) may play an 
effective role on the binding of the substrate to the 
enzyme. 
The K and V values of NADH for human brain 
m max 
DHPR were also measured by using quinonoid 6, 7-dimethyl-
7, 8( 6H) -dihydropterin [3] (p 92) as a substrate and gave 
similar values as those which were obtained for other 
22 
sources of DHPR (see Table 6, p 131). 
3-3-5 pH rate profile study 
An attempt was made to evaluate the kinetic 
parameters of DHPR at several pH values in order to obtain 
some idea of the pKa at the active site. This may provide 
information regarding the ionic species at the active site 
of the enzyme and/or the ionic . species of the active 
substrate. 
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In this experiment, the quinonoid species were 
formed by oxidation with peroxidase and hydrogen peroxide 
in Tris/HCl buffer at pH -7 and kept in an ice bath, 
because the rates of formation of quinonoid species varied 
with pH. The quinonoid species were stable at ooc (pH -7) 
for 30 min. Before the assay, aliquots were taken and 
l 4 5 
mixed with the mixed buffer (MES and ethanolamine) to 
give final pH values between 5.7 - 9.8. 
Quinonoid 6,7-dimethyl-[6,7-D2 ]-7,8-dihydro(6D)-
0 
D 
N CH3 N 
H,NJl N N CH3 
H D 
(65] 
pterin [ 65] was chosen as the substrate because it was 
known to rearrange very slowly (t 1 ;2 112 min in Tris/HCl 
7 2 
buffer, pH 7.6). The pH rate profile for the 
this 
rearrangement ofVquinonoid species is shown in Figure 14. ~ 
However, although a considerable number of kinetic runs 
were performed for DHPR activity, it was not possible to 
obtain values of the app.K and app.V within acceptable 
m max 
limits of error and reproducibility at pH values below 6 
and above 10. Between pH 6 and 10 the enzymic rates were 
uniformly constant within experimental error. It was clear 
that below pH 6 the non-enzymic oxidation of NADH (Figure 
15) varied with pH. Also the rates of rearrangement of 
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Figure 14. The stability of the quinonoid 6,7-dimethyl-
[6,7-D2]-7,8-dihydro(6D)pterin at different pH values. 
The rates were measured at 310 nm, 2s 0 c. 
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-•- enzymic rates, log V /K 
-•- enzymic rates, log V 
-•- non-enzymic rates 
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Figure 15. The enzymic and non-enzymic oxidation of NADH 
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substrate to 7, 8-dihydro ( 3H) pterin varied with pH ( Figure 
14). All these variables including the instability of NADH 
especially in acidic solution made it difficult to obtain 
reproducible results at pH values below 6 and above 9. 
Further studies were abqndoned. 
3-4 Identification of the quinonoid species 
3-4-1 Following the reaction by TLC and lH NMR 
In general it is possible to oxidize 5,6,7,8-
tetrahydropterins to pterins with 
2 2 
almost quantitative yields. 
various oxidants . 1n 
In the case of the 
tetrahydropteridinones [18], [20] and [22], on the other 
hand, only small amounts of 7,8-dihydro(3H) derivatives and 
the fully oxidized pteridinones were detected by TLC. The 
yields of fully oxidized 6-methylpteridin-4(3H)-one [37] 
isolated after peroxidase and hydrogen peroxide oxidation 
are exceedingly low (approx. 3 - 4%), and very 1 i ttle of 
the 7,8-dihydro(3H) derivatives was identified. 
Examination of the products of peroxidase and hydrogen 
peroxide oxidation of compounds (18], (20], [22] and [33] 
by removing samples at time intervals and separating the 
components by TLC showed that within a minute of mixing at 
least six spots appeared. Their relative intensities 
varied with time but the number of spots did not change 
with time. The reaction was repeated on a large scale for 
compounds [ 20] and [ 22], allowed to proceed for 10 h and 
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the products were separated by TLC. One band in each case 
was identified by UV spectra (at three different pH 
values), by 1 H NMR spectra and by TLC (re-run) as the 
respective fully oxidized compounds [37] and [36]. Most of 
0 0 
::rCH, N CH 3 HN HN 
~N ~N N 
CH3 
(37] [36] 
the other bands gave substances, in small amounts, that had 
no UV absorption and a few unidentified proton signals in 
the lH NMR spectra. The lack of UV absorption of some of 
the bands is indication of ring cleavage occurring with loss 
of chromophoric properties by hydration across the C2 ,Nl 
double bond. I n the case of pyrimidine [ 3 3 ] ( p 9 7 ) s i mi 1 a r 
results were obtained (i.e. several spots on TLC), but 2-
carboxy-l,3,5-triazin-4(3H)-one [ 6 6 J or 1,3,5-triazin-
2,4(1H,3H)-dione [67] were not identified among the 
products. These should have been the possible products if 
the oxidation proceeded as reported for 2,4,5-triamino-
l 4 6 
pyrimidin-6(1H)-one [54] (p 114). However, these 
reported reactions did not involve peroxidase (cf. 
reference 147), i.e. the pyrimidinone [33] was reacted with 
hydrogen peroxide in water or hydrogen peroxide in alkaline 
solution. Similar oxidations were carried out in NMR tubes 
and the proton spectra were examined at time intervals 
( Figure 16) . After 16 min, the downfield signal from the 
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Figure 16. 1H NMR spectrum of oxidation of 5,6-diamino-
pyrimidin-4(38)-one [33] by peroxidase and hydrogen 
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0 
A 
HN NH 
~N~O 
[ 66] [67] 
C-2 proton disappeared which was an indication of exchange 
of proton with deuterium or degradation of the pyrimidine 
followed by deuterium exchange. 
Oxidation of the pteridinones with potassium 
ferricyanide with the aim of obtaining clearer oxidation 
products of compounds [ 18] , [ 2 0] , [22] and [33] were 
examined. In this case also many products were formed, 
some of which had similar TLC properties as those from 
peroxidase and hydrogen peroxide oxidations ( see 
Experimental, p 186). The results are consistent with the 
formation of a primary oxidation product (such as quinonoid 
dihydropteridine) that subsequently undergoes degradation 
to products that may react further with the oxidant or the 
solvent. Further identifications of the various reaction 
products were frustrated by the small amounts produced and 
by the lack of definitive information revealed by their UV, 
IR and 1 H NMR spectra. 
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3-4-2 Reaction with Horseradish peroxidase and hydrogen 
peroxide 
In the pterin . series, the structures of the 
quinonoid species ( which are substrates for DHPR) formed 
from the peroxidase and hydrogen peroxide oxidation of 
2 2 5,6,7,8-tetrahydropterins, are well established. 
Although these species rearrange to the corresponding 7,8-
dihydro(3H)pterins (Scheme 7), they are stable enough for 
0 0 
H R 
N N 
N R HN 
H,N.Jl.. N 
• 
H2N~N 
R' R' N N H H H 
Scheme 7 
some structural investigations. They can be generated so 
rapidly (e.g. within 20 sec in assay conditions) that 
i ntermed ia tes cannot be detected under the present assay 
procedures. The pteridin-4(3H)-ones [18], [20] and [22] 
are also oxidized with peroxidase alone (or in buffer 
saturated with 0 2 ), but very slowly (less than 0.1% in 10 
min) compared with the oxidation of the pterins (e.g. 6-
methyl- and 6, 7-dimethyl-5, 6, 7, 8-tetrahydropterins). The 
main difference 1n behaviour between the pterins and the 
pteridin-4(3H)-ones is that the quinonoid species from the 
latter are less stable and the quinonoid species are not 
1, 
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observed by UV spectroscopy. If the quinonoid species from 
the pterins and the pteridin-4(3H)-ones are both substrates 
for DHPR, they should . give the same initial structures 
after oxidation and the differences in behaviour are due to 
the differences in oxidation potential between the two 
species (i.e. with and without the 2-amino group) and the 
following reaction pathways. In order to support this idea 
the substrate activities of both series of compounds were 
examined using the peroxidase and hydrogen peroxide system 
to see whether they exhibited clear Michaelis-Menten 
kinetics. 
The UV spectrum of the peroxidase enzyme used was 
similar to that of the enzyme in the reduced state, whereas 
in the presence of more than one equivalent of hydrogen 
peroxide it was converted into Compound I which was the 
primary peroxide derivative of horseradish peroxidase 
l. 4 8 
(Scheme 8), a process that was known to be very fast 
EH 2 
J ' 
± H+ 
H202 
Compound I EH ',. , 
J r ± H+ 
E 
E: Horseradish peroxidase 
Scheme 8 
(second-order rate constant 0.9 x 10 7 M-l.s-l) and followed 
first order kinetics. 
l 4 8 l 4 9 
' Like the pterins, the 
pteridin-4(3H)-ones showed saturation kinetics, i.e. the 
Ii 
!1 
1:,, 
r 
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rates of oxidation increased with increasing concentration 
of substrate, with a constant amount of peroxidase and 
hydrogen peroxide, until they reached maximum values. 
In this study, the rate of oxidation of substrates 
was measured with . various amounts of peroxidase and 
hydrogen peroxide and keeping the concentration of one of 
these two components constant while altering that of the 
other. Figure 17 illustrates the rates of oxidation of 
6,7-dimethyl-5,6,7,8-tetrahydropteridin-4(3H)-one [22] 
which . lS typical. The rates increased linearly up to a 
concentration of peroxidase (Sigma type I) of 8 µg/ml. The 
decrease in rates at high hydrogen peroxide concentrations 
is probably due to the oxidation of the enzyme by the large 
amounts of hydrogen peroxide. For measuring the kinetic 
parameters, low concentrations of peroxidase were chosen 
from the linear portions of the peroxidase concentrations 
versus the initial velocities plots. 
The kinetic parameters of horseradish peroxidase 
with the pterins and the pteridin-4(3H)-ones are listed in 
Table 7. The data show that the enzymic oxidation of all 
of these substrates follows Michaelis-Menten kinetics. The 
orders of all the parameters in Table 7 are of similar 
magnitude, so probably the enzymic oxidation mechanism of 
tetrahydropteridinones is the same as those of tetra-
hydropterins. However, the subsequent changes after the 
formation of the initial quinonoid species, are different. 
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Figure 17. Effect of peroxidase (Sigma type I) and 
hydrogen peroxide concentrations on the initial rates of 
oxidation of 6,7-dimethyl-5,6,7,8-tetrahydropteridin-4(38)-
one [ 22] ( at the concentrations shown) in O .1 M Tris/BC! 
buffer (pH 7.4) at 2soc. 
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Table 7. Kinetic parameters of Horseradish peroxidase in 
the presence of hydrogen peroxide at 300c. 
7,8-dihydropteridin- Km vmax kcat >..analyt 4(6H)-ones 
- ( µM) (u/mg) (sec- 1 ) (nm) 
Unsubstituted (15] 173(±3) 143(±1) 59(±0.5) 289 
6-Methyl- [ 16] 314(±20) 53(±2) 22(±0.9) 290 
6,7-Dimethyl- [17] 45(±0.2) 161(±0.03) 7(±0.01) 292 
2-Amino-
6-methyl- (68] 46(±1) 28(±0.4) 12(±0.1) 298 
2-Amino-
6,7-dimethyl- [ 3] 103(±2) 51(±0.8) 21(±0.3) 298 
4-Amino-5-imino-
pyrimidin-6-one [ 6 9] 203(±8) 149(±3) 56(±1) 298 
0 0 NJc;, NH N N 
HNJl.N ll NH2 N 2 H 
(68] [69] 
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3-5 Conclusion 
The S,6,7,8-tetrahydropteridin-4(3H)-ones [ 18] , 
[20] and [22] are effective substrates for horseradish 
peroxidase in the presence of hydrogen peroxide, similar to 
the related 5,6,7,8-tetrahydropterins. The transient 
quinonoid species derived from the oxidation of the 
tetrahydropteridin-4 ( 3H) -ones are found to be substrates 
for human brain DHPR and the enzymic activities of the 
compounds which are used in this work strongly support the 
[4] 
0 
HN~NJ 
HNJ.._N~N 
H 
[ 5] [6] 
tautomeric structure [4] for the enzyme active species . 
When the C-2 position of the pyrimidine . ring . lS 
unsubstituted, structure [5] cannot be formed. Also when 
it was substituted with methyl or thiomethyl groups, 
tautomer [5] cannot be formed. Moreover the lumazine 
derivative [63] and the thioxopteridinone [70] were not 
0 0 
,H 
N N ::-
HN H HN !CH, 
O~N N S~N N _ CHJ 
H H -H 
(63] (70] 
substrates for DHPR and support the exclusion of the 
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tautomeric structure [ 5] . However, compounds [18], [20], 
[ 22] and [33] could be oxidized to the ortho-quinonoid 
structure [6]. This tautomer was excluded because the 6,8-
dimethyl compound [64] (p 133) was a substrate, albeit 
among the poorest studied. If tautomer [6] is formed in 
this case, the quinonoid structure of the 6,8-dimethyl 
compound [30] should give a cation with the charge on N-8 
(i.e. [71]). This quinonoid species should deprotonate at 
1 5 0 
pH -7 (cf. pKa of 8-methylpterin 5.42, 6,8-dimethyl-7,8-
1 5 l. 
dihydropterin 4.40 ) which will alter its tautomeric 
0 0 
N NH 2 
HN H HN 
H2N~N 
+ 
H2N~N N I 
CH 3 
[ 71] [ 72] 
structure to [4]. The pKa of the quinonoid dihydropterin 
J.52 J.53 
is ca 5.4 ' and at pH 7.4 it is almost entirely in the 
unprotonated form. If the substrate retained structure 
[ 71] then we should have expected an accelerated hydride 
transfer (in the absence of enzymic steric hindrance from 
8-Me) which is not the case. In general protonated 
Schiff's bases are reduced more rapidly by hydride reagents 
than unprotonated Schiff' s bases. Also the pyrimidinone 
[72], after peroxidase and hydrogen peroxide treatment (not 
48 
studied 1n detail), exhibited some activity with DHPR. 
A structure such as [ 6] for the pteridin-4 ( 3H)-
- 149 -
ones implies the remote possibility that DHPR can reduce 
two different tautomers, [4] and [6], of very similar 
substrates. It 1s true that the cations of the two 
tautomers are mesomeric, [73] and [74], and protonation of 
0 0 
NR NR 
HN+ HN 
.. • 
~N 
+ NR' NR' H H 
(73] (74] 
the quinonoid species will enhance hydride transfer to N-5 
considerably. However, if one postulates tautomeric 
structures for the pterins that are different from the 
pterid i nones, the enzyme wi 11 need to transfer a proton, 
' 
e.g., to N-3 in the case of the pterins and to N-8 in the 
case of the pteridinones after binding of the neutral 
. 
species. The absence of a 2-amino group in the quinonoid 
dihydro(6H)pteridinone would be base-weakening when 
compared with quinonoid dihydro(6H)pterin and make its pKa 
lower than 5. 4 by at least 1. 6 pH uni ts (cf. the pKa of 
1 2 9 5,6,7,8-tetrahydropteridin-4(3H)-one [18] is 3.86 and 
139 140 5,6,7,8-tetrahydropterin [75] is 5.6 ' ). So these 
0 0 H H 
HN N) HN N) 
~N HN~N N 2 N H H 
(18] [ 75] 
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species are even less likely to be protonated at neutral 
pH. Protonation of the quinonoid species would most 
probably take place on the enzyme after or before hydride 
transfer, but this information is not known at the moment. 
84 
However, according to Poddar and Henkin, who studied the 
mechanism of the . enzym1c reaction of DHPR, the rate-
limiting step is a conformational change of the ternary 
complex, probably assisting . 1n (or associated with) 
substrate protonation, immediately before the faster 
hydride transfer (no deuterium isotope effect with NAD2H) 
from NADH to the quinonoid substrate. This is followed by 
rapid release of products. So in the final conclusion the 
transfer of hydride to the quinonoid pterin is most 
probably the same as in the quinonoid pteridin-4 ( 3H) -ones 
and that the tautomeric structure [4] is most probably the 
act iv e form of the substrate . The chemical mechanism of 
the enzymic reaction can be summarized as in Scheme 9 . 
E~A-H 
0 
Scheme 9 
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3-6 Experimental 
3-6-1 Materials and Methods 
A: Materials 
All chemicals were of the highest commercially 
available purity. 
[l,2-D 2 ]-glyoxal bis-(sodium bisulphite) 
47 
monohydrate was kindly supplied by Professor H. Taguchi. 
Horseradish peroxidase was from Boehringer grade 
II horseradish peroxidase (Boehringer, North Ryde, 
Australia) (A403/A279 ratio 1.0) or Sigma type I 
horseradish peroxidase (Sigma, St. Louis, USA) (Rz 0.6, at 
double the concentration) and were used for the generation 
of quinonoid species in the DHPR assay. The former enzyme 
(found A402/A272 ratio 1.35, s 4 03 63 x 10 3 M- 1 .cm-l in 1 mM 
l 5 4 
phosphate buffer, pH 6.6, at 2s 0 c1 lit. values A4 03/A27s 
ratio 3.25, E403 102 x 10 3 M- 1 .cm- 1 ) was used for the 
determination of the kinetic parameters of peroxidase with 
the tetrahydropteridine substrates. 
B: Methods 
Microanalyses were determined by the Australian 
National University Analytical Unit and analytical 
specimens were dried at 250 C/0. 3 mmHg in the presence of 
potassium hydroxide unless otherwise stated. 
l H and l 3c NMR spectra were measured on a Jeol 
FX90Q spectrometer operating at 34°c. Sodium 3-(trimethyl-
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silyl)propionate (TPS) was used as internal standard for 
the 1 H NMR spectra (o values are in ppm and J values are in 
The EI mass .spectra were measured with 16 eV 
ionizing electrons, 1.2 kV accelerating voltage on a 
Hitachi M-70 mass spectrometer (performed by Professor H. 
Taguchi, Kyoto Women's University, Japan) . Samples were 
introduced by a direct insertion probe into the ion source 
maintained at 1200c. 
IR spectra (KBr disc) were measured on a Unicam SP 
1050. The values in parentheses were shoulders. 
Thin-layer chromatography (TLC) was run on silica 
gel 60 F254 (Merck, Hohenbrunn, FRG) and plates were eluted 
with n-butanol . . acetic acid : water = 20 • . 3 . • 7 • The 
spots were revealed by UV light (at 250 and 365 nm) and by 
staining with iodine vapour. In large scale experiments, 
each band was extracted with 1 
chloride. 
• . 1 methanol - methylene 
Melting points were measured . 1n open (pyrex) 
tubes. 
UV spectra and kinetic measurements were performed 
as described before (see Chapter 2, Section 2-9-1, p 73). 
The accurate absorbance for evaluating 
concentrations was performed on a Perkin-Elmer Lambda 1 
single beam spectrometer. 
Human brain DHPR used in the present chapter was 
purified by Mr Bela Paal and was homogeneous by SDS gel 
electrophoresis. 
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3-6-2 Syntheses 
4,5-Diaminopyrimidin-6(1H)-one (33]: 4,5-Diarnino-
l 2 7 
pyrirnidin-6(1H)-one was prepared as described with 
slight modifications. Ethyl cyanoacetate (25 g, 0.25 rnol) 
was dissolved 1n acetic acid (45 g, 0.75 rnol) and then 
sodium nitrite (51.8 g, 98.5%, 0.75 rnol) in water (71 ml) 
I 
was added to it with cooling (below 10°c) (cf. reference 
15 5) . The crystalline mass was extracted with ether 
(discard), washed with saturated NaCl solution and then 
aqueous sodium bicarbonate and dried. The crystals were 
tri turated with benzene to g1 ve ethyl hydroxyirninocyano-
acetate (29.2 g, 82.3%). 
The ethyl hydroxyirninocyanoacetate ( 14. 2 g, 0 .1 
rnol) was condensed with thiourea (7.6 g, 0.1 mol) in sodium 
ethoxide solution [from sodium (4.6 g, 0.2 mol) and ethanol 
(250 ml)]. After boiling under reflux for 3 h, the brown-
red sodi urn salt of 4-ami no-2-rnercapto-5-ni trosopyrirnid in-
6 ( lH) -one (quantitative) was filtered off, washed with a 
little ethanol and dried. To the cooled solution ( 18 ,..., 
35°c) of the sodium salt (19.5 g, 0.1 rnol) in 1 M NaOH (430 
ml), sodium dithionite (68.9 g, 396 rnmol) was added during 
20 . rn 1 n with stirring. Further portions of sodium 
d i th ion i t e ( 1 8 g , 8 7 . 9 mmo 1 and 6 . 5 g , 3 1 . 7. rnrno 1 ) were 
added to the reaction mixture, because reduction was not 
complete (colour was not discharged), and stirring was 
continued for 15 min at room temperature (pH 6,..., 7). Under 
cooling, acetic acid was added to give pH -5. The pale 
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mercapto-diamine that separated (10.9 g, 63.8%) was 
filtered off, washed with a little water, ethano1 and 
ether, and dried. The mercapto-diamine (26.6 g, 0.17 mol) 
was dissolved 1n 1.6% aqueous ammonia (539 ml), heated to 
boiling, and Raney nickel catalyst (76 g) was added 1n 
portions. This mixture was boiled under reflux for 2 hand 
filtered. The filtrate was evaporated to half its volume 
and cooled. The solid was filtered off, washed with 
boiling water and a little ethanol and dried to give 4,5-
diaminopyrimidin-6(1H)-one (12.4 g); m.p. 238-242oc (dee~) 
l 2 7 
[lit. m.p. 239°cJ. From the mother liquor, a further 
quantity [3.5 g, m.p. 238-243°c (dee.)] was obtained. The 
127 
total yield was 74% (lit. 76%). (Found: C, 33.9; H, 
N, 39.3%); 
( pH 7) . 
Pteridin-4(3H)-one (35]: 
l 2 7 
o 7 • 7 6 , s , H 2 ; UV : s 2 7 a 8 9 1 2 
Pteridin-4 ( 3H) -one was prepared 
as before with slight modifications. To a solution of 
g 1 yo x a 1 b i s - ( sod i um bi s u 1 p h i t e ) ( 3 . 1 2 g , 11 . 0 mm o 1 ) i n 
water (39 ml), 4,5-diaminopyrimidin-6(1H)-one (1.3 g, 10.3 
mmol) was added and boiled under reflux for 1 h. The pH 
was adjusted to 0.5 with 11 M HCl, boiled vigorously for 10 
min and adjusted to pH 3.5 with 2.5 M NaOH and then cooled. 
The solution was evaporated to dryness, dissolved in 1% 
aqueous ammonia, filtered off and passed through an 
aluminium oxide (Merck, 'Aluminium oxide 90 active neutral; 
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46 g) column and eluted with 1% aqueous ammonia. The main 
fraction was evaporated to dryness and the residue was 
dissolved in hot water and boiled with a little charcoal 
and then filtered. The filtrate was adjusted to pH 3 - 4 
and cooled. The sol ids were collected and dried. The 
aluminium oxide column chromatography was repeated and 
recrystallization of the product from hot water ( 70 ml) 
gave pteridin-4(3H)-one (929 mg, 61.1%) (very pale brown). 
This was recrystallized further from hot water and gave 
almost pure compound ( 540 mg). It was then sublimed at 
27ooc;9 X 10- 1 mmHg (pale yellow) (Found: C, 4 9. 0; H, 2 . 7; 
N, 38.1%. Calculated for C6 H4 N4 0: C, 4 8. 8; H, 2. 7; N, 
37.8%); lH NMR ( 1 M DCl) : 0 8.97, d, J 2. 3, H6 or H7; 
9.05, d, J 2. 3, H7 or H6; 9.10, s , H2; ( 1 M Na OD) : 0 
8.46, s' H2; 8.74, d, J 2. 2, H6 or H7; 8. 8 5, d, J 2. 2, H7 
or H6 V 3030(3080), 2885, 1724, 1617, 1590, 
max 
. 
' 
IR: 
1550(1560), 1468, 1398(1410), 1374, 1320, 1280, 1228(1220), 
1163, 1108, 1032, 923(913), 872(882), 858, 827, 720(712) 
and 607 cm- 1 • 
5,6,7,8-Tetrahydropteridin-4(3H)-one [18]: 
i) i. 2 8 Catalytic reduction with Raney nickel • 
• A 
suspension of pteridin-4(3H)-one (225 mg, non-sublimed 
material, 1.52 mmol) in ethanol (20 ml) was added to Raney 
nickel (2.0 g) in ethanol (10 ml). 
hydrogenated for 3 h ( 2 5 O C / 7 2 0 mm Hg ) . 
The mixture was 
The catalyst was 
filtered through Celite and washed with a little ethanol. 
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The filtrate was evaporated to dryness and the residue was 
dissolved in hot ethanol (1 ml), concentrated to half its 
volume and ether was added. The solid was collected (3 mg, 
1. 3%) and identified as 5, 6, 7, 8-tetrahydropteridin-4 ( 3H)-
J. 2 8 
one (lit. yield 60 %) • This low yield may be due to an 
unknown impurity in the starting material. 
ii) Attempted catalytic reduction with platinum 
oxide in trifluoroacetic acid: To a suspension of pre-
reduced platinum oxide ( 25 mg) in trifluoroacetic acid ( 5 
ml), a solution of pteridin-4(3H)-one (100 mg, 0.68 mmol) 
in trifluoroacetic acid (2.5 ml) was added, and the mixture 
was hydrogenated at 25°C/720 mmHg. After 3.5 h, a further 
quantity of pre-reduced platinum oxide ( 50 mg) in tri-
f luoroacetic acid ( 5 ml) was added and hydrogenation was 
continued for further 4 h. The UV spectrum . 1n acidic 
solution (A at 270 and 310 nm) did not show any further 
max 
change indicating that reduction had not occurred to a ny 
appreciable extent. The catalyst was filtered off and 0. 7 
M me th anolic-HCl (5 ml) was added to the filtrate followe d 
by ether (60 ml) and methanolic-HCl (5 ml). The solid (- 1 
mg) that separated was washed with ether by centrifugation 
until the pH was neutral, and dried in vacuo. A b road 
signal appeared near 4 ppm in the iH NMR spectrum b u t t h ere 
was no down field signal from the c-2 proton in DCl. 
iii) Reduction with sodium borohydride: Sodium 
borohydride (511 mg, 13.5 rnmol) was added to a solution of 
- 157 -
pteridin-4(3H)-one (500 mg, 3.4 rnrnol) 1n 1 M aqueous sodium 
carbonate (4.7 ml). The reaction was followed by UV 
spectra and TLC properties. The reduction was not complete 
after 10 min, and the solution was heated for 1 min. After 
20 min the reduction was still not complete and a further 
amount of sodium borohydride (100 mg) was added and heated 
for 5 min. After 35 and 55 min, further amounts of sodium 
borohydride (100 mg) were added and the mixture was heated 
for 5 min after each addition. Reduction was then complete 
as evidenced by UV spectra and TLC. The pH of the solution 
was adjusted to 8 - 9 with acetic acid. The sol ids were 
filtered (most of this was inorganic material), the 
filtrate was freeze-dried and the residue wa$ extracted 
with cold ethyl acetate (40 ml x 5) and then cold ethanol 
(40 ml x 4). Both extracts were evaporated to dryness. A 
very small amount of solid (1.2 mg) was obtained from the 
ethyl acetate extract. The residue from the ethanol 
extraction was triturated with water (5 ml), concentrated 
to half its volume and the white crystals were collected. 
On drying, these became slightly yellow ( not hygroscopic, 
120 mg), m.p. >190°c (dee.) i 2 8 [lit. m.p. 230°c (dee.) 
obtained by potassium borohydride reduction] (Found: C, 
41. 5; H, 5. 7; N, 31.8%. C6 H8 N4 0, 0.1NaH 2 B0 3 , H2 0 
. C, 4 1 . 2 ; H, 5 . 6; N, 32.0%) . The tetrahydro-requires 
pteridinone crystals from various preparation always 
contained small amounts of borate (green-edged flame test 
with H2 so 4/ethanol) although they gave one spot on TLC and 
clean 1 H NMR spectra. 
7,7 and 8.59, s, H2. 
i H NMR ( 1 M DC 1 ) : 8 3. 6 9 , m, H-6 , 6 , 
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[6,7-D 2 ]-pteridin-4(3H)-one [ 7 3] : This deuteriated 
127 
pteridinone was prepared as before for the undeuteriated 
compound, with slight modifications. A mixture of 4, 5-
diaminopyrimidin-6(1H)-one (1.3 g, 10.3 mmol) and [1,2-D2 ]-
47 
glyoxal bis-(sodium bisulphite) monohydrate (3.15 g, 11.0 
mmol, 99. 5% deuteriated at C-1 and -2) in water (39 ml) 
was refluxed for 1.7 h. After cooling the pH was adjusted 
to 1 with 11 M HCl and the solution was boiled vigorously 
for ca 10 min, (the colour had changed to dark purple) and 
evaporated to dryness. The residue was dissolved in 1 % 
aqueous ammonia (8 ml) and filtered. The f i 1 trate was 
passed through an aluminium oxide column (46 g in 1% 
aqueous ammonia) and eluted with 1% aqueous . ammonia. The 
main fraction was evaporated to dryness. The residue was 
recrystallized from water (24 ml) to give the pteridinone 
(320 mg). This was dissolved in 1% aqueous ammonia (4 ml) 
and passed through a second aluminium oxide column (12 gin 
1% aqueous ammonia) and eluted with 1% aqueous . ammonia. 
The main fraction was evaporated to dryness ( 282 mg) and 
recrystallized from water (8 ml) to give purer pteridinone 
(141 mg) . 
liquor. 
Anhydrous 
More solid (56 mg) was obtained from the mother 
The total yield of pteridinone was 12. 7%. 
[6,7-D 2 ]-pteridin-4(3H)-one [ 7 6] ( 3 3 mg ) , 
0 
NXD HN ,._ 
~N ... N D 
[ 76] 
I • 
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m.p. >303°c (dee.) was obtained by sublimation ( 49 mg) at 
2 3 0 O C / 1 mm Hg [ Found : C , 4 8 . 2 ; H+D, 4.2; N, 37.5%; m/e 
149 (100%), 150 (30%). [This fragmentation was different 
1 5 6 
from previous reports which used 70 or 80 eV as ionizing 
electrons. The differences in the electron strengths may 
be the cause for different fragmentation.] 
requires C, 48. 0; H+D, 4.2; N, 37.3%; IR : 
"max 3480, 3090(3060), 2925, 1724(1708), 1615(1600), 1545, 
1434, 1378, 1322, 1268(1280), 1210, 1182, 1150, 1013, 1000, 
990, 925(883), 836(823), 710 and 652 cm- 1 (compare with 
non-deuteriated pteridin-4(3H)-one, p 155)]. 
[6,6,7,7-D~]-5,6,7,8-tetrahydropteridin-4(3H)-one [ 19] : 
To a solution of [6,7-D2 ]-pteridin-4(3H)-one (80 mg, 0.53 
mmol) 1n 1 M sodium carbonate (in D2 0, 0.8 ml), sodium 
borodeuteride (Aldrich, Milwaukee, USA) ( 80 mg) was added 
and nitrogen gas was blown over the surf ace and capped 
tightly. The reaction was followed by UV spectra and TLC. 
This reaction mixture was treated with sodium borodeuteride 
(40 mg, each time) and heated for 30 sec after 20, 75, 180, 
250 and 395 min. After 8 h, the pH was adjusted to 8 - 9 
with 11 M HCl and cooled. The sol id was collected and 
triturated with small portions of water to give the crude 
pteridinone (423 mg). This was extracted with ethyl 
acetate, the extract was centrifuged and the supernatant 
was evaporated to dryness to yield the tetra-deuterio 
pteridinone (23 mg) (Found: C, 41.4; H+D, 8.55; N, 31.5%. 
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Calculated for C6 H4 D4 N4 0, 0.02NaH 2 B0 3 , H2 0: C, 41.0; H+D, 
8.1; N, 31.9%); [Found: m/e 156 (100%), C6 H4 D4 N4 0 requires 
M+ 156]. 
6-Methyl-5,6,7,8-tetrahydropteridin-4(3H)-one [ 20] : 6-
Methylpteridin-4(3H)-one (2 g, which was kindly supplied by 
Dr D.J. Brown) was recrystallized from water (90 ml) (1.73 
g, 86.5%; orange). The mother liquor was concentrated to 
1/4 its volume and cooled (0.13 g, 6.5%; white). 1 H NMR 
showed that the crystals were pure 6-methylpteridin-4(3H)-
129 
one. 
i) Catalytic reduction with platinum oxide . 1n 
methanol: Recrystallized 6-methylpteridin-4(3H)-one (150 
mg) in methanol (300 ml) and platinum oxide (250 mg, pre-
reduced in 10 ml of methanol) were shaken with hydrogen 
(25°C/720 mmHg) for 4.2 h. A further quantity of platinum 
oxide (100 mg, pre-reduced in 10 ml of methanol) was added 
and shaking was continued for a further 1.5 h. The 
solution was filtered and evaporated to dryness. The 
residue (144 mg) was recrystallized from water (10 parts) 
to give 6-methyl-5,6,7,8-tetrahydropteridin-4(3H)-one (30.2 
mg), m.p. >2lloc (dee.). The crystals were pure by TLC and 
128 
had UV spectra as reported [s 290 8511 (pH 7), s259 7079 
(pH 1 ) ] ( Found : C, 45.9; H, 6.3; N, 29.9%. 
H2 0 requires C, 45.65; H, 6.6; N, 30.4%). 
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ii} Reduction with sodium borohydride: The 
i 2 8 
reaction was carried out as before with slight 
modifications. To a solution of 6-methylpteridin-4(3H)-one 
(500 mg, 3.09 mmol) in 1 M sodium carbonate (3 ml), sodium 
borohydride (500 mg, 13.2 mmol) was added during 3 min. An 
hour later the solution was warmed (effervescence) and 
after 1.75 h, the pH of the solution was adjusted to 8 - 9 
and cooled. The solid was collected and washed with small 
portions of water. The product was recrystallized from hot 
water (2 ml) under nitrogen gas. The solid was collected 
and washed with a small portion of cold water to give 6-
methyl-5,6,7,8-tetrahydropteridin-4(3H)-one ( 3 4 9 mg, 
68.0%), m.p. >2oo 0 c (dee.). This solid could not be freed 
from small amounts of borate ( flame test) by 
recrystallization (Found: C, 36.4; H, 5.4; N, 24.0%. 
. 
H, 5.1; 
N, 2 4 . 2 % • ) ; 1 H NMR ( 1 M DC l ) : 8 1 . 4 8 , d, J 6 . 3 , 6-Me ; 
3.39, q, Jgem -14.4, Jvic 9.4, H7ax; -3.7, 
q, J -14.4, J . 
-gem -vie 
217-218°c (sealed 
3.0, H7 ; 8.2, s, H2. 
eq 
tube); prepared in 60% 
potassium borohydride.] 
m, H6; 
128 [ 1 it. 
yield 
3.77, 
m.p. 
wit h 
6-Methyl-2,3,5,6,7,8-hexahydropteridin-4(3H}-one [38]: 
To pre-reduced platinum oxide ( 50 mg) in trifluoroacetic 
acid (2.5 ml), 6-methylpteridin-4(3H)-one (200 mg) 
trifluoroacetic acid ( 5 ml) was added and this suspension 
. 1n 
was shaken with hydrogen (25°c/720 mmHg). After 2 h, the 
- 162 -
catalyst was f i 1 tered off, the f i 1 tra te was added to an 
ice-cold solution of 1. 3 M methanolic-HCl ( 2 ml) followed 
by dilution with dry ether (60 ml), whereby the colourless 
hydrochloride separated. This was collected and washed 
with ether (15 ml x 3) by centrifugation and then dried in 
vacuo. These crude solids ( 242 mg) were further purified 
from methanol containing a few drops of methanolic-HCl and 
excess ether, and had m.p. 213-218°c (effervescence); 
(Found: C, 35.5; H, 6.1; Cl, 21.6; N, 23.1%. C7 H12 N4 0, 
l.45HC1, H20 requires C, 35.2; H, 6.5; Cl, 21.5; N, 
2 3 • 4 % ) ; UV: £2ss(inflex) 158 (pH 0), £29 3 1054 (pH 7.3) 
and £286 1776 (pH 13.2); 1H NMR (1 M DCl): o 1.62, d, J 
6. 2, 6-Me; 3. 61, q, 
~em 
-14.2, J . 
-VlC 10. 6, H7 · ax' 3. 9 5, q, 
J -14.2, J . 4. 4, H7 . -4.0, m' H6; 4.99, s' H2 (see 
-gem -VlC eq , 
Figure 1 ' p 10 2) ; 13c NMR (proton coupled) ( D20, dioxan as 
an internal standard 67. 6 ppm downf ield from 
tetramethylsilane): o 16.0, q, J 131, 6-Me; 44.7, m, C7; 
49.2, m, C6; 52.1, t, J 159, C2; 157.6, s, C8a; 162.9, 
s, C4 (see Figure 2, p 103). 
6-Methyl-[6,7-D2 ]-5,6,7,8-tetrahydropteridin-4{3H)-one 
[ 21] : To a solution of 1 M sodium carbonate ( 1 ml), 6-
methylpteridin-4(3H)-one (100 mg) was added followed by 
sodium borodeuteride ( 100 mg). The reaction was carried 
out under a stream of nitrogen, and the solution was 
refluxed for 30 sec after 28, 55 and 100 min. After 3.3 
and 4 h, further quantities of sodium borodeuteride (50 mg 
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each) were added and heated until clear. After 5 h, the pH 
of the solution was adjusted to 8 - 9 with 11 M HCl and 
cooled. The solid that separated was collected, triturated 
with water and dried. The solid (234 mg) was 
recrystallized from water to yield the required tetrahydro-
pteridin-4(3H)-one (75 mg), m.p. 213-218oc (dee.), which 
still contained borate (flame test) (Found: C, 44.5; H+D, 
7 • 3 ; N, 29.3%. 
C, 44.0; H+D, 7.3; N, 2 9. 5 % ) , [Found: m/ e 16 8 
(100%), 153 (75%), 139.3 (metastable). 
M + 1 6 8 , M + - 1 5 ( Me ) 1 5 3 ] . The UV s p e ct r a ( e: 2 9 o 9 6 8 5 , pH 7 . 0 ; 
1 2 8 
lit. for 6-methyl-5,6,7,8-tetrahydropteridin-4(3H)-one 
e:290 8511, pH 7) and TLC properties were identical with 
those 
above. 
of 6-methyl-5,6,7,8-tetrahydrooteridin-4(3H)-one 
- -
The deuterium incoporation was better than 95% 
(from 1 H NMR spectra by comparison with CH 3 integral). 
6,7-Dimethylpteridin-4(3H)-one [ 36] : The reaction was 
1 2 7 
carried out as before with slight modifications. A 
solution of 4,5-diaminopyrimidin-6(1H)-one (2.0 g, 15.9 
mmol) in ethanol ( 200 ml) and water ( 20 ml) was heated to 
boiling and diacetyl (2 ml) was added to it. The solution 
was boiled under reflux for l hand cooled. The solution 
was concentrated to half its volume and cooled at 4°c. The 
precipitate (2.42 g) was collected, washed with a little, 
cold ethanol and ether, and dried in vacuo. The mother 
liquor was concentrated to half its volume, cooled and the 
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solid was collected, washed and dried to gi ve a furt her 
quantity of pteridine (64 mg). The total yield was 87.9% ; 
1 H NMR ( 1 M DC 1 ) : c 
7-Me; 9.23, s, H2. 
2.78, s, 7- or 6-Me; 2.81, s, 6- or 
cis-6,7-Dimethyl-5,6,7,8-tetrahydropteridin-4(3H)-one (22]: 
The preceeding 6, 7-dimethylpteridin-4 ( 3H) -one ( 500 mg ) . in 
3 M HCl (25 ml) was hydrogenated with platinum oxide (1 00 
mg, pre-reduced in 25 ml of 3 M HCl) for 5.25 h. The 
catalyst was filtered off and the filtrate evaporated to 
dryness. The colourless residue was dissolved in hot-3 M 
methanolic-HCl ( 40 ml). The crystals that separated on 
cooling were collected and dried . in vacuo to . give the 
hydrochloride of the title compound (500 mg); m.p. >219 °c 
(dee.) (Found: C, 36.7; H, 6.1; Cl, 25.5; N, 21.3 %. 
C, 36.7; H, 
6 . 1 ; C 1 , 2 5 • 5 ; N, 21 . 3 % ) ; 1 H NMR ( 0 • 5 M DC 1 ) : c 1 • 2 8 , d , 
J 6. 6, 6- or 7-Me; 1.35, d, J 6.6, 7- or 6-Me; 3.85 a nd 
3.93, m, J 6.6 and 3.3, H6 and H7; 8.09, s, H2 (see F igure 
3 , p 1 0 5 ) ; UV : € 2 6 2 6 6 8 0 ( pH O ) and € 2 9 2 9 0 2 5 ( pH 7 • 0 ) • 
cis-6,7-Dimethyl-[6,7-D2 ]-5,6,7,8-tetrahydropteridin-4(3H)-
one (23]: To a suspension of pre-reduced platinum o x i d e 
( 5 0 mg) . in 3 M DCl ( 15 ml ) , 1 ' f a so_ut1on o 6,7-
dimethylpteridin-4(3H)-one (250 mg, 1.42 mmol) in 3 M DC l 
( 20 ml) was added, and this suspension was hydrogenate d 
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w i th D 2 gas ( 2 5 ° C / 7 2 0 mm Hg ) for 6 h . The catalyst was 
removed by filtration through Celite and the filtrate was 
evaporated. The residue (crude, 0.45 g) was dried in vacuo 
over phosphorous pentoxide. The solid was dissolved . 1n 
methanol ( 4 ml) and 7 M methanolic-HCl ( 5 ml) was added 
followed by ether until turbid. The solution was cooled 
and the solid was collected (centrifugation) to give cis-
6,7-dimethyl-5,6,7,8-tetrahydropteridin-4(3H)-one 
hydrochloride (241 mg, slightly yellow); m.p. >218oc (dee.) 
(Found: C, 34.3; H+D, 6.6; Cl, 25.2; N, 19.7%. 
C, 34.3; H+D, 
6.7; Cl, 25.3; N, 20.2%), [Found: m/e 184(87%), 182(38%), 
167(100%), 152(75%), 138(55%), C8 H10 D2 N 4 0 requires M+ 182, 
M++2(?) 184, M+-15(Me) 167, M+-30(2Me) 152, M+-44(?) 138]. 
1H NMR integrals indicated better than 95% deuterium 
incorporation at C6 and C7. 
2,6,7-Trimethylpteridin-4(3H)-one (45]: The reaction was 
1 5 7 
carried out as before with slight modifications. 4,5-
1 3 3 
Diamino-2-methylpyrimidin-6(1H)-one sulphate, which was 
generously supplied by Dr D.J. Brown, (0.5 g) and diacetyl 
(5 ml) in water (10 ml) was boiled under reflux for 1.5 h. 
The pH was adjusted to 4 then cooled to give the 2, 6, 7-
trimethylpterid in-4 ( 3H) -one which had m.p. >241°c (dee.) 
l 5 7 . (lit. m.p. 261-262°c) (138 mg, 55 %) , after washing with 
ethanol and drying (Found: C, 54.5; H, 5.3; N, 28.55%. 
H, 5.5; N, 28.4%); 
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2.54, s, 2-Me; 2.66, s, 6- or 7-Me; 
2.68, s, 7- or 6-Me. 
cis-2,6,7-Trimethyl-5,6,7,8-tetrahydropteridin-4(3H)-one 
[24]: Pre-reduced platinum oxide (50 mg) in 3 M HCl (5 
ml) and 2,6,7-trimethylpteridin-4(3H)-one (50 mg, 263 µmol) 
was shaken with hydrogen at 20°c/720 mmHg for 9.5 hand the 
catalyst was filtered off. The filtrate was evaporated to 
dryness. The residual solid (70 mg) was dissolved in 7 M 
methanolic-HCl and ether was added until turbid and cooled. 
2,6,7-Trimethyl-5,6,7,8-tetrahydropteridin-4(3H)-one 
hydrochloride was collected and dried (yield 30 mg, 10.3%). 
It had m.p. 210.5-211.SOC (dee.) (Found: C, 37.2; H, 6.3; 
Cl, 23.7; N, 19.1%. Calculated for C9 H14 N40, 2HC1, l.4H 20 
. 
. C, 37.1; H, 6.5; Cl, 23.9; 
c 1. 2 6, d, J 6. 6, 6- or 7-Me ; 
N, 19 . 2 % ) ; 1 H NMR ( D2 0) : 
1.3, d, J 6.6, 7- or 6-Me; 
2.34, s, 2-Me; 3.81, m, J 6.6 and 3.3, H6 and H7 (see 
Figure 4, p 105); UV: E253 8280 (4 mM HCl). 
6,7-Dimethyl-2-thioxo-2,3-dihydropteridin-4(1H)-one [ 46] : 
1 2 7 
4,5-Diamino-2-thioxopyrimidin-6(1H)-one (2.5 g) in water 
(50 ml) and acetic acid (15 ml) was condensed with diacetyl 
( 2. 5 ml) by boiling under reflux for 1 h. The react ion 
mixture was cooled and the solids were filtered off, washed 
with water, ethanol and ether and then dried in vacuo to 
give 2. 94 g of solid. This crude material was 
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recrystallized from methanol ( 300 ml) (charcoal) to give 
the title pteridine (1.97 g); m.p. >27ooc (dee.) 
l 3 4 1 3 5 (lit. ' m.p. 280-28Soc). From the mother liquor a 
further quantity (0.49 g) of pteridine was obtained. 
( Found : C , 4 5 . 9 ; H, 3.9; N, 26.4; S, 15.6%. 
requires C, 4 6 . 1 ; H, 3 . 9; N, 2 6 . 9; S, 15. 4 % ) ; 1 H NMR ( 2 
M DC 1 ) : cS 2 • 6 4 , s , 6 - or 7 - Me ; 
NaOD): cS 2.47, s, 6- and 7-Me. 
2.68, s, 7- or 6-Me; (1 M 
cis-6,7-Dimethyl-2-thioxo-3,4,5,6,7,8-hexahydropteridin-
4(1H)-one (27]: The preceding 6,7-dimethyl-2-thioxo-2,3-
dihydropteridin-4 ( lH) -one ( 0. 5 g) in 1 M sodium carbonate 
( 40 ml) was reduced by boiling under reflux with sodium 
borohydride ( 6 g total, added in several small portions) 
until the UV spectrum . in 1. 5 M HCl indicated complete 
reduct ion ( 15 h) , and cooled. The so 1 id ( 0 . 2 6 g ) was 
collected, washed with water (centrifuge) and dried. The 
solid (0.15 g from 0.26 g of crude solid) was dissolved in 
methanol (15 ml), ethanol (15 ml) was added and the 
solution was filtered and cooled. The yellow sol id was 
collected, washed with small volumes of methanol and dried 
to give colourless cis-6,7-dimethyl-2-thioxo-3,4,5,6,7,8-
hexahydropteridin-4(3H)-one (28 mg); m.p. >259oc (dee.) 
(Found: C, 41.7; H, 5.6; N, 23.37 S, 13.2%. Calculated 
for C8 H12 N40S, 0.5CH 30H, O.l8NaH 2 B0 3 , 0.1H 20: C, 41.6; H, 
6.0; N, 22.8; S, 13.1%); lH NMR (0 .0 1 M NaOD): cS 1.07, d, 
J 6.7, 6- or 7-Me; 1 • 0 8 , d, J 6 . 7, 7- or 6-Me ; 3.24, 
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octet, J 6.7 and 3.2, H6 or H7; 3.55, octet, J 6.7 and 
3 . 2 , H 7 or H 6 ( s e e F i g u re 5 , p 1 0 7 ) ; OV : t: 2 a 2 5 3 4 2 ( pH O ) . 
6,7-Dimethyl-2-thioxo-3,4,7,8-tetrahydropteridin-4(18)-one 
(47]: To pre-reduced platinum oxide (50 mg) in 3 M HCl 
(5 ml), 6,7-dimethyl-2-thioxo-2,3-dihydropteridin-4(1H)-one 
(50 mg) in 3M HCl (5 ml) was added and hydrogenated for 
5.5 hat 25°C/720 mmHg. The catalyst was filtered off and 
the filtrate was evaporated to dryness to yield the title 
compound (68 mg). The 1 H NMR and UV spectra were 
characteristic for the 7,8-dihydro derivative. Also 
similar hydrogenations carried out in methanol (for 11 h) 
or trifluoroacetic acid (28 h), gave the same 7,8-dihydro 
derivative in both cases; lH NMR (5 M DCl): 8 1.55, d, J 
7.1, 7-Me; 2.53, s, 6-Me; 4.94, q, J 7.1, H7. 
2-Amino-6,7-dim~thylpteridin-4(3H)-thione [ 48] : 2,4,5-
1 5 8 
Triaminopyrimidin-6(1H)-thione hydrochloride which was 
supplied by Dr 1i7 .L.F. Armarego, ·(200 mg) was dissolved in 
water ( 5 ml), the pH was adjusted to 4 and diacetyl ( 0. 2 
ml) was added. The solution was boiled under reflux for 70 
min. The solid ( 150 mg) that separated on cooling was 
collected and recrystallized from water (140 mg); m.p. 
>290°c (dee.) (Found: C, 45.9; H, 4.4; 
14.5%. C, 45.8; 
N, 33.3; 
H, 4.5; 
s' 
N, 
33.4; S, 15.3%); 1 H NMR ( 1 M DC l ) : cS 2. 6 6 , s , 6- or 7 -
Me; 2.68, s, 7- or 6-Me. 
,, 
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. 
C1S- and trans-2-Amino-6,7-dimethyl-5,6,7,8-tetrahydro-
pteridin-4(3H)-thione [26a]: 
i) Reduction with sodium borohydride: 2-Amino-
6, 7-dimethylpteridin-4( 3H)-thione (30 mg) was reduced with 
sodium borohydride (200 mg) in 1 M sodium carbonate (3 ml) 
under nitrogen. The solution was boiled under reflux and 
after 45 . min, 90 min and 12 h, further additions of 200, 
100 and 150 mg of sodium borohydride respectively were 
made. The reaction was continued for 13 h. Ice-cold 7 M 
methanolic-HCl was added to the cooled mixture to acidify, 
and the solution was evaporated to dryness. This residue 
(2.33 g) was passed through a Dowex-50Wx4 (Sigma, 50 - 100 
mesh, H+ form, 2 ml) column, washed with 0.5 M to 1.5 M HCl 
and eluted with 2 M HCl. Evaporation of the last eluate 
mixture of . and trans . (60 mg); gave a cis isomers m.p. 
>211°c (dee.), . the ratio of 1.6 1.0 by lH NMR (cf . in • • 
Figure 6' p 109) (Found: C, 2 6. 3; H, 4 . 7; Cl, 2 3. 4; s, 
9. 5% . Calculated for CaH13N5S, l.6HC1, 0.8NaCl, 0.8H 3B0 3 : 
C, 2 6. 3; H, 4. 7; Cl, 23.3; S, 8 . 8 % ) ; lH NMR ( 2 M DCl at 
270 MHz assigned by proton decoupli~g) cis isomer: 8 1.33, 
d, J 6.8, 6- or 7-Me; 1 . 41 , d, J 6 . 8 , 7 - or 6-Me ; 3 . 9 8 , 
m, J 6.8 and 3. 3, H6 or H7; 4.05, m, J 6. 8 and 3. 3, H7 or 
H6 and trans isomer: 8 1. 4 2, d, J 6 . 6 , 6- or 7-Me; 1. 5 3, 
d, J 6 . 6, 7- or 6-Me; 3.56, m, J 6.6 and 8 . 3, H6 or H7; 
3.74, m, J 6.6 and 8. 3, H7 or H6) . 
ii) Catalytic reduction with platinum oxide in 
trifluoroacetic acid: 2-Amino-6,7-dimethylpteridin-4(3H)-
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thione (15 mg) in trifluoroacetic acid (2 ml) was added to 
pre-reduced platinum oxide (20 mg in 2 ml of 
trilfluoroacetic acid) and hydrogenated for 11 h at 
25 °c/720 mmHg. The catalyst was filtered off through 
Celite and washed with methanol. The filtrate was 
evaporated to dryness in vacuo. The residue (23 mg, yellow 
oil) was purified from methanol and 7 M methanolic-HCl by 
addition of ether, and gave the reduced pteridine with a 
cis to trans ratio of 2.3 : 1.0 by 1H NMR. 
cis-2-Amino-6,7-dimethyl-5,6,7,8-tetrahydropteridin-4(3H)-
thione [ 26b] : To pre-reduced platinum oxide ( 5 mg) . in 
methanol ( 1 ml) , 2-amino-6, 7-dimethylpterid in-4 ( 3H) -th ione 
(5 mg) in methanol (1.5 ml) was added and the mixture was 
hydrogenated for 24 has above. The catalyst was filtered 
off and the filtrate was poured into 7 M methanolic-HCl 
. 
and evaporated to dryness in vacuo. 
only cis-tetrahydropteridine 
Figure 7, p 10 9) • 
. isomer 
This solid contained 
[26b] by la NMR (see 
6,7-Dimethyl-2-methylthiopteridin-4(38)-one [ 50] : 6,7-
Dimethyl-2-thioxo-2, 3-dihydropteridin-4 ( lH) -one ( 5 g, 24. 2 
mmol) in O. 5 M NaOH ( 50 ml) was boiled under reflux wi th 
methyl iodide ( 4. 4 2 ml, 33.9 mmol) for 15 . min. The 
crystals [2.43 g; m.p. 280-284°c (dee.)] were collected, 
washed with water and dried in vacuo. The mother liquor 
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was concentrated to a small volume and cooled to give more 
methylthiopteridine (1.0 g); m.p. >26loc (dee.). The first 
crop (150 mg) was recrystallized from propan-1-ol (10 ml) 
to . give pure 
( 1 0 6 mg ) ; m . p • 
6,7-dimethyl-2-methylthiopteridin-4(3H)-one 
l 3 4 
>255°c (dee.) (lit. m.p. 280-28loc which 
was previously synthesized from 5, 6-diamino-2-methylthio-
1 3 6 
pyrimidin-4(3H)-one, lit. m.p. 283°c) (Found: C, 49.0; 
H, 4 . 6; N, 25.4; S, 14.1%. C~H 10 N4 0S requires 
,., 48.6; 
'-- ' 
H, 4. 5; N, 25.2; S, 14.4%); .!.H NMR ( 0 • 1 M NaOD) : 0 2. 5 4, 
s' CH 3 S; 2.60, s (broad) , 6- and 7-Me; ( 2 M DCl) : 0 2.70, 
s, 6- and 7-Me; 2. 8 3, s' CH 3S. 
cis-6,7-Dimethyl-2-methylthio-5,6,7,8-tetrahydro-
pteridin-4(3H)-one [28]: 
i) Hydrogenation with platinum oxide in 
methanol: 6,7-Dimethyl-2-methylthiopteridin-4(3H)-one (50 
mg, 225 µmol) in methanol ( 5 ml) was added to pre-reduced 
platinum oxide (45 mg) in methanol (5 ml), and hydrogenated 
(25°c/720 mmHg) for 7.5 h. The cate.lyst was filtered off 
and the filtrate was evaporated to dryness and dried in 
vacuo to . give cis-6,7-dimethyl-2-methylthio-5,6,7,8-
tetrahydropteridin-4(3H)-one (67 mg, 91.1%); m.p. >1150C 
(dee.) (Found: N, 17.0; S, 9.5%. Calculated for 
L H NMR ( CDCl 3) : o 
1. 18, d' J 6. 6, 6- or 7-Me; 1. 2 2, d, J 6 . 6 , 7- or 6-Me; 
2.49, s , CH 3 S; 3.49, octet, J 6. 6 and 3 . 0, H6 or H7; 
3. 7 4, octet, J 6. 6 and 3 • 3 I H7 or H6 (see Figure 8 ' p 111) ; 
-
UV: e: 2 7 4 6710 ( 1 . 5 M HCl) . 
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ii) Reduction with sodium borohydride: 6,7-
Dimethyl-2-methylthiopteridin-4(3H)-one (20 mg, 90 µmol) 
and sodium borohydride ( 6 0 mg) were refluxed . ln lSO-
propanol (2 ml) for 2.25 h (after 70 min, another 20 mg of 
sodium borohydride was added). The reaction mixture was 
extracted with iso-propanol and the inorganic salts were 
removed by centrifugation. To the supernatant, 7 M 
methanolic-HCl was added, the solution was evaporated to 
dryness and then methanol and methanolic-HCl was added 
followed by ether. The first sol id that separated was 
removed by centrifugation ( inorganic salts) and the 
supernatant was evaporated to dryness and dried in vacuo to 
give cis-6,7-dimethyl-2-methylthio-5,6,7,8-tetrahydro-
pteridin-4(3H)-one (30 mg) (Found: C, 38.5; H, 5.6; Cl, 
15. 0; N, 18.7; S, 10.0%. 
C, 38.9; H, 5.6; Cl, 15.1; N, 
20.2; S, 11.5%). The UV spectrum of this compound was 
identical with that from the above derivative. In the 
presence of acid this compound released methylthiol 
(odour), so presumably some decomposition occurred in 
acidic solution. 
cis-6,7-Dimethyl-2-methylthio-[6,7-D 2 ]-5,6,7,8-tetra-
hydropteridin-4(3H)-one [ 29] : To pre-reduced platinum 
oxide ( 30 mg) in tetradeuteriated methanol ( 2. 5 ml) and 
6,7-dimethyl-2-methylthiopteridin-4(3H)-one [30 mg, which 
was dissolved in tetradeuteriated methanol (5 ml), 
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evaporated to dryness and then re-dissolved . 1n tetra-
deuteriated methanol ( 2. 5 ml)] was added. Hydrogenation 
was carried out with D2 gas for 23 hat 2sOc/720 mmHg. The 
catalyst was removed by filtration through Celite, 
evaporated to dryness and dried in vacuo to give the title 
compound (18 mg). Greater than 90% deuterium incorporation 
was demonstrated by 1H NMR for this reduction. 
6,7-Dimethyl-2-methylthio-7,8-dihydropteridin-4(3H)-one 
[ 511 : Pre-reduced platinum oxide ( 5 0 mg ) . 1n 
trifluoroacetic acid ( 5 ml), and pteridinone ( 50 mg) in 
trifluoroacetic acid (5 ml) were hydrogenated for 1.25 has 
above. The reaction was followed by UV and lH NMR 
spectroscopy. The catalyst was filtered off and the 
filtrate was evaporated to dryness . 1n vacuo. Methanol and 
methanolic-HCl were added to it and the solid (12 mg) that 
was collected was examined by lH NMR and was starting 
material. The mother 1 iquors were evaporated to dryness 
and the colour of the residual oil (45 mg) changed to dark 
green and had a slight odour of methylthiol on further 
drying. 
7-Me; 
The 1H NMR spectrum ((5 M DCl): o 1.57, d, J 7.1, 
2 • 5 8 , s , CH 3 S ; 2.95, s, 6-Me; 4.99, q, J 7.1, H7] 
showed that it was mostly 6,7-dimethyl-2-methylthio-7,8-
dihydropteridin-4(3H)-one. 
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cis-6,7-Dimethyl-2-methylamino-5,6,7,8-tetra-
hydropteridin-4(3H)-one (25] hydrochloride: This compound 
was supplied by Dr P. Waring and had s 270 13,800 M-1.cm-l 
(4 mM HCl) (Found: C, 35.4; H, 6.35; Cl, 22.8; N, 22.6% . 
2HC1, 
22.8; N, 22.85%). 
. 
requires C, 3 5. 3; H, 6 • 5 ; 
6,6,8-Trimethyl-5,6,7,8-tetrahydropterin (31] 
was supplied by Dr D. Randles. 
6,8-Dimethyl-5,6,7,8-tetrahydropterin (30] 
Cl, 
l 2 6 
and 
6-methyl-5,6,7,8-tetrahydrolumazine 
were supplied by Dr W.L.F. Armarego. 
[32] hydrochlorides 
3-6-3 The rate of rearrangement of quinonoid pteridines 
The stock solution of each tetrahydropteridine was 
made in 4 mM HCl (pH -2) to give a final concentration of 
ca 120 - 280 µM. All concentrations were determined from 
their absorbances and knowns values. The reaction mixture 
contained 1 M Tris/HCl (100 µl, pH 7.4) [or 1 M Bicine (100 
µl, pH 7.1) or 3M potassium phosphate (100 µl, pH 7.0)], 
substrate ( 100 µl), hydrogen peroxide ( 100 µl, 11 µmoles) 
and water (600 µl), and the reaction was initiated by 
addition of peroxidase ( 100 µl, 20 µg of Boehringer grade 
II enzyme or 40 µg of Sigma type I enzyme). The 
concentration of hydrogen peroxide was determined from its 
E237 value of 67 M- 1 .cm- 1 in water. The assays were 
I 
1, 
1, 
II 
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I 
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carried out with a single beam spectrometer and using the 
respective analytical wavelengths (cf. Table 1, p 115) at 
The values of k and t1;2 were computed using a 
programme supplied by Dr D. Randles. The rates for the 
deuteriated analogues were measured in the same way and the 
deuterium isotope effects were calculated (Table 2, p 117). 
The changes of UV spectra were measured on l\Cary 
219 spectrometer (automatic scanning) with the same (above) 
reaction cocktail (see Figures 9 and 10, p 113). 
Potassium ferricyanide solution ( 100 µl, 200 µM) 
and water (700 µ1) was used instead of the peroxidase and 
hydrogen peroxide solution when potassium ferricyanide was 
used as oxidant. 
3-6-4 Non-enzymic oxidation of NADH 
The solutions for the measurements of the rate of 
non-enzymic oxidation of NADH by quinonoid pteridinones 
generated in situ consisted of 1 M Tris/HCl buffer (100 µl, 
pH 7.4) (or 3 M potassium phosphate buffer, pH 7.1, 100 
µl), peroxidase (100 µl, 20 µg of Boehringer grade II or 40 
µg of Sigme type I enzyme), hydrogen peroxide (100 µl, 11 
µmoles), substrate (in 100 µl of 4 mM HCl), and water (500 
µ1), and the reactions were initiated by addition of NADH 
(in 100 µl of 50 mM Tris/HCl buffer, pH 7.3). The rates 
were measured with a single beam spectrometer at 25°c and 
340 nm (Table 3, p 122). 
When potassium ferricyanide was used to generate 
I 
1, 
I 
I~ 
I 
II 
I 
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the quinonoid species, the reaction was carried out in the 
following solution; 1 M Tris/HCl buffer (100 µl, pH 7.4), 2 
mM potassium f erri cyanide ( 100 µ 1, 20 0 µM )", pterid ine 
solution (50 or 100 µl in 4 mM HCl, <70 µM) and water (to 
make 1 ml in final volume). The reaction was initiated by 
addition of NADH solution (30 ul in 50 mM Tris/HCl buffer, 
pH 7 . 3) . The difference in E values between potassium 
ferricyanide and potassium ferrocyanide at 340 nm was small 
(~E340 210 M- 1 .cm- 1 ) compared with the E3 4 o value of NADH 
(6,200 M- 1 ,cm- 1 ). Therefore the effects of the absorbance 
changes due to the iron complex were very small compared 
with the changes for NADH and were neglected. Also in the 
kinetic assay, these effects were completely neglected 
because they were compensated ~ -
below). 
in the two cuvettes (see 
Moreover, the rates of oxidation of NADH with 
potassium ferricyanide were very small when the 
concentration of potassium ferricyanide was varied, i.e. 
this ef feet was neglected from the rate of non-enzym1c 
oxidation of NADH. 
3-6-5 The effect of borate on DHPR activity 
~i The assay was carried out using a double beam UV 
IL, 
spectrometer at 2s 0 c with Aanalyt. 340 nm. The assay 
solution contained 1 M Tris/HCl (100 ul, pH 7.4), 
peroxidase (Sigma, 100 ul, 40 µg ) , hydrogen peroxide (100 
ul, 11 µmol), borate solution (100 µl), 6-MeTHP (5 µl, 55.0 
1, 
1: 
II 
' 
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µM), NADH (30 µl, 100 µM) and water (565 µl). The react io n 
was initiated by injecting the enzyme ( 1 µl, O. 04 µg ) into 
one cuvette. Each borate stock solution was made in water 
to give final concentrations of 50, 100 µM and 1 mM of 
boric acid. The blank assay was performed with water 
instead of borate solution. All of above borate 
concentrations had no effect on the activity of DHPR. 
The tetrahydropteridinones which contained borate 
were 5,6,7,8-tetrahydropteridin-4(3H)-one [ 181 
[6,6,7,7-D~]-5,6,7,8-tetra-
H 2 0) , 6-methyl-5,6,7,8-tetrahydropteridin-4(3H)-one 
D 2]-5,6,7,8-tetrahydropteridin-4(3H)-one (21] 
~.1NaH 2 B0 3 , 0.9H 2 0) and cis-6,7-dimethyl-2-thioxo-3,4,5,-
6,7,8-hexahydropteridin-4(3H)-one 
0 • 5 CH 3 0 H , 0 • 18 Na H 2 BO 3 , 0 • 1H 2 0 ) • 
(27] 
3-6-6 Enzyme assay and kinetic parameters 
The assays were performed essentially as descr ibe d 
9 
by Nielsen et al. in the first place (cf. Chapter 2, 
Section 2-9-1, p 73). The assay was initiated by inject i on 
of DHPR. With this method, the reproducibility was very 
poor, because of the instability of the quinonoid s p ecies 
of compounds [18], [20], [22] and [33]. To avoid that, t h e 
pteridine solutions and NADH solutions were eac h 
simultaneously added to both cuvettes by using two platinum 
- 178 -
buckets which were then moved up and down (10 times) into 
the assay solutions in the sample and blank cuvettes. When 
the reaction was initiated by addition of pteridine 
solution or NADH solution, good reproducibility was 
obtained. To obtain the optimum enzyme concentration for 
each substrate, the assays were performed with different 
enzyme concentrations and keeping the concentrations of 
NADH and substrate constant (Figure 13, p 124). For the 
kinetic assays, the enzyme concentrations were taken from 
the linear portions of the plots of enzyme concentrations 
versus initial velocities (Figure 13). 
Finally, the solutions for the kinetic runs for 
DHPR activity contained the following: 1 M Tris/HCl buffer 
(pH 7.4) (100 µl) [or 3 M potassium phosphate buffer (pH 
7 .1) ( 100 µl)], peroxidase ( 100 µl, 20 µg of Boehringer 
grade II or 40 µg of Sigma type I enzyme), hydrogen 
peroxide (100 µl, 11 µmol), DHPR (see Table 4, p 126, 
about concentration, added to one cuvette), NADH (30 µl, ca 
1 0 0 µ M ) , subs tr ate ( 3 0 µ 1 , con cent rat ion O • 5 ,..,, 3 Km ) and 
water to make 1 ml. The first three components were made 
as a stock solution (kept at O - 20c during runs). 
After mixing all ingredients except the substrate, 
the recorder was activated to ensure that the absorbance 
remained unaltered for approximately 30 sec. The reaction 
w2.s initiated by simultaneous addition of pteridine 
solution to both cuvettes, and the initial rates were 
obtained from the rate of change of absorbance at 340 nm 
for NADH oxidation. Rates from duplicate runs from at 
11 
'• 
i 
I 
I 
I: 
ii 
l\ 
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least five concentrations of substrates were used to derive 
the kinetic parmeters. All of kinetic parmeters were 
calculated . using a computer programme that was kindly 
.1. 5 9 
supplied by Dr A. Cornish-Bowden, and values derived 
from double reciprocal plots of concentrations versus 
initial velocities agreed well with computed values. The 
pH values at the end of each run were measured with a glass 
electrode and were 0.1 pH unit lower than the values of the 
stock buffers originally used. 
When the quinonoid species were generated by using 
potassium ferricyanide as an oxidant, the stock solution 
contained 1 M Tris/HCl buffer (100 µl, pH 7.4), 2 mM 
potassium ferricyanide ( 3 times higher concentration than 
the highest pteridine solution) and water (to make 1 ml in 
final volume). The pteridine solution (100 µl in 4 mM HCl, 
0.1 - 1.5 K) and NADH solution (30 µl in 50 mM Tris/HCl 
m 
buffer, pH 7. 3) were each added simultaneously with 
platinum buckets which were then moved up and down ( 10 
times) into the assay solution to ensure complete mixing. 
The reaction was initiated by addition of pteridine or NADH 
solution, and at the same time one of the buckets also 
contained DHPR (>1 µl). Soon after mixing the recorder was 
initiated. The loss of NADH concentration was small during 
the initial rate measurement but the concentration of NADH 
was still or near saturating levels (Table 3, p ~22). 
The app.K and app.V values for NADH were 
m max 
similarly measured using the following solution: 1 M 
Tris/HCl buffer ( pH 7. 4) ( 100 µ 1), peroxidase ( Sigma type 
I 
:, 
J 
ll 
I 
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I, 10 µl), hydrogen peroxide (100 µl, 11 nmol), DHPR (1 µl, 
0.04 µg) and water (740 µl). The blank cu vet te did not 
contain DHPR. NADH (30 µl) was added simultaneously (0.5 -
5 Km) to both cuvettes (sample and blank) and the reaction 
was initiated by the simultaneous addition of 6,7-dimethyl-
5,6,7,8-tetrahydropterin stock solution (10 µl in 4 mM HCl, 
50 µM) (see Table 6, p 131). 
3-6-7 pH rate profile study 
11 The 6,7-dimethyl-[6,7-D2 ]-5,6,7,8-tetrahydropterin 
IJ 
111 
I 
~·. 
I 
was used as substrate and quinonoid species were generated 
by peroxidase and hydrogen peroxide oxidation. Although 
the stabilities of quinonoid species were different at 
various pH values (Figure 14, p 136), the quinonoid species 
formed at neut r a 1 pH we re stab 1 e in an ice-bath for at 
least 30 . min. For example, pterin stock solution (in 4 mM 
HCl, 20 µl), 0.5 M Tris/HCl buffer (pH 7.2) (50 µl), 
peroxidase (Sigma type II, 100 µl), hydrogen peroxide (100 
µl, 11 nmol) and water (730 µl) were mixed at room 
temperature. After the formation of quinonoid species this 
solution was placed in an ice-bath. Aliquots (50 µl) were 
taken and mixed with buffer cocktail (0.5 M Tris/HCl 
1 4 5 
buffer, 100 µl; mixed buffer, 100 µl; water 720 µl), 
NADH (30 µl, 141 µM) and the reaction was initiated by 
injection of DHPR (5 µl, 0.2 µg) (Figure 15, p 137). [The 
purpose of the mixed buffers was to produce sufficient 
buffering action with varying pH values and consisted of 1 
) 
1, 
11 
' 
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MMES and 0.5 M ethanolamine and adjusted to the required 
pH with HCl or NaOH solution. Tris/HCl buffer was added 
separately. In the final assay cocktail, the concentration 
of each ingredient was 50 mM Tris, 100 mM MES and 50 mM 
ethanlamine and the ionic strength was kept at ca 0.2 by 
adding NaCl to each different pH buffer stock solution. 
The pH of the stock solutions were pH 5. 81, 6. 2 4, 6. 8 8, 
7.87, 8.56, 9.21 and 9.88, and . the mixture the 1n assay 
final pH was always 0.1 pH unit lower than the above.] 
The stability of quinonoid species at different pH 
values was measured by addition of quinonoid solution 
formed by peroxidase and hydrogen peroxide oxidation (900 
µl) to each buffer mixture (100 µl) at 2soc using a single 
beam spectrometer (Figure 14, p 136). 
The rates of non-enzymic oxidation of NADH at 
different pH values were measured by initiating the 
reaction by adding NADH ( 30 µl, 152 µM) to the quinonoid 
solution ( 100 µl, 61 µM as tetrahydro derivative), 0. 5 M 
Tris/HCl buffer (100 µl), mixed buffer (100 µl) and water 
(670 µl) at . using a single beam spectrometer and 
observing the absorbance change at 340 nm (Figure 15, 
p 137). 
It was not possible to obtain reliable kinetic 
parameters (app.K and app.V ) at the various pH values, 
m max 
because the reproducibility of initial rates was very 
poor. 
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3-6-8 Attempted identification of the oxidation products 
of 4,5-diaminopyrimidin-6(1H)-one (33] and ·pteridinones 
(18], (20], (22] 
A: by TLC and NMR 
i) Peroxidase ( 100 µl), hydrogen peroxide ( 100 
µl, 3. 3 % ) , 1 M Tris/HCl buffer ( 100 µl), pteridinone 
solution (see below) and water (to make a total volume of 1 
ml) were mixed at 20°c and aliquots were taken at time 
intervals and placed on TLC plates (p 152). In the case of 
4,5-diaminopyrimidin-6( lH)-one [33] ( 100 µl, 350 µM), at 
least five spots including spots from the blank 
(peroxidase, hydrogen peroxide and Trisr two . main spots) 
were observed. The number of spots had not changed between 
1.5 min and 7 h incubation periods. None of them had the 
same characteristics as 2-carboxy-l,3,5-triazin-4(3H)-one 
[66] (p 141) or l,3,5-triazin-2,4(1H,3H)-dione [67] 
(p 141). In the case of tetrahydropteridin-4(3H)-one [18] 
( 6 0 µ 1 , 1 . 9 7 mM ) e i g ht spots were ob ta i n e d i n c 1 u d i n g the 
spots from the blank. One blue fluorescent (250 nm lamp) 
spot (Rf ~0.9) was extracted and gave a solution with only 
"tail" absorption in the UV spectrum. The fluorescence of 
this spot increased with time. This may be due to dimeric 
pteridine . species. In the case of 6-methyl-5,6,7,8-
tetra:1ydropteridin-4(3H)-one [20] (30 µl, 1.19 mM), seven 
spots were revealed. Also the same blue fluorescent spot 
appeared (Rf ~0.9). In the case of 6,7-dimethyl-5,6,7,8-
- 183 -
tetrahydropteridin-4(3H)-one [22] (100 µl, 585 µM), six 
spots appeared after 1 min and the relative intensities, 
but not the number of spots, altered with time. Attempts 
to identify the spots in those solutions were uniformly 
unsuccessful. 
absorption. 
Most of the spots had "tail" or no UV 
Only traces of the fully oxidized pteridines 
were identified. The oxidation is not clear and produces a 
variety of products from the early stages of the reaction. 
ii) 6-Methyl-5,6,7,8-tetrahydropteridin-4(3H)-
one [20] (50 mg, 0.215 mmol) was mixed with 30% hydrogen 
peroxide (0.2 ml) and stirred at 20°c. After 10 h, the 
solids were removed (<1 mg) by filtration and the filtrate 
was freeze-dried ( 60 mg). The residue (10 mg) was 
dissolved in water and separated by TLC (cf. p 152). The 
six bands were extracted with 1 : 1, methanol - methylene 
chloride and examined by UV and lH NMR spectroscopy. Only 
6-methylpteridin-4(3H)-one 
identified. 
[37] (<10% yield) was fully 
iii) 4,5-Diaminopyrimidin-6(1H)-one [33] (100 mg) 
in 30% hydrogen peroxide (0.5 ml) was stirred for 15 hat 
Some ammonia was released (odour). The so 1 ids ( 4 7 
mg, m.p. >30o 0 c) that separated were collected and 
showed similar Rf values (-0.5) on TLC as the one from 2-
1 4 7 
amino-l,3,5-triazin-4,6(1H,5H)-dione (Ammelide) [77] 
which was obtained from the reaction of 2,4-diamino-
pyrimidin-6(1H)-one [ 7 8] and hydrogen peroxide. The 
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reported A value of Ammelide 
max 
0 
A 
N NH 
HNJlN~O 
2 H 
(77] 
l. 4 8 1s 221 nm (in water). 
0 
H 
HN 
H2N~N NH 2 
(78] 
On the other hand, the solid obtained had A at ca 220, 
max 
280 (weak) and 330 (very weak) nm (in water), and gave very 
strong yellow fluorescence when it was dissolved into 10 M 
NaOH solution. The UV spectrum indicates that perhaps the 
pyrimidine ring was cleaved and that another UV absorbing 
heterocyclic compound was formed (e.g. Scheme 10). 
0 )l 
N NH 
llN~COOH 
(33] [69] [66] 
Scheme 10 
iv) A mixture of 4,5-diaminopyrimidin-6(1H)-one 
[33] (100 mg), 30% hydrogen peroxide (0.5 ml) and 2 M NaOH 
(1.25 ml) was stirred for 3 h at 200c. Ammon i a was 
released (odour) and the yellow solids formed were 
collected (10 mg); m.p. >3oooc. The filtrate was furt her 
reacted with 30% hydrogen peroxide ( 0. 2 ml) for 2 h and 
more yellow solids were collected (50 mg); m.p. >300°c. On 
0 
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TLC, none of spots had the same Rf as authentic 4,6-~ 
dihydroxy-1,3,5-triazine-2-carboxylic acid (oxonic acid, 
potassium salt) [79], and the UV spectrum had >i. at ca 
max 
147 220 and 280(weak) nm (pH 7). Zav'yalov and Pokhvisneva 
COOK 
HN~N 
O~N~O 
H 
(79] 
COONa 
N~N 
H2N ~ N .Jl ON a 
[80) 
reported that sodium 4-amino-6-hydroxy-1,3,5-triazine-2-
carboxylate [80], which was obtained from the 2,4-diamino-
pyrimidin-6(1H)-one [78], had >i. at 250 nm (in water) and 
- max 
m.p. >3oo 0 c (dee.). If in the present case the same 
reaction was occurring, the product should have had a >i. 
max 
shorter than 250 nm because of the absence of the 2-amino 
group. 
v) 4,5-Diaminopyrimidin-6(1H)-one [33] (3 mg) was 
dissolved into D2 0 ( 2 ml) and aliquots of this solution 
(0.6 ml) were added to 3.3% hydrogen peroxide in D
2
0 (0.15 
ml) and peroxidase (1 mg in 2.5 ml of D2 0, 1 drop) in a NMR 
tube. After 16 . min, the signal from the C2 proton 
disappeared which was indication of exchange with deuterium 
or degradation of the pyrimidine followed by deuterium 
exchange (Figure 16, p 140). 
vi) 6,7-Dimethyl-5,6,7,8-tetrahydropteridin-
, 
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4(3H)-one [22] solution (30 µl, 147 µM) was mixed with 1 M 
Tris/HCl buffer (pH 7. 6) ( 100 µl), 5 mM potassium 
ferricyanide ( 100 µl, 500 µM) and water ( 770 µl) at 200c 
and aliquots were taken at various time intervals and were 
examined by TLC. Soon after mixing, the yellow colour of 
the iron complex became weaker and the solution gave six 
main spots, two of which were from buffer and oxidant. The 
number of main spots did not change during the 18 h of 
incubation. The blue fluorescent spot at the solvent front 
was similar to the one from the peroxidase and hydrogen 
peroxide oxidation above. Only traces of 6, 7-
dimethylpteridin-4(3H)-one [36] (p 99) were identified in 
the products after 18 h. As above the other bands gave 
unidentifiable products which had no maximum 1n the UV 
spectra suggested that they did not contain an unsaturated 
heterocyclic chromophore. Only traces of these 
pteridinones were following the same oxidation pathway as 
the pterins to give fully oxidized pteridinones. 
vii) cis-6,7-Dimethyl-2-thioxo-3,4,5,6,7,8-
hexahydropteridin-4(1H)-one [27] (p 96) (1.5 mg, 1.4 mM) 
was mixed with 1 M Tris/HCl buffer ( pH 7. 4) ( 0. 5 ml) and 
water (3.25 ml) and then potassium ferricyanide (1.25 ml, 5 
mM) was added. The reaction was followed by TLC. Soon 
after addition of oxidant the spot from tetrahydro 
derivative disappeared, and after 40 min another spot which 
had the same Rf as fully oxidized pteridinone appeared. 
This spot became stronger with time. After 1 h, this spot 
II 
11 
·, 
I 
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was the main spot on TLC which had two other weak 
unidentifiable spots. 
B: The reaction with horseradish peroxidase and hydrogen 
peroxide 
The kinetic runs for obtaining the K and V 
m max 
values of peroxidase in the presence of hydrogen peroxide 
at 2 5 ° C were performed with 1 M Tris/HCl buff er ( pH 7. 4) 
( 100 µl) [or 3 M potassium phosphate buffer (pH 7 .1) ( 100 
µl)], substrate (100 µl, 0.5 - 2 Km concentration), 
hydrogen peroxide (100 µl, 11 or 22 nmol; the 
concentration of stock solution was determined from the 
s237 value of 67 M- 1 .cm- 1 in water) and water to make 990 
µl (or 1 ml in the blank cuvette). The reaction was 
initiated by injection of peroxidase (10 µl, Boehringer, 2 
µg) to the reaction cuvette and the initial rates were 
obtained by measuring the rate of decrease in absorbance at 
an analytical wavelength set for each substrate (see Table 
7, p 146). When measuring the effects of each component, 
the concentration of hydrogen peroxide or peroxidase was 
altered by changing the amount of hydrogen peroxide or 
volume of enzyme solution repectively (see Figure 17, 
p 14 5) . The non-en z ym i c rates , i n O • 1 M Tris /H C 1 bu ff er 
(pH 7.4) were negligible for compounds [18], (20], (22] and 
(33] in the absence of hydrogen peroxide and 8.9, 7.0, 7.6 
and 5.9% substrates [i.e. tetrahydropteridin-4(3H)-ones 
(18], (20], (22] and (33] J were oxidized respectively in 
I, 
1 
l, 
1 o 
LU .. 
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the first 10 min in the presence of 11 mM hydrogen peroxide 
alone. The amounts oxidized in the first 10 min were 
slightly less than above, when hydrogen peroxide was 11 uM. 
The kinetic parameters (K and V ) were calculated using 
m max 
1 5 9 
a computer programme (see Table 7, p 146). 
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CHAPTER 4 
INHIBITION OF DIHYDROPTERIDINE REDUCTASE FROM HUMAN BRAIN 
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4-1 Introduction 
Inhibitors of human DHPR have been reported by 
several authors. 
9 0 9 7 
Shen et al. ' have described the 
inhibition of human liver DHPR by a variety of 
catecholamines and related compounds including dopamine. 
1 5 1 6 0 
Armarego and Waring ' have shown that the true 
catecholamine inhibitors are in fact the oxidation products 
of the catecholamines, the quinone dopachromes, generated 
by horseradish peroxidase and hydrogen peroxide in the 
9 0 9 7 
assay procedure used by Shen et al. ' However, Shen 
96 101.....,104 
et al. ' have also described several other phenolic 
compounds which are true inhibitors. These are not readily 
oxidized under the assay conditions and are known to be 
inhibitors for other enzymes involved in the metabolism of 
9 0 
catecholamines (e.g. monoamine oxidase). Other authors 
also had shown that aminopterin, which is a strong tight 
binding inhibitor of dihydrofolate reductase is also an 
inhibitor of human liver DHPR, albeit a weaker inhibitor. 
1 0 
Firgaira et al. reported briefly the inhibition 
of human liver DHPR by thiol specific reagents and metal 
ions, for example, HgC1 2 (0.1 µM; 60%), p-chloromercuri-
benzoate (10 µM; 70%) and 5,5'-dithiobis(2-nitrobenzoic 
acid) ( 100 µM; 60%) which markedly inhibited the enzyme, 
whereas N-ethylmaleimide (1 mM; 76%) and iodoacetamide (10 
mM; 70%) showed weaker effects. The use of these compounds 
at concentrations one order magnitude higher than those 
shown above produced total inhibition of activity. 
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However, MgC1 2 (10 mM) and MnC1 2 (10 mM) had no effect on 
enzyme activity, but CoC1 2 caused 30% inhibition at a 
concentration of 0.01 mM. On the other hand, Williams 
5 1 
et al. found that DHPR from a Pseudomonas species was 
inhibited by MgC1 2 , MnC1 2 and CdC1 2 but not by CoC1 2 • 
9 5 9 3 
Dhondt et al. , Purdy et al. and Leeming 
9 4 
et al. described the inhibition of DHPR (from rat 
tissues) by metals (Pt, Pb and Al respectively) and stated 
that the metals may cause significant inhibitions also of 
the human enzyme which may be serious because these metals 
could accumulate . in the body either accidentally 
drug therapy using these metals e.g. cis-platin 
diaminodichloroplatinum) [l]. 
-Cl 
/ 
Pt (II) 
/ " Cl 
-
[1] 
. 
or via 
(cis-
The strongest known inhibitors of human DHPR have 
Ki values in the micromolar range and a search for more 
potent inhibitors is required for the preparation of active 
site directed irreversible inhibitors for determining amino 
acid residues at or close to the active site (affinity 
labelling reagents), and for inducing DHPR deficiency . in 
experimental animals so as to mimic hyperphenylalaninemia 
due to this cause. 
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4-2 Inhibition by oxidized pteridines 
l 7 
Cheema et al. reported that 6,7-dimethylpterin 
(app.Ki 300 µM) and 6,7-dimethylpteridin-4(3H)-one (app.Ki 
50 uM) showed non-competitive inhibitior activities for 
sheep liver DHPR. In the present work, pteridin-4(3H)-one 
and 6,7-dimethylpteridin-4(3H)-one were examined for their 
inhibitory effect on human brain DHPR. These compounds 
were pre-incubated for some time (e.g. 30 min) with the 
enzyme 1n potassium phosphate buff er ( pH 7. 3) and then 
assayed with quinonoid 6-methyl-7 ,8-dihydro(6H)pterin and 
NADH. They exhibited no inhibitory effect on human brain 
DHPR (5.6 uM) at inhibitor concentrations up to 206 uM and 
185 uM respectively at pH 7.3. 
Sheep liver DHPR (kindly supplied from Dr W.L.F. 
Armarego) was examined with 6,7-dimethylpterin and 6,7-
dimethylpteridin-4(3H)-one 1n order to compare with 
l 7 
Cheema's report, as well as with 6,7-dimethyl-2-thio-
lumazine. To follow the reported experimental conditions, 
6, 7-dimethyltetrahydropterin was used as a substrate 
precursor but potassium ferricyanide [K 3 Fe(CN) 6 ] was used 
as oxidant to generate the quinonoid substrate. The iron 
complex was a more convenient oxidant than dichlorophenol-
indophenol which was used in the reported work. 6,7-
Dimethylpterin at 447 µM, 6,7-dimethylpteridin-4(3H)-one at 
111 uM and 6, 7-dimethyl-2-thiolumazine at 211 uM exerted 
50%, 0% and 20% inhibition of sheep liver DHPR respectively 
after incubation for 3 . min. These results for 6,7-
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dimethylpterin were consistent with those reported, but the 
non-inhibitory effect observed with 6,7-dimethylpteridine-
1 7 
4(3H)-one was different. Cheema et al. stated that the 
latter substance showed non-competitive inhibition with 
sheep liver DHPR. There are small differences between the 
present and the reported methods, e.g. the oxidants, the 
sources of the pteridines (i.e. syntheses) and the buffers 
used, but it is unlikely that these are the reasons for the 
large difference in the results obtained. No plausible 
explanation can be given at present for the discrepancy. 
The inhibitions of human brain DHPR by the 
pterins, pteridinones and the thio-derivative studied were 
very weak or absent, and further studies along those lines 
were discontinued. 
4-3 Inactivation by potassium ferrocyanide 
When DHP R activity is assayed with a qui non o id 
dihydro(6H)pterin substrate which is generated by K3 Fe(CN) 6 
oxidation of the tetrahydropterin, we are concerned that 
This the DHPR activity may be affected by K3 Fe(CN) 6 • 
oxidant could conceivably inhibit the enzyme by reacting 
with amino acid residues via electrophilic attack or it may 
l 6 1 
oxidize some amino acid residues. 
K3 Fe(CN) 6 was examined at concentrations of up to 
30 mM, but showed no effect on the human brain DHPR 
activity when it was pre-incubated with DTT free enzyme. 
On the other hand, potassium ferrocyanide [K 4 Fe(CN) 6 J at 10 
11· 
, 
I 
Ii 
I 
If ) 
I , 
1: 
1, 
I 
,! 
1, 
' 
11 
,, 
'1 , 
'~ ' 
- 194 -
30 mM concentrations affected human brain DHPR 
activity. Up to ca 90% inhibition was observed after 2 h 
at the above concentration. The . . rema1n1ng 10% of enzyme 
activity may be due to protection by traces of bound NADH 
or deterioration of the enzyme-inhibitor complex by 
oxidation of the active inhibitor with time. Dialysis of 
these incubation solutions did not help to recover the 
original enzyme activities, 1.e. the in~ctivations included 
an irreversible step. Dithiothreitol (2.6 mM) had a slight 
protective effect on this inactivation when the K
4
Fe(CN) 6 
concentration was 20 mM, and the protection by NADH was 
better at higher NADH concentrations (Figure 1). 
If the inactivation process involved a fast pre-
equilibrium between the enzyme and inhibitor prior to 
showing irreversible inhibition, i.e. k_1 >> k2 then the 
E + I 
k-1 
reaction rate should be controlled by k 2 and exhibit first 
order kinetics. This was not the case here and a plot of 
the log values of the remaining activities versus 
incubation times gave curved lines, i.e. this inactivation 
by K4 Fe(CN) 6 did not follow the simple first order kinetics 
law, and is clearly more complicated than shown in Equation 
( 1) (cf. time dependent inactivation by K2 PtC1 4 , p 207). 
In a fluorescence study, the inhibition of human 
brain DHPR by K Fe(Cd) 6 showed time dependent quenching of 
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Figure 1. Time dependent inactivation of human brain DHPR 
by Ki.Fe(CN) 6 ( 200c, pH 7 .2). All incubation mixtures 
contained 3.60 µM of DHPR. 
- ·-·-
phosphate buffer (pH 7.2); -•-•-
in 0.03 M potassium 
100 µM NADH and 20 mM 
K4 Fe(CN) 6 in the same buffer; -•-•- 5.5 µM NADH and 20 mM 
K4 Fe(CN) 6 in the same buffer; -o-o- 10 mM K4 Fe(CN) 6 in the 
same buffer; -6-6- 20 mM K4 Fe(CN) 6 in the same buffer. 
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enzyme fluorescence. DHPR (DTT free) was mixed with 
K4 Fe(CN) 6 solution in 0.1 M potassium phosphate buffer (pH 
7. 2) and the fluorescence emission spectral changes were 
observed (Figure 2) • Slow time dependent decrease . 1n 
fluorescence was observed at 350 nm ( 3% in 10 min) [with 
higher concentration of K4 Fe (CN) 6 the fluorescence change 
became much faster]. When NADH (0.9 µM) was added to the 
above mixture, fluorescence quenching due to NADH binding 
was observed but it was weaker than expected because 
already some of K4 Fe(CN) 6 was bound irreversibly to some of 
the enzyme molecules. On the other hand, when K4 Fe ( CN) 6 
(100 µM) was added to a mixture of DHPR and NADH (100 µM), 
no further change of fluorescence intensity was observed, 
i.e. NADH protected enzyme from K4 Fe(CN) 6 inactivation. 
These data were important to make sure that the 
I 
routine assays were not seriously influenced by the 
presence of these iron complexes. It should be pointed out 
that the concentration of K4 Fe(CN) 6 which is derived from 
K 3 Fe(CN) 6 at the beginning of the usual assay is very low 
and its effects on the initial rates would be minimal. 
The reason for the differences in reactivity 
between K 3 Fe(CN) 6 and K 4 Fe(CN) 6 on DHPR activity is 
possibly because Fe 2 + can react with the protein at the 
His, Asp, Glu, Cys, Lys, or Arg residues. According to 
l 6 2 
2 Pe a r s o n , Fe + h a s h i g he r a f f i n i t y for the RSH group than 
Fe 3+. If the reactivity of Fe2+ towards RSH or Rs-, etc. 
is higher than with CN-, Fe2+ may react irreversibly with 
these residues on the protein. 
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Figure 2. Fluorescence emission spectra of DHPR with 
K'+Fe(CN) 6 at 200c, pH 7 .2. 
in 0.1 M potassium phosphate buffer (pH 7.2). The emission 
spectra were scanned at time intervals (excitation 
wavelength was 280 nm); After 10 min, NADH (4 µM) 
was added (no change after 2 min); 
µM) in 0.1 M potassium phosphate buffer (pH 7.2). 
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No formation of enzyme dimer occurred in the above 
inactivated enzyme as shown by SDS-PAGE, implying that this 
inhibitor does not cause intermolecular crosslinking. 
4-4 Inactivation by potassium tetrachloroplatinate 
4-4-1 Pt(II) complexes and cancer chemotherapy 
The involvement of inorganic, metal-based 
compounds in cancer treatment was very limited until the 
discovery of the potent anti-cancer activity in certain 
1 6 3 
platinum(II) coordination compounds by Rosenberg et al. 
After the discovery of this anti-tumour activity, the first 
platinum drug, cis-platin [1] (p 191), was developed and 
has now proved to be of significant value in treating 
several human tumours, particularly those from the head and 
genitourinary organs. The anti-tumour activity was shown 
164 165 
to be due to binding of the metal complex to DNA. ' 
However, cis-platin was found to cause cytotoxic 
damage especially to the kidneys ( Table 1). To minimize 
this cytotoxicity and to raise membrane permeability , 
several other Pt(II) complexes were developed, but . ClS-
plat in is st i 11 the most widely used drug. . Moreover, 1n 
these complexes, only the . ClS and non-electrica l ly charged 
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Table 1 . Organ distribution of cis-platin in rat 
.L 6 6 
tissues. 
organs 
Blood* 
Skin* 
Thyroid 
Liver* 
Spleen 
Pancreas 
Stomach 
Small intestine 
Large intestine 
Kidneys 
Adrenals 
Heart 
Lung* 
Brain* 
Muscle 
Tumour 
Bone 
Marrow 
Bladder 
Tendons 
% of injected dose/g of tissue 
0.378 
0.495 
0.119 
0.755 
0.334 
0.306 
0.110 
0.411 
0.351 
1.747 
0.614 
0.166 
0.569 
0.035 
0.002 
0.226 
0.584 
0.234 
0.520 
0.674 
22 
* DHPR had been isolated from these human tissues. 
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( i . e • neutral) isomers ( e • g. [ 1 ] ) had anti-tumour 
activities; the trans isomers (e.g. [2]) were much less 
effective. 
4-4-2 Pt(II) complexes and other enzymes 
Platinum complexes have been widely used in the X-
ray crystallographic studies of the three-dimen s ional 
l 6 7 
structures of proteins with whic~ they complexed. 
Several amino acids were found to form complexes with 
Pt(II) complexes at reactive sulphydryl groups 
l 6 8 
proteins, and the tetrachloroplatinate ion (PtC1 4 2-) 
. 
1n 
[ 3] 
was found to preferentially bind to methionine residues 
which reacted with Pt(II) complexes by nucleophilic attack 
l 6 9 
by the sulphur atom. It is known that different 
platinum (Pt) complexes have different binding sites on 
proteins, although the sites have not yet been identified 
directly except in studies by X-rays. 
proteins, 
Cl. 2-
/ 
" Cl Cl - • 
[ 3] 
In the interactions between Pt complexes and 
it has been stated that negatively charged 
complexes are more effective binders than the neutral or 
l 7 0 positively charged complexes. This is in contrast to 
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the reactions w i th nu c 1 e i c a c ids i n w h i ch the neut r a 1 pt 
complexes appear to react better (perhaps by inter-
calation). The ligands on the Pt(II) atom showed 
different effects on the rates of interaction between 
.L 7 .L 
Pt(II) complexes and proteins. Friedman et al. showed 
that tetrabromoplatinate ion (PtBr4 2-) [4] inhibited malate 
dehydrogenase more strongly than PtCl 2-4 [ 3] ' 
. 
1. e. the 
reaction depended on the release of a ligand group from the 
Pt complexes in aqueous buffers. This phenomenon was 
explained as follows; the real inhibitors were the aquo 
.L 7 2 
species rather than tetrahalo compounds, and bromide 
1 igands on the platinum complex could be exchanged with 
water much faster than chloride ligands, and these Pt-aquo 
species will exchange their water ligands with some amino 
.L7.L .173 
acid residues on proteins. Teggins et al. ' reported 
that bromide ligands were more labile than chloride ligands 
- - 2-
-
- 2-Br Br NC /CN 
"' 
/ 
"' Pt (II) Pt( II) / 
" 
/ 
" Br Br NC CN .. - - -
[4] [ 5] 
1n substitution reaction of these Pt(II) complexes in their 
malate dehydrogenase inhibition studies. However, in 
general it is known that the affinity of Pt(II) metals for 
several ligands is in the order R2 S, RSH, Rs-> RNH 2 , NH 3 > 
.L 7 4 
Br-> c1- > H2 0 and this is also approximately the order 
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of decreasing trans-effects of these ligands. Moreover, 
complexes such as tetracyanoplatinate . 10n [ 5] 
with more stable ligands can bind proteins 
electrostatically ( i . e • no ligand exchange), while 
complexes such as PtC1 4 2 - generally form covalent protein 
l 7 4 
linkages. 
In aqueous solution, Pt(II) complexes (e.g. 
PtCl 4 2 -) undergo 1 igand-exchange with water molecules and 
the equilibria in Scheme 1 are set up. Al though X-ray 
Scheme 1 
analysis of Pt binding sites on the enzymes were carried 
l 7 5 
out in the solid state, Dickerson et al. showed that in 
these enzymes the preferential binding site of PtC1 4 2- was 
at the methionine residues which are on the surface of the 
protein molecule. In a study of Pt (II) complexes 
[potassium tetrachloroplatinate (K 2 PtC1 4 ) [6], cis- [1] and 
trans- [ 2 ] plat in] l 7 6 with seven enzymes, Aull et al. 
reported that the enzymes which had no cyst e in e res id u es 
- 2- ,_ -,_ H2 Br Cl Cl 
"' 
/ N / / 
" 
H2C 2+ 
K2 Pt (II) I Pt(II) 
/ 
" 
H2c,N / "" 
Cl Cl H2 Br ... 
-
- -
[ 6] [7] 
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were not inhibited, whereas those possessing cysteine 
residues were inhibited. There was one exception, however, 
1 7 7 
leucine aminopeptidase, which was known to be a metal-
requiring enzyme and possessed no essential thiol residues, 
was inhibited by PtBr 4 2 - (4] (100% inhibition at 5 mM, 
after 1 h ) ' cis-dibromo[ethylenediamine]platinum 
(Pt[en]Br 2 ) [7] (80%; 5 mM; 50 h) and bromo[diethylenetri-
amine]platinum (Pt[dien]Br+) [8] (20%; 5 mM; 50 h). Also 
mono-aquo tribromoplatinate [PtBr 3 (H 2 o)-J [9], which was 
... 
-+ - ,.-H2 Br (H20) /N" /Br 
" 
/ H2C 
I Pt(II) Pt (II) 
H2c, / " / 
" 
N'°' _,,,,. NH 2 H C-C Br Br H2 H2 ... 
--
-[8] [9] 
formed by aging the aqueous solution showed stronger 
inhibitory effect than PtBr
4
2-. In this case the 
interaction may have been with the w-NH 2 group of e.g. a 
lysine residue, or the -SMe group of a methionine residue 
at or near the active site. 
In summary the Pt(II) complexes of, for example, 
1 7 0 
PtC1 4 2 - [3] (malate dehydrogenase) , PtBr 4 2- [4] (malate 
170 172 dehydrogenase, leucine aminopeptidase) ' . , ClS- [ 1] and 
trans-platin [2] (malate dehydrogenase, liver alcohol 
168 170 
dehydrogenase, lactate dehydrogenase) ' , Pt(CN) 4 2 - [SJ 
1 7 8 (liver alcohol dehydrogenase) caused loss of activity of 
the respective enzymes in brackets. In these examples 
inactivation followed first order kinetics and the 
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equilibrium constants k_1/k1 (Equation 1) were reported. 
In examples where the inhibition was irreversible, e.g. 
l 7 8 
Au(CN) 2 - (liver alcohol dehydrogenase) and trans-platin 
l 7 9 
(thymidylate synthase) , the inhibition did not follow 
simple first order kinetics. 
4-4-3 Inactivation studies of human brain DHPR with 
different Pt{II) complexes 
Several works were reported about the interaction 
between DHPR and metal complexes (see Chapter 1, p 30 and 
9 3 
Section 4-1, p 190). Purdy et al. studied the effects of 
9 5 lead compounds. Dhondt and Bellahsene published some 
effects of cis-platin. They reported significant 
i nh ibi t ion of DHPR ( both worked on rat enzyme) , al though 
the experimental details of the latter authors were not 
clear. If human DHPR behaves in the same way, then cis-
platin chemotherapy may cause DHPR deficiency in patients, 
95 
although cis-platin does not enter brain easily. DHPR 
from human brain and other parts of the body is genetically 
the same, and all human DHPR seem to have similar 
properties (cf. Chapter 2, p 37 or reference 22). The 
human brain enzyme was chosen for the present studies 
because it is more readily available to us and also because 
brain . lS relatively free from infectious diseases (Cf. 
Table 1, p 199). 
A detailed study of the inactivation of human 
brain DHPR by K 2 PtC1 4 [6] is presented in this chapter 
together with a comparison of the effects of c1s- and 
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trans-platin and Pt[en]Cl 2 complexes. Also the reactivity 
of the thiol groups in enzyme-Pt(II) complexes has been 
investigated, because this may provide information about 
the nature of the cysteine residues in the protein. 
A comparative study of the effects of . various 
concentrations of cis-platin, trans-plat in, Pt [en] Cl 2 and 
K2 PtC1 4 on the inactivation of human brain DHPR 1s 
summarized in Table 2. 
Table 2. 
complexes. 
The inhibition of DHPR by different Pt(II) 
Remaining activity ( % ) 
Time 
K2 PtC1 4 trans-Pt(NH 3 ) 2 Cl 2 cis-Pt(NH 3 ) 2 Cl 2 Pt[en]Cl 2 
* * ( h) (232µM) (1 mM) (200µM ) (lmM) (200µM ) (200µM) 
0.25 39.3 58.5 72.4 100 100 
0.5 38.9 36.4 100 100 
1.0 28.6 27.7 69.4 100 100 100 
2.0 22.9 13.8 47.1 90.7 100 100 
* Incubated 1n 0.1 M instead of 1 M Tris/H2 so 4 buffer. 
The data show that the inactivation is in the order K 2 PtC1 4 
> trans-plat in > cis-platin ~ Pt [en] Cl 2 • Also the 
octahedral complex, hexachloroplatinic acid (H2 PtC1 6 ) [11] 
was considerably less active ( I 5 0 360 µM after 4 h 
.. 
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incubation) than the square planar complex K2 PtC1 4 (I 50 20 
µM after 15 min incubation) towards human brain DHPR. The 
rhodium complex, tris(triphenylphosphine)rhodium chloride 
[ ( Ph 3 P) 3 RhCl] [ 12] which is also geometrically planar was 
completely inactive. It is known that some rhodium 
l 8 0 
complexes have little anti-tumour activity. These 
results imply that the inactivation of human brain DHPR by 
Pt(II) complexes could occur in a multi-dentate manner 
because K2 PtC1 4 was much more effective than other Pt 
complexes. On the other hand, in the case of malate 
dehydrogenase the degree of inhibition by cis-platin and 
l 7 0 
trans-platin was the same, so the Pt(II) complexes may 
be binding in a mono-dentate manner to this enzyme. 
K2 PtC1 4 was found to inactivate human brain DHPR 
in a time dependent manner. The enzyme and inhibitors were 
incubated for some time . prior to the activity assays. 
Close to zero time, almost no inactivation was observed but 
the inhibitory effect · increased with longer incubation 
times. 
At lower concentration of K2 PtC1 4 (PtC1 4 2 -) (21 
µM) the enzyme activity decreased rapidly during the first 
hour and then slowed down considerably although the 
of enzyme (5.6 µM) concentration 
stoichiometric. Higher concentrations 
was less than 
of the platinum 
complex (210 µM), on the other hand, caused complete 
inactivation in one hour (Figure 3). At intervals of time, 
aliquots were dialyzed, but the enzyme activities were 
found to be unchanged, . 1 • e • partly or completely 
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Figure 3. Time dependent inhibition of human brain DHPR by 
K2 PtCllt (20°C, pH 7.2). The concentration of DHPR was 
5.6 µM. -~-~- enzyme activity of blank; -•-•- K2PtC1 4 21 µM; -+-+- 52 µM; -•-•- 104 µM; -•-•- 208 µM. 
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Figure 4. Time dependent inhibition of human brain DHPR by 
KiPtCl .. (20oC, pH 7.2). The values were obtained from 
Figure 3. 
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inactivated enzyme could not be reactivated. In general, 
~revious enzymes which were inhibited in a time dependent 
manner by inhibitors were also found to be irreversibly 
l 8 l 
inhibited. 
Here it was not possible to determine a Ki value, 
because analysis of the curves obtained by plotting the log 
values of remaining enzyme activities versus incubation 
times also gave curves, i.e. the initial pre-equilibrium 
with the enzyme was faster than in the case of ma late 
dehydrogenase and the reactions did not follow simple first 
order kinetics (Figure 4 ) . The present pattern of plots 
l 8 2 (Figure 4) are similar to those proposed by Fritzsch for 
"two states model" mechanism which . summarized in a is 
Scheme 2 . In the present examples it . not clear that the is 
two 
El _. El ' 
E 
(E¢ - E-NADH) 
E : enzyme, I: inhibitor, Io: inactive inhibit o r, 
EI: enzyme and inhibitor complex! EI': inactivated 
enzyme and inhibitor complex, E~: another form of t h e 
enzyme which does not react with inhibitor. 
Scheme 2 
. 
species in the mechanism are due to 
different enzyme species or due to different inhibitor 
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. 
species. However, the mechanism can be explained by 
proposing that the inhibitor inactive enzyme species (E~) 
are in fact the E-NADH complex which has a small 
dissociation constant (see Chapter 2, Section 2-7, p 65). 
Points from the earlier portions of the curves in 
Figure 3 (p 207) fitted the equation for first order 
kinetics and gave rough estimates of the early reaction 
speeds (Table 3). 
Table 3. First-order rate constants for the inactivation 
of DHPR by K2PtCl~ at 200c. 
K 2 Pt Cl 4 concentration ( µM) 
208 104 52 21 
k (h-1) 13.3 13.0 6.2 2.5 
t1;2 (min) 3.1 3.2 6. 6 17.0 
error ( % ) 0.08 0.04 1. 4 3.0 
The final DHPR concentration was 5.6 µM and the 
blank enzyme activity (no inhibitor) did not change within 
the incubation period. [Data were calculated from the 
linear portions of the curves in Figure 4.] 
In these measurements, solutions of the complexes were made 
up in water and incubations of the enzyme with complexes 
were carried out . in 1 M potassium phosphate buffer (pH 
7 • 3) • 
As shown in Scheme 1 (p 202), an equilibrium is 
set up between the chloroplatinate and various 
aquohaloplatinates which are the true inhibitor species. 
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The inhibitor stock solution 1s mixed with the enzyme and 
buffer solution. The equilibria in the stock solutions are 
set up rapidly (within 5 min) because when the solutions 
are allowed to age before addition to the enzyme at pH 7.3, 
no significant differences in the inactivation curves were 
l 8 3 
observed. The reported equilibrium constant for the 
acid hydrolysis of Ptc1 4 2- at 25°c is 3.0 x 10-2 (Equation 
2). By using this value, when 208, 104, 52 and 28 11M of 
K2 PtC1 4 stock solutions were made up in water, they would 
' 
- - - (2) 
give mono-aqua species with 6.2, 3.1, 1.6 and 0.6 µM 
concentrations respectively. The mono-aqua . species are 
also in the equilibrium with diaquo species (Equation 3) 
and would give concentrations of 0.6, 0.3, 0.15 and 0.06 µM 
of diaquo . species respectively by using 1. 0 X as 
equilibrium constant. 
' 
::::,, 
- - - (3) 
The nature of the . anion, however, does have a n 
effect on the inhibition curves. Stock solutions of 
K2 PtC1 4 were made up in 4 mM HBr, 4 mM HCl, 4 mM H2 S0 4 or 
water and incubated with DHPR 1n Tris/HBr, Tris / HC l , 
Tris/H 2 S0 4 or phosphate buffers ( at pH -7. 3) and assayed 
at time intervals. The results showed that the degree of 
inhibition was in the order phosphate > Tris/H 2 S0 4 > 
- 211 -
Tris/HCl > Tris/HBr buffer (Table 4). 
Table 4. The effect of buffer anion on the inactivation of 
DHPR by K2PtCl~ at 200c. 
DHPR ( 5. 6 µM) was incubated with inhibitor ( 200 
µM) in each buffer solution and aliquots (1 µl) were 
assayed in the respective buffer. 
Time Remaining enzyme activity ( % ) 
( h) Tris/HBr Tris/HCl Tris/H 2 S0 4 Phosphate 
0.25 28.7 17.9 13.4 4.8 
0.5 12.6 8.5 8.9 2.5 
1.0 6.8 4.3 3.7 0 
2.0 2.0 0 
This is different from the result which was obtained by 
l 7 l l 7 3 
Teggins et al. ' on the inhibition of malate 
dehydrogenase. They demonstrated that bromide ligands were 
more labile than chloride ligands in substitution reaction 
l 7 3 
of Pt(II) complexes. 
The concentration of buffer was also found to 
affect the rate of inactivation of DHPR. Incubation at pH 
7.3 with 0.03 M Tris/H 2 So 4 or 0.03 M phosphate buffer 
caused more rapid inactivation of DHPR than the 
corresponding buffers at O. 3 M concentrations with same 
enzyme and PtC1 4 2- concentrations (Table 5). 
- 212 -
Table 5. The effect of different buffer concentrations on 
the inactivation of DHPR by K2 PtCl~ at 200c. 
DHPR (5.6 uM) was incubated with K2 PtC1 4 (230 uM in 4 rnM H2S0 4 ) 1n each buffer and aliquots ( 1 ul) were 
assayed. 
Remaining enzyme 
Time 
activity ( % ) 
Tris/H 2 S0 4 Phosphate ( h) 
0.03 M 0.3 M 0.03 M 0.3 M 
0.25 13.4 45.1 4.8 10.4 
0.5 8.9 39.0 2.5 5.9 
1.0 3.7 0 2.7 
2.0 2.0 33.3 0 1.2 
12.5 0 22.9 0 0.9 
Attempts to remove all the chloride from PtC1 4 2-
by reaction with silver nitrate caused immediate inhibition 
of DHPR, but this is most probably due to traces of silver 
l 8 4 
which is a potent inhibitor of enzymes. The complete 
inhibition by 4 uM silver nitrate of human brain DHPR was 
almost instantaneous (this work). 
9 5 
Dhondt and Bellahsene reported that inhibition 
of DHPR from rat tissues by cis-platin was partially 
protected by increasing . ions in the solutions. The 
present study confirms this observation. When stock 
solutions of K2 PtC1 4 were made in 0.3 M KCl and in 3.0 M 
KCl and then incubated with human brain DHPR 1n O .1 M 
phosphate buffer ( pH 7. 3), i.e. final concentrations were 
- 213 -
0.1 Mand 1 M KCl, the rate of inhibition in the solution 
made from the latter stock solution was slower (Table 6). 
Table 6. The effect of KCl on DHPR inactivation by K2 PtCl~ at 20°c, pH 7.2. 
Time 
( h) 
0.25 
0.5 
1.0 
2.0 
These data support 
' 
Remaining enzyme activity ( % ) 
H2 0 0.1 M KCl 1 M KCl 
6.0 28.8 43.6 
2.6 8.6 43.6 
1. 1 6.4 13.2 
1.3 2.6 9.1 
the contention that more of PtCl 2-4 
complex species are present in the 1 M KCl solution than 
the other solutions during the incubation and that they are 
less reactive towards the enzyme than the other platinum 
species in the equilibria in Scheme 1 (p 202). 
The statement was made earlier (p 209) that the 
inactivation process involves a pre-equilibrium step 
followed by faster irreversible inactivation of the enzyme. 
The Pt(II) complex bound enzyme does not dissociate easily 
because when the solutions used for the data in Figure 3 (p 
207), except the blank solutions, were dialyzed, the 
original enzyme activities were not recovered. 
Good evidence that the platinum complex reacted at 
or near the active site of DHPR was that the activity was 
n 
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completely protected when NADH at 114 µM was pre-incubated 
with the enzyme (2.6 µM) and then mixed with K2 PtC1 4 at 204 
µM. When the enzyme was pre - incubated with K 2 Pt C 1 4 and 
then NADH was added at intervals of time, immediate 
protection occurred (i.e. no further time dependent 
inactivation), but the original activity of the enzyme was 
not recovered. These could be explained by Scheme 2 (p 
208), because in the earlier time of the incubation there 
was still some free enzyme (i.e. not bound to PtC1 4 2-), and 
NADH can protect the free enzyme but not replace the bound 
Pt ( I I ) i n the enzyme comp 1 ex read i 1 y • Thus the platinum 
complex at or near the active site cannot be reversibly 
removed by NADH, but NADH at the active site will inhibit 
the reaction of K2 PtC1 4 at this site. On the other hand, 
NAD+ at 152 µM provided no protection from inactivation by 
Also incubation of DHPR with K2 PtC1 4 (233 µM) in 
the absence of NADH but in the presence of 2. 7 mM DTT 
afforded complete protection. This, however, is attributed 
to the formation of stable Pt(II)-DTT complexes (DTT is in 
large excess) which react very slowly (or not at all) with 
the enzyme and implies that Ptc1 4 2- reacts with thiol 
groups and consequently with a thiol group(s) at the active 
site (see Section 4-3-5, p 222). Because NADH protected 
DHPR, the enzyme used in all the above measurements was 
exhaustively dialyzed to remove bound NADH. 
-
I 
II 
It. 
I 
II 
J 
~: 
1,j 
,~ 
Ii 
Ii 1, 
ri 
- 215 -
4-4-4 Gel electrophoresis, 0V and fluorescence studies of 
the enzyme inactivated by potassium tetrachloroplatinate 
Polyacrylamide gel electrophoresis of the PtC1
4
2-
inactivated human brain DHPR, after dialysis at 40c under 
non-denaturing conditions to remove free PtC1
4 
2-, gave a 
diffused band at high molecular weight similar to that 
observed for the non-denatured DHPR ( Figure 5, A). This 
suggests that the Pt-enzyme complex remained in a dimeric 
form like the active enzyme and also PtC1 4 2- 1s binding to 
the enzyme subunit without intermolecular (oligomer) 
binding ( see below). It should be noted that Firgaira 
l 0 
et al. had found that on PAGE human liver DHPR gave a 
band at higher Mr values ( the Mr values depended on gel 
concentrations,) than for the dimer (Mr ca 50,000) due to a 
low net charge to size ratio for this protein. 
E 1 e ct rop ho res is of the inhibited enzyme in the 
presence of SDS (denaturing conditions), on the other hand, 
gave a single monomer band at a slightly higher Mr value 
(27,000) than the uncomplexed monomer enzyme (26,000) 
( Figure 5, B) indicating that the platinum may well be 
still bound to the enzyme. This could not be confirmed by 
elemental analysis because large amounts of enzyme were 
required for this purpose. Human brain DHPR always shows 
two very close bands on SDS-PAGE when mercaptoethanol is 
excluded (probably due to the presence of 'oxidized' 
enzyme), whereas the platinum inactivated enzyme gives only 
a simple band (cf. Chapter 2, Section 2-2, p 38). It must 
A) PAGE 
67-;-QOO 
43,000 
30,000 
20,000 
14,400 
B) SOS-PAGE 
67,000 
43,000 
30,000 
20,100 
14,400 
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be pointed out that platinum complex inactivated DHPR 1s 
not stained by Commassie Blue as readily as active DHPR and 
larger amounts of enzyme were required for staining. 
When a solution of DHPR (DTT free) was incubated 
with K2 PtC1 4 in potassium phosphate buffer (pH 7.2) at 
25°c, the UV maximum at 280 nm moved to shorter wavelength 
with time and at complete inactivation (5 h) it was at ca 
270 nm ( Figure 6). This may be indicative of 
conformational changes due to the reaction of the enzyme 
In order to study this further the fluorescence 
spectra of th is system were ex amine d . The intensity of the 
fluorescence maximum at 350 nm (excitation at 280 nm) of 
DHPR was found to decrease with time after addition of 
(one molecular equivalent) with a small 
bathochromic 
decrease of 
shift of 
intensity 
3 nm ( Figure 
increased with 
7) . The rate of 
increasing 
concentration. No change in intensity was observed when 
K2 PtC1 4 was added to DHPR which had been denatured with 4M 
urea for 17 h, (4 M urea had weak fluorescence with A at 
max 
364 nm due to impurities), also the emission maximum had 
not changed from 357 nm which was the emission maximum 
for urea denatured DHPR (Figure 8). On comparing the rate 
of inactivation of DHPR with the rate of decrease in the 
intensity of the band at 350 nm it was found that the 
former rate was ca 2.4 times faster than the rate of 
quenching, and quenching was still proceeding after the 
enzyme had been completely inactivated ( Figure 9). This 
----
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0 
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Wavelength (nm) 
Figure 6. 0V spectral changes of potassium tetrachloro-
platinate inactivated DHPR. DHPR (1.3 µM) was incubated 
with K2PtC1 4 (107 µM) in 50 mM phosphate buffer (pH 7.2) at 
25°c. The spectra were scanned at 30 min intervals. 
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Figure 7. Fluorescence emission spectral changes obtained 
from incubation of human brain DHPR and K2 PtCl~ at 200c • 
. I\ : DHPR (0 .34 µM) in 0 . 1 M phosphate buffer (pH 7 . 2); B: 
DHPR (0 .31 µM) and K 2 PtC1 4 (93 .6 µM) in the same buffer, 
times after mixing are in parentheses (h); C : 
(93 .5 µM); D: buffer . 
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demonstrates that the enzyme undergoes conformational 
changes by further reactions with the same (intramolecular) 
or other Pt(II) complex molecules after the active site had 
been completely inactivated. 
The fluorescence spectrum of DHPR was unaltered in 
the presence of 2 mM DTT and this spectrum was then almost 
unchanged on addition of K2 PtC1 4 (85.4 µM) (Figure 10). 
The spectrum of a solution of DHPR which was pre-incubated 
with NADH (0.9 µM) (see Chapter 2, Section 2-5, p 47) was 
unaltered when K2 PtC1 4 (9.5 µM) was added (Figure 11-A) . 
Also when DHPR was mixed with K2 PtC1 4 , the decrease 
. 1n 
fluorescence intensity with time at 350 nm could be 
immediately halted by addition of NADH (Figure 11-B). 
Moreove~ when a mixture of NADH and K2 PtC1 4 was added to a 
solution of DHPR the normal quenching due to NADH binding 
was obtained but no time dependent quenching of the 
fluorescence was observed (Figure 12). This confirmed that 
NADH protected DHPR from reacting with PtCl 2 - and 4 that 
NADH binds with the enzyme much more rapidly than PtC1 4 2 -
can react in a way that affects the fluorescence. 
The substrate for DHPR, quinonoid 6-MeDHP [13] . lS 
generated in the cuvette by oxidation of 6-MeTHP [14] with 
K3 Fe(CN) 6 which is in turn reduced to K4 Fe(CN) 6 • These two 
0 
CH3 
0 
~f:' N H N HN 
H,NJl N N H,NAN N H H 
[13) [14] 
A) 
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iron complexes have negligible affects on the fluorescence 
of DHPR at the concentrations used (100 µM) (see Section 4-
3, p 193). Quinonoid 6-MeDHP exhibited some fluorescence 
due to traces of oxidized pterin at A 445 nm (emission 
max 
wavelength) which increased with time as it rearranged to 
6-methyl-7,8-dihydro(3H)pterin [15] and oxidized further to 
6-methylpterin [16]. 
0 0 
HN NrCH, HN NrCH, 
H,N~ N H,NAN N N H 
(15] (16] 
The fluorescence emission at 350 nm of DHPR pre-incubated 
with K2 PtC1 4 was quenched when quinonoid 6-MeDHP (which was 
' 
generated as described above) was added to the mixture 
( Figure 13) . Similarly addition of a mixture of the 
substrate and K2 PtC1 4 to DHPR gave a spectrum which was the 
same as that of a mixture of DHPR and the pterin cofactor 
( Figure 14) . Thus like NADH the pterin substrate also 
protects DHPR from PtC1 4 2 - and the pterin substrate binds 
to DHPR much more rapidly than PtC1 4 2- can react in a way 
that affects the fluorescence. 
4-4-5 Interaction with thiol groups 
The above data imply that PtC1 4 2 - reacts primarily 
with some amino acid(s) at or near the active site of DHPR 
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with covalent binding. The following results strongly 
support the contention that thiol groups in the protein are 
involved in the interaction. Further information was 
obtained by . using thiol specific reagents in conjunction 
with K2 PtC1 4 • The results could be summarized as in Scheme 
3 (p 227). 
The human brain DHPR reacted with 3 molecular 
equivalents of PCMB (see Chapter 2, Section 2-6-2, p 60) 
inferring a total of 3 reactive cysteine residues per 
subunit (Scheme 3). Equimolar amounts of DHPR and K
2
PtC1
4 
were incubated for 1 h at 20°c (with 60% loss of enzyme 
activity) and dialyzed (no further loss of activity). Upon 
titration, the enzyme reacted with 0.7 molar equivalents of 
PCMB (further loss of 24% of enzyme activity), i.e. ca one 
cysteine residue. Thus K2 PtC1 4 reacted with two thiol 
groups. Also normally titration of DHPR with DTNB (see 
Chapter 2, Section 2-6-1, p 57) revealed that one molecular 
equivalent of DTNB reacted with protein thiol groups 
with out loss of enzyme activity under the non-denaturing 
conditions. On the other hand, when DHPR was incubated 
with an equimolar amount of K2 PtC1 4 ( 1 h, 60% loss of 
enzyme activity) followed by dialysis; then titration with 
DTNB showed that 1.3 equivalents (ca one -SH) of the latter 
reacted. If this solution was dialyzed again, the enzyme 
then consumed one molecular equivalent of PCMB with 3 2% 
loss of enzyme activity. When the original incubation time 
of DHPR and K2 PtC1 4 was lengthened to 4 h, no thiol group 
was titrated by DTNB. These data are consistent with 
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PtC1 4 2 - reacting with more than one thiol group of the 
enzyme (possibly two -SH groups). Moreover, PtC1
4
2- binds 
to (or masks) (i.e. at or near the active site) two 
internal ( buried ) thiol groups . first and then later binds 
to ( or masks) one cysteine residue which . lS located far 
from the first two thiol groups or a second Pt(II) molecule 
reacts with the enzyme (Scheme 3). 
The further loss of 24% of enzyme activity by 
reacting with one molar equivalent of PCMB (Scheme 3) could 
be explained by further conformational changes of the 
enzyme caused by this binding, or PCMB exchanged one of 
bindings between Pt(II) and enzyme which was not yet 
stabilized. It can be concluded that when the reaction 
between Pt (II) complex and enzyme is complete, more than 
one Pt(II) molecule per subunit have reacted because it is 
unlikely that all -SH groups are in such proximity to the 
enzyme as to form tri-dentate binding on to one platinum 
molecule. 
4-5 Conclusion 
Among several inhibitors studied K 2 Pt Cl 4 showed 
the strongest inactivating effect on human brain DHPR by 
reacting in at last a bi-dentate manner after a long 
incubation period. In an incubation period it appears that 
the stoichiometry is one Pt per subunit (cf. this . lS . 1n 
good agreement with the result from SDS-PAGE, p 215) but 
after long incubation the stoichiometry is at least two Pt 
- 227 -
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per subunit. The coordination of compounds of elements 
related to platinum (e.g. mercury, silver and lead) with 
thiol groups on the protein and causing inhibition is not 
161 184 
new. ' Pt(II) complexes react with thiol groups of 
peptides and proteins, and X-ray crystallographic studies 
also provide strong evidence that PtC1 4 2 - coordinates with 
l 7 5 
the sulphur atom of a methionine residue. It is not 
possible from the above work to say conclusively whether 
platinum is binding to thiol groups of cysteine directly or 
whether it is binding strongly to e.g. a methionine residue 
through the sulphur atom, which is in close proximity to a 
cysteine residue and therefore masking it from further 
reaction with thiol specific reagents. The molecular 
details of the interaction of platinum with DHPR will have 
to wait for an X-ray study of the crystalline metal-enzyme 
complex. 
Moreover, the results from the fluorescence study 
suggest the usefulness of NADH or pterin analogues as 
potentially useful affinity labelling probes for studying 
the environment of the active site of human brain DHPR 
because of their high binding capacities for this enzyme. 
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4-6 Experimental 
4-6-1 Materials and methods 
A: Materials 
All commercial chemicals were of the highest 
commercially available purity. 
K2 PtC1 4 , cis-platin, trans-platin were from 
Aldrich Chemical Co., Milwaukee, USA. 
(Ph 3 P) 3 RhCl were purchased from Fluka AG, Buchs, 
l 8 5 Switzerland. Pt[en]Cl 2 was prepared as before. 6-MeTHP 
and 6, 7-Me 2 THP hydrochlorides were kindly supplied by Dr 
W. L. F. Armarego and pterid i nes were synthesized in th is 
work (cf. Chapter 3). 
Human brain DHPR used in this chapter was purified 
for this work and the details were described in Chapter 2, 
Section 2-2 (p 38), and then dialyzed against 50 mM or 0.1 
M potassium phosphate buffer (pH 7.2) 
B: Methods 
Ultraviolet spectra, kinetic assays and PCMB 
titrations were performed on Unicam SP 1800 or Cary 219 
double beam spectrometers. The determination of 
concentrations at A and DTNB titrations were carried out max 
on a Perkin-Elmer Lambda 1 single be2m spectrometer. 
Fluorescence spectra were measured as described 
before (cf. Chapter 2, Section 2-9-1, p 72). 
The protein concentration was determined by the 
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Bio-Rad microassay (cf. Chapter 2, Section 2-9-5, p 81). 
Gel electrophoresis was performed as before (cf. 
Chapter 2, Section 2-9-1, p 72). 
PCMB and DTNB ti trat ions were also performed as 
before (cf. Chapter 2, Section 2-9-8, p 83). 
The incubations of inhibitor and the enzyme were 
carried out in clean, capped glass vials. 
4-6-2 Inhibition by oxidized pteridines 
i ) Human brain DHPR (10 µl in 0.1 M potassium phosphate 
buffer, 5.6 µM), 0.1 M phosphate buffer (pH 7.2) (10 µ1) 
and inhibitor solution (10 µl in 4 mM HCl) were incubated 
The blank incubation was carried out by using 4 
mM HCl (10 ml) instead of the inhibitors. Pteridin-4(3H)-
one ( 206 µM) and 6, 7-dimethylpteridin-4 ( 3H) -one ( 185 µM) 
solutions ( in 4 mM HCl) were used as inhibitors. After 3 
30 . aliquots ( 1 or min, µ 1) were assayed with phosphate 
buffer (100 µl, 0. 1 M) ' NADH r25 µl in 50 mM Tris/HCl \ 
buffer, 100 µM) ' 6-MeTHP ( 15 µl . in 4 mM HCl, 20 µM) and 
water (810 µl) at 3o 0 c. The reaction was initiated by 
addition of 2 mM K3 Fe(CN) 6 (50 µ l ' 100 l-l M ) and the initial 
rates of changes of the absorbance at 340 nm ( s 6,200 
M-1.cm-1 for NADH) were measured. The blank cuvette did 
not contain the enzyme solution. Both the 3 and 3 0 . min 
incubations showed no inhibitor activity by these 
pteridines. 1 7 If, as described in the literature, these 
were reversible i nh ibi tor.s, the long incubation period was 
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not necessary. So it was concluded that these pteridines 
were not inhibitors for human brain DHPR. 
ii) The inhibition of sheep liver DHPR which was kindly 
supplied from Dr W.L.F. Armarego, carried out . the was 1n 
l 7 . 
the literature ( i . e . same way as 1 n no previous 
incubation). The assay solutions contained inhibitor 
solution (SO µ1), phosphate buffer (pH 7.2) (100 µl, 0.1 
M), NADH (25 µl, 100 µM), 6,7-Me 2 THP (40 µl, 20 µM) and 
water (735 µl, 30 °c). Sheep liver DHPR (5 µl) was added 
only to the sample cuvette and the reaction was initiated 
by addition of 2 mM K3 Fe(CN) 6 (50 µl, 100 µM) to both 
cu vet tes ( Table 7) . The blank experiment was carried out 
with 4 mM HCl (50 µ1) instead of inhibitor solution. 
Table 7 Inhibition of sheep liver DHPR with pteridinones 
at 30°c, pH 7.2 
0 0 0 :.x·t~ .. ~-f~ J:• c~ Inhibitor SlN NXCH, H,Ni N N CH, ~ N N :;,'"' C~ blank 
H 
concn ( µM) 89.4 447.0 55.3 110.6 106.0 211 
. . 
rema1n1ng 
activity 100 50 100 100 100 80 100 ( % ) 
11 
I! 
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4-6-3 Effects of potassium ferricyanide on DHPR activity 
Incubation of DHPR and K3 Fe(CN) 6 were carried out 
at 20°c in the following solutions; DHPR (DTT free) (10 µl, 
3.6 µM), 0.1 M potassium phosphate buffer (pH 7.2) (10 µl) 
and 92.2 mM (or 60.3 or 30.3 mM) K3 Fe(CN) 6 (10 µl, final 
concentrations in incubation mixtures were respectively 
30.7, 20.1 or 10.1 mM). Aliquots (2 µl) of these solutions 
were taken at time intervals and mixed with the assay 
cocktail [potassium phosphate buffer (pH 7.2) (100 µl, 0.1 
M), NADH (25 µl, 96 µM), 6-MeTHP (15 µl, 22.2 µM) and water 
(810 µl)J in the sample cuvette at 25cc. The blank 
incubation solution contained 50 mM potassium phosphate 
buffer (pH 7.2) ( 10 µl), 0.1 M phosphate buffer (pH 7 .2) 
(10 µ1) and K3 Fe(CN) 6 (10 µl, final concentrations were 
respectively 30.7, 20.1 or 10.1 mM) and kept at 20°c, and 
the aliquots were taken to the blank cuvette. The reaction 
was initiated by addition of 2 mM K3 Fe(CN) 6 (50 µl, 100 µM ) 
to both cuvettes. The incubation in the absence of t h e 
K3 Fe(CN) 6 was carried out with DHPR (10 µl), 0.1 M 
phosphate buffer (10 µ1) and water (10 µl), and aliquots (2 
µl) were assayed as above. 
No inhibition of DHPR activity was noted even 
after 3 h incubation. 
4-6-4 Inactivation by potassium ferrocyanide 
The incubations were carried out in the following 
solution; DHPR (DTT free) (10 µl, 3.6 µM), 0.1 M phosphate 
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buffer (pH 7.2) (10 µl) and K4 Fe(CN) 6 (10 µl, final 
concentrations were 10.1, 20.2 and 30.2 mM) at 200c. 
Aliquots ( 2 µl) were added to the mixture of phosphate 
buffer (pH 7.2) (100 µl, 0.1 M), NADH (25 µl, 86 µM), 6-
MeTHP (15 µl, 23 µM) and water (810 µl, 25°c). The 
reaction was initiated by addition of 2 mM K
3
Fe(CN)
6 
(50 
µ 1 , 10 0 µM) . The blank incubation was carried out with 
water instead of inhibitor solution. The results are shown 
in Table 8 and Figure 1 (p 195). 
Table 8. Inactivation of human brain DHPR with potassium 
ferrocyanide at 20°c, pH 7.2. 
Time 
( h) 
0.08 
0.25 
0.5 
1.0 
2.0 
3.0 
6.0 
Remaining activity ( % ) 
K4 Fe ( CN) 6 (mM) 
0 10.1 20.2 
-- 85.8 46.7 a b C 
-- 18.3 57.6 100 
100 34.7 16.4 84.0 93.8 
100 20.2 14.0 17.6 63.5 78.4 
100 12.0 11.6 15.5 31.0 70.0 
100 11.6 12.5 21.0 75.0 
100 14.9 14.0 
a: incubated with 2.0 mM dithiothreitol 
b: incubated with 5.5 µM NADH 
c: incubated with 100 µM NADH 
30.2 
41.0 
16.9 
13.0 
14.0 
12.5 
11.1 
14.9 
iii) DHPR (DTT free) (10 µl, 3.6 µM) was incubated with 
dithiothreitol (10 µl in 0.1 M phosphate buffer, 4.0 mM) 
for 10 min at 18°c and then K4 Fe(CN) 6 (lO µl, 20.4 mM) was 
added to it (final DTT concentration was 2.0 mM). Aliquots 
(2 µl) were assayed as above (Table 8). 
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iv) DHPR (DTT free) (10 µl) was incubated with NADH [10 
µl 1n 0.1 M phosphate buffer (pH 7.2), 8.3 or 150 µM] for 
10 min at 18°c and then K 4 Fe(CN) 6 was added to the mixture 
(10 µl, 20.4 mM) (final NADH concentration was 5.5 or 100 
µM) • Aliquots (2 µl) were taken at intervals of time and 
then assayed as above. The blank experiment was carried 
out with water (10 µl) instead of inhibitor solution (Table 
8 and Figure 1, p 195). 
v ) Attempts were made to de term i n e the K i v a 1 u e of th i s 
inhibitor. The enzyme and inhibitor solutions were 
incubated as above (ii) for 5 min and the enzyme activity 
was assayed at various concentrations of 6-MeTHP. The 
1 5 9 
results were analyzed with a computer programme, but the 
results did not fit into the known inhibition patterns 
properly, i.e. the errors of the Ki values were not 
acceptable. The plot of the log values of remaining 
activities against incubation times showed curved lines. 
In general to obtain kinetic parmeters, this plot should be 
a straight line, i.e. reversible reaction. 
vi) DHPR (DTT free) (10 µl, 0.3 µM) was incubated with 
5.2 mM K4 Fe(CN) 6 (10 µl, 100 µM) and 0.1 M phosphate buffer 
(pH 7.2) (490 µ1) and the fluorescence emission spectra 
(slit 5 nm) were scanned with time at 20°c. The excitation 
wavelength was 280 nm (slit 5 nm) and\ of this mixture 
max 
was 355 nm, and the fluorescence intensity at this 
wavelength decreased by 3% in 10 min. After 10 min, NADH 
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(10 µl, 4 µM) was added to it and the solution was scanned 
again (Figure 2, p 197). The quenching of DHPR due to NADH 
binding (cf. Chapter 2, Section 2-5, p 47) was now not so 
strong. 
4-6-5 Inactivation by Pt(II) complexes 
i) Pt(II) complexes (10 µl in 4 mM H2S0 4 ) were incubated 
with DHPR (60 µM DTT) (10 µl, 5.3 µM) in Tris/H 2 S0 4 buffer 
(pH 7.2) (10 µl, 0.3 M) at 20°c. Aliquots ( 1 µl) were 
assayed with Tris/H 2 S0 4 buffer ( pH 7. 2) ( 100 µl, 0 .1 M), 
NADH (25 µl, 110 µM), 6-MeTHP (15 µl, 23 µM) and water (810 
µl, 25°c) and the reaction was initiated by the addition of 
K 3 Fe(CN) 6 ( 50 µl, 100 µM). The blank cuvette did not 
contain incubation aliquots and the changes of absorbance 
~t 340 nm were measured at 25°c. The blank experiment was 
carried out by using 4 mM H2 S0 4 (10 µl) instead of 
inhibitor solution and the activity did not alter during 2 
h (Table 2, p 205 and Table 9). The Pt(II) complexes were 
K 2 PtC1 4 , cis-platin, trans-platin, Pt [en] Cl 2, H2 PtC1 6 and 
rhodium complex, (Ph 3 P) 3 RhCl (this complex required heating 
to dissolve). 
Table 9. Inactivation of DHPR by metal complexes. 
Time 
( h) 
0.08 
0.17 
1:8 
Remaining activity (%) 
(360 µM) 
100 
83 
50 
(Ph 3 P) 3 RhCl 
( -300 µM) 
100 
100 
100 
100 
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4-6-6 Inactivation by potassium tetrachloroplatinate 
Time dependent inactivation of human brain DHPR: All 
stock solutions of K 2 PtC1 4 were freshly prepared prior to 
each experiment. K 2 PtC1 4 (10 µl in water) was incubated 
with DHPR (10 µl, 5.6 µM) in potassium phosphate buffer (pH 
7.2) (10 µl, 0.1 M) at 200c. Aliquots (1 µl) were sampled 
at time intervals and mixed with phosphate buffer (100 µl, 
0.1 M), NADH (25 µl, 110 µM), 6-MeTHP (15 µl, 23 µM) and 
water (810 µl, 25°c). The assay was initiated by addition 
of 2 mM K 3 Fe(CN) 6 (50 µl, 100 µM) to both cuvettes. 
blank experiment was carried out . using water (10 
The 
µl) 
instead of the inhibitor solution (Tables 10, 11 and 
Figures 3, 4, p 207). 
After 2 h, the incubation mixtures were dialyzed 
1n small dialysis tub~against 4 µM NADH in 50 mM phosphate 
buffer (pH 7.2) for 24 hat 4°c and no recovery of enzyme 
activity was observed ( including dilution factor on 
dialysis). 
Table 10. 
at 20°c. Time dependent inactivation of DHPR by K2PtCl~ 
Time 
Remaining activity ( % ) 
K2 PtC1 4 (µM) ( h) 
0 20.8 52 104 1 208 
0.25 100 50.3 24.1 7.2 6.0 
0. 5 100 26.7 10.1 3.5 2.6 
0.75 100 21.0 9.4 
1. 0 100 10.5 5.9 2.6 1. 1 
1 . 5 100 10.1 4.8 0.9 
2.0 100 8.8 3.9 0.4 1. 3 
1, 
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Table 11. 
at 20°c. Time dependent inactivation of DHPR by K2PtCl~ 
log [remaining activity ( % ) ] 
Time 
K2 PtC1 4 ( µM) ( h) 
20.8 52 104 208 
0.25 1.70 1.38 0.86 0.78 
0.5 1.43 1.00 0.54 0.41 
0.75 1.32 0.97 
1.0 1.02 0.77 0.41 0.04 
1.5 1.00 0.68 
-0.05 
2.0 0.94 0.59 -0.40 0.11 
First order rate constants for the earlier part of 
curves 1n Figure 3 were calculated by using computer 
programme which was kindly supplied by Dr D. Randles. The 
results were shown in Table 3 (p 209) . 
Effect of . K2 PtC1 4 stock anion: solutions (10 µ l ' 200 JJ M ) 
made . were 1n 4 mM HBr, 4 mM HCl, 4 mM H2 S0 4 or H20 and 
incubated with DHPR ( DTT free) (10 JJ l ' 5. 6 µM) . 10 µ l of 1n 
0. 1 M Tris/HBr (pH 7 . 3) , 0.1 M Tris/HCl (pH 7 . 3 ) , 0.1 M 
Tris/H 2 S0 4 (pH 7 . 3 ) or 0. 1 M potassium phosphate (pH 7 . 2) 
buffer respectively at 200c and aliquots (1 µl) were 
assayed as above in the respective buffer (Table 4, p 211). 
Effect of buffer concentration: K2 PtC1 4 stock solution 
(10 JJl in 4 mM H2S0 4 ) was incubated with DHPR (OTT free) 
(10 µl, 5.6 µM) in 10 µl of Tris/H 2 S0 4 buffer (pH 7.3) 
(0.03 or 0.3 M) or potassium phosphate buffer (pH 7.2) 
(0.03 or 0.3 M) at 20°c and aliquots (1 µl) were assayed as 
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above in the respective buffer (0.1 M). The blank activity 
(no inhibitor) was unchanged during 12.5 h (Table 5, p 
212) . 
Effect of c1- concentration: 
i ) K 2 PtC1 4 stock solution (10 µl, 210 µM) was dissolved 
. 
water, 0.3 M KCl . water 3. 0 M KCl . water and 1n 1n or 1n 
incubated with DHPR (DTT free) (10 µl, 5.6 µM) in potassium 
phosphate buffer (pH 7 . 2) (10 µ 1, 0.3 M) • Aliquots ( 1 µ 1) 
were assayed as above in 0.1 M phosphate buffer (Table 6, p 
213) . 
ii ) K2 PtC1 4 ( 2. 4 9 mg, 6.0 µmol) was dissolved . 1n water 
(10 ml) and silver nitrate (4.08 mg, 24 µmol) was added to 
it and stirred at 25°c, overnight. The prec ip i ta te was 
removed by centrifugation and the supernatant was used for 
the incubation. This solution [ 10 µl, expected as 200 µM 
of Pt(H 20) 4 2 +] was incubated with DHPR (10 µl, 5.6 µM) in 
0.1 M phosphate buffer (pH 7.2) (10 µl) and aliquots (1 µl) 
were assayed at time intervals as above. Enzyme activity 
was already lost after 15min. 
When dilute HCl was added to this supernatant, the 
solution immediately became turbid, indicating that Ag+ 
ions were present in the solution. Silver is a well known 
enzyme inhibitor which binds to thiol groups and this might 
be the true inhibitor in this experiment. 
iii) Silver nitrate stock solution (10 µl in water, final 
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concentrations 1n the incubation were 4, 400 and 800 uM) 
was incubated with DHPR (10 ul, 5.6 uM) in 0.1 M phosphate 
buffer ( 10 µl) at 200c. 
and 30 min and assayed. 
Aliquots were taken after 5, 10 
No remaining enzyme activity was 
observed even with 4 µM silver nitrate and 5 min incubation 
period. 
Protection with NADH, dithiothreitol or NAD+: 
i) DHPR (10 µl, 2.6 µM) was pre-incubated with NADH (7 µl 
in 50 mM Tris/HCl buffer, 114 or 266 µM) in 0.1 M Tris/HCl 
buffer (pH 7.3) (8 ul) for 10 min at 200c. The stock 
solution of K 2 PtC1 4 (5 µl in 4 mM HCl, 102 or 204 µM) was 
added to the above incubation mixture and aliquots (2 µl) 
were assayed as before at time itervals. 
incubation was carried out without inhibitor. 
the enzyme activity was observed. 
The blank 
No loss of 
ii ) DHPR (10 µl, 2.6 µM) was pre-incubated with K 2 PtC1 4 
(10 µl in 4 mM HCl, 204 µM) in 0.1 M Tris/HCl buffer (pH 
7.3) (10 µl) for 1.25 h at 200c and then NADH (7 µl, 242 
µM) was added. Aliquots (2 µl) were assayed at time 
intervals but no further time dependent loss of enzyme 
activity was observed, although the orginal enzyme activity 
could not be recovered within the 11.5 h incubation 
period. 
iii) Dithiothreitol (5 µl, 4 mM) was pre-incubated with 
K2 PtC1 4 ( 10 µl in 4 mM HCl, 350 µM) 1n O .1 M Tris/HCl 
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buffer (pH 7.3) (5 µl) for 3 hat 20°c and then DHPR (10 
µl, 2.6 µM) was added to the mixture (final concentrations 
of DTT and K2 PtC1 4 were 2.7 mM and 233 µM respectively) and 
aliquots ( 2 µl) were assayed as before at time intervals. 
The blank incubation was carried out with 4 mM HCl (10 µl) 
instead of the, inhibitor solution. Enzyme activity did not 
change within a 2 h incubation period. 
The pre-incubation was also carried out with DHPR 
(10 µl) and DTT (5 µl, 2.7 mM) in 0.1 M Tris/HCl buffer (pH 
7.3) ( 5 µ 1 ) for 3 0 . min and then K 2 PtC1 4 (5 µl, 350 µM) was 
added and aliquots (2 µ1) were assayed (Table 12). 
Table 12. Protection by OTT {2.7 mM). 
Time Remaining activity ( % ) 
(min) K2 PtC1 4 (233 µM) Blank 
2 100 100 
7 75 100 
15 64 
30 64 100 
45 64 100 
iv) DHPR (10 µl, 2.6 µM) was pre-incubated with NAD+ (5 
µl) in 0.1 M Tris/HCl buffer (pH 7.3) (10 µl) for 10 min at 
20°c and then K2 PtC1 4 (10 µl in 4 mM HCl, 102 µM) was added 
(final concentrations of NAD+ were 38.0 and 151.9 µM). 
Aliquots (2 µl) were assayed at time intervals. The blank 
incubations were carried out with 4 mM HCl (10 µl) at two 
different NAD+ concentrations or in the absence of NAD+ 
solution (Table 13). 
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Table 13. The effect of NAo+ on the inactivation of DHPR 
(2.6 µM} by K2 PtCl~ (102 µM). 
* 
# 
Time 
( h) 
* 0 
0.25 7.2 
0.5 3. 5 
1.0 2.6 
2.0 0.4 
10.0 --
Remaining activity ( % ) 
38.0 
61.2 
32.9 
25.5 
NAD+ ( µM) 
151.9 
52.3 
30.0 
20.4 
16.0 
Blank# 
38.0 
100 
100 
100 
100 
88.5 
151.9 
100 
100 
100 
100 
100 
Contains K2 PtC1 4 (104 µM) but no NAD+ in 
solution. 
No K2 PtC1 4 in solution. 
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Gel electrophoreses: 
i ) DHPR (20 µl) ( 20 µl . 1n 
water, 220 µM) in 0.1 M phosphate buffer (pH 7.2) (20 µl) 
for 2 h at . . no rema1n1ng enzyme activity was 
observed. This solution was dialyzed against 0.1 M 
phosphate buffer (pH 7.2) for 4.5 hat 4°c (250 ml x 3) but 
no enzyme activity was recovered. Aliquots were applied on 
a g e 1 for PAGE ( 7 . 5 % run n i n g g e 1 ) ( Figure 5 , p 2 1 6 ) . The 
inhibited DHPR always showed a dif fuse 
dimer position as with native DHPR. 
band around the 
ii) DHPR ( 40 µl) was incubated with K2 Pt Cl 4 ( 40 µl in 
water, 220 µM) in 0.1 M phosphate buffer (pH 7.2) (40 µl) 
for 1 hat 25°c and then the mixture was dialyzed against 
0.1 M phosphate buffer (pH 7.2) (200 ml x 3) for 2 hat 
40c. Aliquots (20 µl) were mixed with 10% SDS (10 µl) and 
8-mercaptoethanol ( 1 drop), and incubated for 3 min at 
100°c and sucrose solution (to make up 10% concentrat i on) 
was added and then applied on a gel for SDS-PAGE ( 15% 
running gel) (Figure ,... 
:) ' p 216) • The blank sample was 
prepared by mixing DHPR ( 10 µl), 10% SDS ( 5 µl) and 8-
mercaptoe~h anol (1 drop), and incubated for 3 min at 100°c 
prior to applying onto gel. 
UV spectra: 
i ) DHPR (DTT free) (50 µl in 0.1 M phosphate buffer, 1.3 
µM) was incubated with K2 PtC1 4 (50 µl in water, 107 µM) in 
50 mM phosphate buffer ( pH 7. 2) ( 200 µ 1) for 7. 5 h at 
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The blank cell contained 0.1 M phosphate buffer (SO 
µl) instead of enzyme solution. The spectra were scanned 
every 30 . min with a Cary 219 double beam spectrometer 
( Figure 6 , p 218) . 
Fluorescence spectra: 
i) DHPR (10 µl, 0.31 µM) was incubated with K 2 PtC1 4 (50 
µl in water, 93. 6 µM) in O .1 M phosphate buffer ( pH 7. 2) 
(490 µl) at 20°c and the fluorescence emission spectra were 
scanned from 310 to 550 nm (slit 5 nm). The fluorescence 
due to the protein decreased with time (Figure 7, p 218). 
ii) DHPR (5 µl) was incubated with 4 M urea in 0.1 M 
phosphate buffer (pH 7.6) (595 µl) at 200c and the 
fluorescence emission spectra were scanned for 13 h. In 
this incubation the fluorescence intensity decreased with 
time, but after 7 h to 13 h it did not change further 
(61.3% of original intensity), and A was finally at 357 
max 
nm whereas A was at 352 nm prior to addition of urea. max 
After 17 h, K2 PtC1 4 solution (50 µl, 79.2 µM) was added to 
the above solution but the fluorescence intensity and A 
max 
did not change after a further 21 h incubation period 
( Figure 8 , p 219) • 
iii) The rate of inactivation of DHPR and the rate of 
decrease in fluorescence intensity at A were compared by 
max 
incubating DHPR (10 µl, 0.25 µM) with K2 PtC1 4 (SO µl, 93.6 
µM) 1n 0.1 M phosphate buffer (pH 7.2) (490 µl) in the 
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fluorescence spectrometer cuvette at 200c. The 
fluorescence intensity at 350 nm was measured at time 
intervals and aliquots ( 5 µl) were simultaneously assayed 
for enzyme activity as before (Figure 9, p 219). 
iv) DHPR (5 µl, 0.14 µM) was incubated with 2 mM DTT in 
0.1 M phosphate buffer (pH 7.2) (595 µl) at 200c and 
K2 PtC1 4 (SO µl, 85.4 µM) was added, and then the 
fluorescence emission spectra were scanned ( Figure 1 O, p 
2 21) • The spectral changes were slower than the one . 1n 
Figure 7 (p 218) in which the protein concentration was 
higher (0.31 µM) than in this case. 
v) DHPR (10 µl, 0.32 µM) was pre-incubated with NADH (10 
µl, 0.9 µM) in 0.1 M phosphate buffer (pH 7.2) (490 µl) at 
20°c and the fluorescence emission spectra were scanned (no 
changes within 15 min after quenching due to NADH binding). 
K2 PtC1 4 (50 µl, 9.5 µM) was added to the above solution but 
the fluorescence emission spectra were not changed (Figure 
11-A, p 221). 
vi) DHPR (10 µl, 0.32 µM) was pre-incubated with K2 PtC1 4 
(10 µl, 2.3 µM) in 0.1 M phosphate buffer (pH 7.2 ) (490 
µl) at 20 °c and the fluorescence emisss ion spectra were 
scanned. NADH ( 10 µ 1, 0. 8 µM) was added to it and the 
fluorescence emission spectra showed quenching due to NADH 
binding but no time dependent decrease of fluorescence 
(Figure 11-B, p 221). 
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vii) DHPR (10 µl, 0.31 µM) was dissolved 1n 0.1 M 
phosphate buffer (pH 7. 2) ( 490 µl) and then a mixture of 
NADH (10 µl, 0.8 µM) and K2 PtC1 4 (10 µl, 2.2 µM) was added 
to the enzyme solution. The fluorescence spectra were 
scanned at 20°c and the spectra were immediately quenched 
but no time dependent fluorescence change was observed 
( Figure 12, p 223). 
viii) DHPR (10 µl, 0.31 µM) was pre-incubated with 
K2 PtC1 4 (10 µl, 2.3 µM) in 0.1 M phosphate buffer (pH 7.2) 
( 490 µl) at 20 Oc and the fluorescence emission spectra 
showed time dependent changes. Quinonoid 6-MeDHP, which 
was generated by mixing of 6-MeTHP (10 µl, 43 µM) and 
K3Fe(CN) 6 (10 µl, 100 µM), was added to the above mixture 
and the fluorescence spectra showed quenching due to the 
substrate binding on to the protein (Figure 13, p 223). 
ix) DHPR (10 µl, 0.31 µM) was dissolved into 0.1 M 
phosphate buffer (pH 7. 2) ( 490 µl) and then the mixture of 
K2 PtC1 4 (10 µl, 189 µM) and 6-MeTHP (10 µl, 43 µM) and 
K3 Fe(CN) 6 (10 µl, 100 µM) was added to the enzyme solution. 
The fluorescence emission spectra showed quenching due to 
substrate binding but no time dependent decrease 
fluorescence occurred (Figure 14, p 224). 
4-6-7 Interaction with thiol groups 
. 
1n 
i) DHPR (100 µl, 1.92 nmol) was incubated with K2 PtC1 4 
(19 µl, 1.9 nmol) in 0.1 1 phosphate buffer (pH 7.2) (181 
- 246 -
µl) for 1 h at 20 °c and aliquots ( 1 µl) were assayed at 
time intervals. 60 percent of the original enzyme activity 
was lost within 1 h. The enzyme solution was dialyzed 
against 50 mM phosphate buffer (pH 7.2) (250 ml x 4) for 14 
h at 4°c and during the dialysis no change of enzyme 
activity was observed. Aliquots were mixed with 50 mM 
phosphate buffer (60 µl) and titrated with PCMB. The blank 
cuvette contained 300 µl of 50 mM phosphate buffer (pH 7.2) 
and also aliquots (3 µl) were assayed. 0. 7 molecular 
equivalents of PCMB had reacted with 24% loss of enzyme 
activity (Figure 15). 
. 
ii) DHPR (100 µl, 1.92 nmol) was incubated with K2 PtC1 4 
(19 µl, 1.9 nmol) in 0.1 M phosphate buffer (pH 7.2) (181 
µl) for 1 hat 21°c and aliquots (1 µl) were assayed (60% 
loss of the original enzyme activity). This solution was 
dialyzed against 0.1 M phosphate buffer (pH 7.2) (200 ml x 
2) for 8.5 h at 4°c (no enzyme activity change was 
observed) and aliquots (200 µl) were mixed with 0.1 M 
phosphate buffer (pH 7. 2) ( 100 µl) and 10 mM DTNB solution 
( 3 0 µ 1 , 3 0 0 nmo 1 ) . 1.3 equivalents of DTNB reacted with 
enzyme th iol groups in a 3 h incubation period. This 
solution was again dialyzed against 0.1 M phosphate buffer 
(pH 7.2) (200 ml x 2) for 9 h at 4Dc and aliquots (250 µl) 
were mixed with 0.1 M phosphate buffer (pH 7.2) (50 µl) and 
titrated with PCMB at 250c ( A 250 nm). 1. O 
analyt. 
equivalent of PCMB reacted with further 3 2% loss of the 
enzyme activity. 
- 247 -
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enzyme activity. 
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iii) DHPR (100 µl, 1.92 nmol) was incubated with K
2
PtC1
4 
(19 µl, 1.9 nmol) in 0.1 M phosphate buffer (pH 7.2) (181 
µl) for 4 hat 2i 0c (60% loss of enzyme activity) and then 
dialyzed against O .1 M phosphate buffer ( pH 7. 2) ( 200 ml x 
2) for 15 hat 4°c. Aliquots (200 µl) were incubated with 
10 mM DTNB (30 µl) in 0.1 M phosphate buffer (pH 7.2) (100 
µl) for 6.7 h at 210c. 0.09 equivalents of DTNB reacted 
with thiol groups, i.e. negligible reaction. 
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New pteridine substrates for dihydropteridine reductase and 
horseradish peroxidase 
Wilfred L. F. ARMAREGO, * Akiko OHNISHI* and Hiroyasu T AGUCHit 
*Department of Biochemistry, John Curtin School of Medical Research, Australian National University, P.O. Box 334, 
Canberra, A.C.T. 2601, Australia, and tDepartment of Natural Science, Kyoto Women's University, 35 Kitahiyoshi-cho, 
Imakumano, Higashiyama-ku, Kyoto-shi, Kyoto-fu, Japan 605 
The oxidation of 4,5-diaminopyrimidin-6(1H)-one, 5,6,7,8-tetrahydropteridin-4(3H)-one, its 6-methyl and 
cis-6, 7-dimethyl derivatives, and 6-methyl- and cis-6-7-dimethyl-5,6, 7,8-tetrahydropterins, by horseradish 
peroxidase/H20 2 is enzymic and follows Michaelis-Menten kinetics, and its Km and kcat. values were 
determined. This oxidation of 5,6, 7 ,8-tetrahydropterins produces quinonoid dihydropterins of established 
structure, and they are known to be specific substrates for dihydropteridine reductase. By analogy the 
peroxidase/H20 2 oxidation of the 5,6, 7,8-tetrahydropteridin-4(3H)-ones should produce similar quinonoid 
dihydro species. The quinonoid species derived from 5,6,7,8-tetrahydropteridin-4(3H)-one and its 6-methyl 
and cis-6,7-dimethyl derivatives are shown to be viable substrates for human brain dihydropteridine 
reductase, and apparent Km and Vmax. values are reported. 
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INTRODUCTION 
Dihydropteridine reductase (EC 1.6.99.7) catalyses the 
reduction of quinonoid 7,8-dihydro-L-erythro-(6H)bio-
pterin (1) to 5,6,7,8-tetrahydro-L-erythro-(3H)biopterin 
( 4) in the presence of NADH. Simple alkylpterins, e.g. 
compounds (2) and (3), are effective substrates and can 
replace the natural compound (1) in this enzymic reaction 
(Armarego et al., 1984). In Nature quinonoid dihydro-
biopterin is produced from the tetrahydro derivative ( 4) 
during the hydroxylation of phenylalanine, tyrosine and 
tryptophan by the enzymes phenylalanine hydroxylase 
(EC 1.14.16.1), tyrosine hydroxylase (EC 1.14.16.2) and 
tryptophan hydroxylase (EC 1.14.16.4) in the presence of 
of 0 2 to form tyrosine, 3,4-dihydroxyphenylalanine 
(dopa) and 5-hydroxytryptophan respectively (Kaufman 
& Fisher, 1974). Quinonoid dihydropterins can also be 
formed quantitatively from the respective 5,6,7,8-
(1) R 1 = (2'-R, 3 '-S) -CHOHCHOHMe 
R2 = H 
(4) R 1 = (2'-R, 3'-S)-CHOHCHOHMe 
R2 = H 
(7) 
(2) R 1 = Me, R2 = H 
(3) R 1 = R2 = Me 
(5) R 1 = Me, R 2 = H 
(6) R 1 = R2 = Me 
(8) RI = R2 = R3 = R4 = H 
(9) R 1 = Me, R2 = R3 =R 4 =H 
(10) R 1 = R3 = Me, R2 = R4 = H 
(11) R 1 = R2 = R3 = R4 =H 
(11a) R 1 =R 2 =R 3 =R 4 = 2 H 
(12) R 1 =Me, R 2 =R 3 =R 4 =H 
(12a) R 1 =Me,R 2 =R 4 = 2 H,R 3 =H 
(13) R 1 =R 3 =Me,R 2 =R 4 =H 
(13a) R 1 = R3 =Me,R 2 =R 4 = 2 H 
Abbreviation u ed: pterin is the generic name for 2-aminopteridin-4(3H)-one. 
Vol. 234 
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tetrahydropterins at physiological pH by oxidation with 
molecular 0 2 (Kaufman, 1961; Viscontini & Bobst, 1965; 
Mager, 1975; Pearson & Blair, 1975; Armarego & Schou, 
1978), Br2 (Lazarus et al., 1982), Fe3+ (Archer et al., 
1972), K 3Fe(CN)6 , 2,6-dichlorophenolindophenol (Kauf-
man, 1961; Nielsen et al., 1969; Archer et al., 1972), 
ferricytochrome c (Hasegawa et al., 1978) and peroxidase 
in the presence of H 20 2 (Nielsen et al., 1969) or 0 2 (Armarego et al., 1983a). The most commonly used 
method for generating quinonoid dihydropterins rapidly 
and quantitatively for assaying dihydropteridine reduct-
ase is the Nielsen et al. (1969) peroxidase/H
2
0
2 
method 
(Craine et al., 1972; Chauvin et al., 1979; Firgaira et al., 
1979; Armarego et al., 1983a,b, 1984; Shen, 1984). The 
structures of the quinonoid dihydropterin produced by 
the different oxidants and the aromatic amino acid 
hydroxylases are the same, and have been the subject of 
several studies. Kaufman (1964) proposed the para-
quinonoid structure (7) after a suggestion by Hemmerich 
(1964), and presented good evidence for the pyrazine 
moiety of structure (7). This has subsequently been 
confirmed by several other methods (cf. Armarego et al., 
1984). However, the exact tautomeric structure of the 
pyrimidine ring has been questioned and kinetic evidence 
presented to show that the tautomer with the endocyclic 
double bond [i.e. between C-2 and N-3, as in structures 
(I), (2) and (3)] was the reactive tautomer (Armarego & 
Waring, 1982, 1983b). A study of the chemical shifts of 
the 15N nuclear magnetic resonances upon oxidizing the 
tetrahydropterin (6) to the quinonoid dihydropterin 
labelled with this isotope revealed that in aqueous 
solution at physiological pH the predominant tautomer 
is the one with the endocyclic double bond in the 
pyrimidine ring (3) (Benkovic et al., 1985). We argued 
that if the quinonoid dihydropterin tautomer that reacts 
as a substrate for dihydropteridine reductase has the 
tautomeric structure (1)-(3), then the quinonoid dihydro-
pteridines (8)-(10) derived from the 5,6,7,8-tetrahydro-
pteridines (11), (12) and (13), which do not have the 
2-amino group, should also be substrates for this enzyme. 
We have studied the tetrahydropteridines (11)-(13), and 
report that their products of oxidation by 
peroxidase/H20 2 are substrates for dihydropteridine 
reductase and show Michaelis- Menten kinetics from 
which satisfactory Km and k cat. values were determined. 
Further, in order to demonstrate that the quinonoid 
dihydropteridines (8)-(10) may have tautomeric structures 
similar to the quinonoid dihydropterins (2) and (3), the 
oxidation of their respective 5,6, 7,8-tetrahydryro deriva-
tives (11), (12) and (13), and of compounds (5) and (6), 
by peroxidase/H20 2 was studied. All these compounds 
were shown to be oxidized enzymically, and their 
apparent Km and Vmax. values are reported. 
MATERIALS AND METHODS 
General methods 
Kinetic measurements were performed on a Unicam 
SP.1800 double-beam spectrometer and Rikadenki 
model B-281H recorder with 5 mV across the slide wire 
to produce a maximum pen movement corresponding to 
0.1 absorbance unit. For higher sensitivity a Cary 219 
instrument adjusted to produce maximum pen move-
ment of 0.01 absorbance unit was used, and accurate 
W. L. F. Armarego, A. Ohnishi and H. Taguchi 
measurements of absorbances for concentration deter-
minations were performed on a Perkin-Elmer Lambda 1 
single-beam spectrometer. T.1.c. was run on silica gel 
60 F 254 (Merck) and eluted with butan-1-ol/ acetic 
acid/water (20: 3: 7, by vol.). The spots were revealed 
by u.v. light (at 250 and 365 nm) and staining with I
2 vapour. 
Tetrahydropteridines 
The tetrahydropteridines ( 11 )-( 13a) used were analytic-
ally pure and their syntheses and spectroscopic properties 
are reported elsewhere (Armarego et al., 1986). 
Dihydropteridine reductase 
The enzyme from human brain was purified as 
described previously (Armarego & Waring, 1983a) but 
with a freshly prepared naphthoquinone column (Cotton 
& Jennings, 1978), and gave one band (Mr 26000) on 
SDS/polyacrylamide-gel electrophoresis without passage 
through a 5' -AMP-Sepharose column. Protein concentra-
tions were measured with the Bio-Rad Laboratories 
(Richmond, CA, U.S.A.) standard assay kit and the 
microassay kit (for concentrations less than 25 µg/ml), 
with bovine serum albumin (Bio-Rad Laboratories) as 
standard. This stock enzyme solution (0.39 mg/ml) was 
divided into 2 ml portions and frozen in glass vials. These 
can be thawed and refrozen several times without loss of 
activity, and the frozen solutions can be stored at below 
-10 °C for more than a year without loss of activity. 
Dilute solutions (1: 10) of this stock (but not stock 
solutions) lost enzyme activity rapidly when stored in 
polypropylene vials (but not glass vials), possibly owing 
to adsorption on the plastic (Randles & Armarego, 1985). 
Its activity was 81 nmol of NADH oxidized/min per 
0.39 µg in an assay mixture containing Tris/HCl buffer 
(I 00 µ1, 1 M), 6-methyl-5,6, 7,8-tetrahydropterin (85 µM), 
horseradish peroxidase (Boehringer grade II; 10 µg), 
H 20 2 (11 mM) and NADH (73 µM) in a total volume of 
1 ml at pH 7.4 (25 °C) in the twocuvettes of a double-beam 
u.v. spectrometer, and the reaction was started by 
addition of 1 µl of enzyme. The initial rate was measured 
by the change in absorbance at 340 nm by using £
340 6.22 x 103 M-1.cm- 1 for NADH. 
Horseradish peroxidase 
Boehringer grade II horseradish peroxidase (A
403 / A279 
ratio 1.0) or Sigma type I horseradish peroxidase (RZ 0.6, 
used at double the concentration) was used for the 
generation of quinonoid pterin species in the dihydropteri-
dine reduc!ase kinetic runs. Boehringer grade I horseradish 
peroxidase [A 402 / A272 ratio 1.35, e403 63 x 103 M-1. cm- 1 
in 1 mM-phosphate buffer, pH 6.6, at 25 °C; literature 
values (Schonbaum & Lo, 1972) A 403 / A 275 ratio 3.25, £403 102 x 103 M-1. cm- 1 ] was used for the kinetic measure-
ments, which showed that the tetrahydropteridines were 
viable substrates for peroxidase I (peroxidase-H
2
0
2 complex). 
Kinetic measurements 
Solutions for the kinetic runs for obtaining the Km and 
Vmax. values with peroxidase at 25 °C contained the 
following: Tris/HCl buffer, pH 7.4 (100 µl, 1 M), [or 
potassium phosphate buffer, pH 7.1 (100 µl, 3 M)], 
substrate (100 µ1, concn. 0.5-2 Km), H 20 2 (100 µl, 11 or 
22 nmol; stock solution concn. determined from 
£ 237 = 67 M - 1 ·cm- 1 in water) and water to make 990 µl 
1986 
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VoJ. 11 ,, 
ew ub trate for dih dropteridine reductase and peroxidase 
( or 1 ml in the blank cu ette). The reaction was initiated 
by injection of peroxidase (10 µ1, 2 µg of Boehringer 
grade I) and initial rates were obtained by measuring the 
rate of decrea e in absorbance at an analytical 
wa elength set for each substrate (see Table 2). The 
non-enzymic rates in 0.1 M-Tris/HCl buffer, pH 7.4, were 
negligible for compounds (11) (12), (13) and (14) in the 
ab ence ofH20 2 and 8.9, 7.0, 7.6 and 5.9° 0 were oxidized 
respecti ely in the first 10 min in the presence of 
11 mM-H 20 2 alone. The amounts oxidized in the first 
10 min were slightly less than these when H 20 2 was 11 µM. 
Solutions for the kinetic runs for dihydropteridine 
reducta e acti ity at 25 °C contained the following: 
Tri /HCl buffer, pH 7.4 (100 µ1, 1 M) [or potassium 
phosphate buffer, pH 7.1 (100 µ1, 3M)], peroxidase 
( 100 pl 20 pg of Boehringer grade II or 40 pg of Sigma 
type I enzyme) H 20 2 (1001d 11 Jlmol), enzyme (1-3 pl, 
0.39-1.17 pg, of tock or 10 times these values of 
1: IO-diluted enzyme, added to one cuvette), NADH 
(30 µ1, 2. 7-4.4 mM · Sigma Chemical Co.; see Table 3), 
ub trate (30 ;d concn. 0.5-3 Km) and water to make 
1 ml. The fir t three components were made as a stock 
olution (kept at 0--2 °C during runs), enzyme was 
injected into one cu ette (with a Hamilton Whittier-cal 
PB600 dispen er with a 50 µl Hamilton syringe delivering 
1 pl at a time) followed by simultaneous addition of 
ADH to both cu ettes (by placing the solutions in two 
small platinum baskets attached to a metal beam and 
mo ing them up and down in the solution eight times). 
After mixing the recorder was activated to ensure that 
the ab orbance remained unaltered for approx. 1 min. 
The reaction was initiated by simultaneous addition of 
ubstrate (as in the case of NADH addition above), and 
the initial rates were obtained from the rate of change of 
ab orbance at 340 nm for NADH oxidation. Rates from 
duplicate runs from at least five concentrations of 
ub trate (see abo e) were used to derive the kinetic 
parameters. All these parameters were calculated with the 
aid of a computer program kindly supplied by 
Dr. A. Cornish-Bowden (1981) and alues deri ed from 
double-reciprocal plots of concentrations ersus initial 
velocitie agreed fa ourabl with computed alues. The 
pH alue at the end of each run in this section were 
mea ured v ith a glass electrode and were identical with 
the alue of the tock buffer originally used. 
0 HQ: H1 
H~ 
( 14) 
( 16) 
Vol. _34 
H1 
0 
:XH l NH 2 
( 15) 
(17) R 1 = e R:= H 
( 18) R 1 = R 1 = e 
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RESULTS AND DISCUSSION 
Nature of the substrates for dihydropteridine reductase 
The 5,6,7,8-tetrahydropteridin-4(3H)-ones [(l l}-(13) 
pKa approx. 3.8; cf. Albert & Matsuura (1962)] do not 
undergo aerobic oxidation in aqueous buffer at approx. 
pH 7 as readily as the more strongly basic 5,6,7,8-
tetrahydropterins [e.g. (5) and (6), pKa approx. 5.6; cf. 
Bobst & Viscontini (1966), Kaleen & Jencks (1968) , 
Matsuura & Sugimoto (1970) and Pfleiderer & Mengel 
(1971)] even though they exist entirely as neutral species. 
In this solution the pteridines (1 l}-(13) show virtually no 
changes in u.v. spectra in 1 h. Addition of 50--70 mol-
equivalents of H 20 2 causes changes in spectra, but they 
are too slow (less than 5% change in 10 min) for deriving 
kinetic parameters. However, when peroxidase and H 20 2 
are added together very rapid spectral changes occur (Fig. 
1). The spectral changes for each compound are slightly 
different but all showed the same pattern, i.e. a fall in 
intensity of the major peak such that finally after 24 h the 
main u.v.-absorbing band had disappeared leaving a very 
weak band at long wavelength (approx. 380 nm). These 
are very similar to those observed with 4,5-diamino-
pyrimidin-6(1H)-one (14) and 2,4,5-triaminopyrimidin-
6(1H)-one under the same conditions. The latter is 
known to give the quinonoid pyrimidine (15), which is a 
good substrate for dihydroptridine reductase (Armarego 
et al., 1983b ). These changes were found to obey first-
order kinetics for more than 85 % of the reaction, and the 
rate constants and half-lives are listed in Table 1. 
Preliminary assays of the peroxidase/ H 20 2 oxidation 
products of compounds (l l}-(14), without simultaneous 
addition of reagents to the reaction and reference 
cuvettes, indicated that the oxidation products were 
substrates for dihydropteridine reductase, but the 
reproducibility of the rate traces was very poor. We were 
A 
2.0 
1.5 
1.0 
0.5 
0 L_ _____ ~ __ __::::::::;;;::::::::~=::::::::.--
200 300 
Wavelength (nm ) 
400 
Fig. 1. U.v. spectra of 6-metbyl-5,6 7,8-tetrabydropteridin-
4(3H)-one (117 µ:,.1) after treatment with peroxidase 
(20 µg) and H 20 2 (11 µmol) in 0.1 ~1-Tris HO buffer, 
pH 7.4, at 25 °C 
Scan 1-4 and _3 are after 0. 0.66, 2.3. 3. and 35 min 
re pectively. 
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Table 1. First-order rate constants for the oxidation of compounds (11)-(14) with horseradish peroxidase/ H 20 2 at 25 °C 
Reaction mixtures contained Tris / HCI (unless otherwise indicated (100 µl; 1 M), substrate (100 µ!) , Hp2 (100 µl, 11 µmo!) and water (600 µ1), and the reaction was initiated with peroxidase (100 µ1 ; 20 µg) at pH 7.3 . Measurements were made with a single-beam spectrometer . 
Final concn. Analytical 
Compound (µM) wavelength (nm) 10-a x kobs . (s- 1) t1 (min) 
(11) 149 289 
(I la) 187 289 
(12) 143 290 (12)* 117 290 
(12)t 117 290 (12a) 173 292 
(13) 172 292 
(13)* 166 292 
(13) t 166 292 (13a) 256 292 
(14) 190 282 
(14)t 190 282 
(14)t 190 282 
* In 0.1 M-Bicine buffer, pH 7.0. 
t In 0.3 M-potassium phosphate buffer, pH 7.0. 
:j: In 0.1 M-Bicine buffer, pH 6.7. 
concerned that this might be due to the rearrangement of 
the rapidly formed quinonoid species (8)-(10) to the 
assumed thermodynamically more stable 7,8-dihydro-
pteridines (16, RI = H). In the pterin series this 
rearrangement occurs readily, e.g. (3) -+ (16, RI= NH2, R 2 = R 3 = Me, R 4 = H), and is subject to general 
acid/base catalysis. It was also shown that when H-6 in 
alkylpterins [e.g. compounds (2) and (3)] was replaced by 
deuterium then the rate of rearrangement of quinonoid 
species to the 7,8-dihydro derivatives [e.g. (16), 
RI= NH2 ] in Tris/HCI buffer at approx. pH 7 is subject 
.to kiHfk,H values as large as 10 (Archer & Scrimgeour, 
1970; Armarego, 1984). We consequently synthesized the 
6,7-dideuteriated derivatives (I la), (12a) and (13a) and 
examined the u.v. spectral changes immediately after 
oxidation with peroxidase/ H 20 2 as in the case of the 
respective protio compounds (11), (12) and (13). These 
also followed first-order kinetics for more than 85% of 
the reaction, and the rate constants are given in Table 1. 
Direct comparison revealed only small deuterium isotope 
effects, and the quinonoid dihydropteridines formed do 
not rearrange smoothly to the corresponding 7,8-dihydro 
derivativesasdotherespectivepterins. 7,8-Dihydropterins [i .e. (16), RI= NH2 ] are subsequently oxidized to pterins, 
usually in good yields based on the original tetrahydro-
pterin . With the pteridines (11)- (13), on the other hand, 
the yields of fully oxidized pteridin-4(3H)-ones isolated 
after peroxidase/H20 2 oxidations are exceedingly low (approx. 3-4%), and very little of the 7,8-dihydro 
derivatives is identified by t.l.c. Examination of the 
products of peroxidase/H20 2 oxidation of compounds (11)-(14) by removing samples at time intervals and 
separating the components by t.l .c. showed that within a 
minute of mixing at least seven spots appeared, and that 
their relative intensities varied with time but the number 
of spots did not decrease with time. The reaction was 
repeated on a larger scale for compounds (12) and (13), 
allowed to proceed for 24 h and the products were 
separated by t.l.c. One band in each case was identified 
4.95 ( ± 0.08) 2.3 
6.19 (±0.07) 1.9 
2.07 ( ± 0.02) 5.6 
1.92 ( ± 0.02) 6.0 
0.82 ( ± 0.01) 13.9 
2.10 (±0.02) 5.5 
2.12 (±0.04) 5.5 
1.20 (±0.01) 9.6 
0.39 (±0.01) 29.4 
2.32 ( ± 0.04) 5.0 
6.07 (±0.01) 1.9 
8.22 (±0.01) 1.4 
7.11 (±0.08) 1.6 
conclusively by u.v. spectra at three pH values, by 
IH-n.m.r. spectra and by t.l.c. (re-run) as the fully oxi-
dized compounds (17) and (18). Most of the other bands 
gave substances, in small amounts, that had no u.v. 
absorption and a few unidentified proton signals in the 
n.m.r. spectra. Similar oxidations were performed in the 
n.m.r. tube and the proton spectra were examined at time 
intervals. After 3- 5 min the downfield signal from H-2 
disappeared whereas the upfield signals from the methyl 
groups persisted longer. These results indicate that 
oxidation at C-2 could have occurred to form, say, 
lumazines, and/or the pyrimidine ring was disrupted by 
hydration across the C-2=N-l double bond followed by 
ring opening. The lack of u. v. absorption of some of the 
bands is indication of ring cleavage. In the case of the 
pyrimidine (14) similar results were obtained (i.e. several 
spots on t.l.c.), but we could not identify 2-carboxy-
l ,3,5-triazin-4(3H)-one or 1,3,5-triazin-2,4(1H,3H)-
dione among the products. These would have been the 
possible products if the oxidation proceeded as that of 
2,4,5-triaminopyrimidin-6(1H)-one (Jongejan et al., 
1983). We examined the oxidation with Br2 and K3Fe(CN)6 with the aim of obtaining clear oxidation 
products of compounds (11)-(14), but in these cases also 
many products were formed, some of which had similar 
t.l.c. properties as those from the peroxidase/H20 2 oxid-
ations. The results are consistent with the formation of 
a primary oxidation product (such as quinonoid 
dihydropteridine) that subsequently undergoes degrada-
tion to products that may react further with the 
oxidant. 
Kinetic parameters for horseradish peroxidase 
The structure of the quinonoid species (1)- (3) from the 
peroxidase/H20 2 oxidation of the tetrahydropterins (4)-(6), which are substrates for dihydropteridine 
reductase, is well established (cf. Armarego et al., 1984). 
Although these species rearrange to the corresponding 
7 ,8-dihydro(3H)pterins ( 16, RI = NH2 ), they are stable 
1986 
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enough for some structural investigations. They can be 
generated so rapidly (e.g. within 20 sin assay conditions; 
see the Materials and methods section) that intermediates 
cannot be detected under the present assay procedures. 
The pteridin-4(3H)-ones (11)--(13) are also oxidized 
with peroxidase alone ( or in buffer saturated with 0 2), but 
very slowly (less than 0.1 % in IO min) compared with the 
oxidation of the pterins (5) and (6). The main difference 
in behaviour between the pterins and the pteridin-4(3H)-
ones is that the quinonoid species from the latter are less 
stable and distinct species cannot be observed. 
The close structural similarities of the tetrahydropterins 
(5) and (6) and the tetrahydropteridin-4(3H)-ones (12) 
and (13) prompted the suggestion that their oxidation 
products (2) and (3) and (9) and (I 0) should have the same 
structures and that differences in behaviour are due to the 
differences in oxidation potential between the two series 
(i.e. with and without the 2-amino group). In order to 
obtain further evidence to support this suggestion we 
tested both series of compounds to see if they were 
substrates for peroxidase/H20 2 and exhibited Michaelis-
Menten kinetics. We found that this was the case. The u .v. 
spectrum of the peroxidase used was similar to that of the 
reduced enzyme, whereas in the presence of more than I 
equivalent ofH20 2 it was converted into peroxidase I (cf. 
Schonbaum & Lo, 1972), a process that is known to be 
very fast (second-order rate constant 0.9 x 107 M-1.s-1 ; 
Chance, 1949 ; Kato et al., 1984). A preliminary study 
with a constant amount of peroxidase and H 20 2 with 
various amounts of compounds (5), (6), (11), (12), (13) 
and (14) revealed that the rates of oxidation of all these 
compounds exhibited saturation kinetics, i.e. the rates 
increased with increasing concentration of substrate until 
they reached a maximum value. A detailed investigation 
was undertaken of the rates of oxidation of all these 
substrates with various amounts of peroxidase and of 
H20 2, and keeping the concentration of one of these two 
components constant while altering that of the other. A 
typical series of curves is shown in Fig. 2. The rates 
increase linearly up to a concentration of peroxidase of 
8 µg/ml. The rates increased as the H 20 2 concentration 
increased up to approx. 100 µM, and then the rates 
decreased, most probably owing to deterioration of the 
339 
enzyme (Schonbaum & Lo, 1972). For the measurements 
of the kinetic parameters we settled on a low 
concentration of H 20 2 (11 µM). From the plots of this 
concentration of H 20 2 we chose enzyme concentrations 
from the linear portions of the curve where the slope was 
such that doubling the amount of enzyme doubled the 
rate of reaction. The kinetic parameters for the enzyme 
with the above substrates are listed in Table 2, together 
with the concentrations of the reagents used. 
The Km and k cat. values obtained show that the 
enzymic oxidation of all these substrates obeys Michaelis-
Menten kinetics. The orders of these parameters imply 
0.8 
0.6 
C 
-€ 
~ 
"'( 0 .4 
::! 
~ 
"' a: 
0.2 
0 4 8 12 
Concn . of horseradish peroxidase (µg/ ml) 
Concn. 
(mM) 
0.1 
0.2 
1.0 
0.05 
11 
111 
Fig. 2. Effect of peroxidase (Sigma type I) and H 20 2 concentra-
tions on the initial rates of oxidation of 6,7-dimethyl-
5,6,7,8-tetrahydropteridin-4(3H)-one at the various 
concentrations shown in 0.1 M-Tris/HCl buffer, pH 7.4, 
at 25 °C 
Table 2. Kinetic parameters of horseradish peroxidase/H20 2 with the pteridines (11)--(13), pyrimidine (14) and pterins (5) and (6) at 
pH 7.4 and 25 °C 
l / Reaction mixtures contained Tris/ HCI (unless otherwise indicated) (100 µI; IM, substrate (100 µI , in 4 mM-HCl), Hp2 (100 µ!; 
11 O µM) and water to make a final volume of 1.000 ml, and the reaction was initiated by adding peroxidase (Boehringer grade I) 
(2 µgin 10 µI to one cuvette or 0.2 µgin 10 µJ with the pterins). For k cat . the effective concentration of enzyme was calculated 
to be as 61.8 % from e403 = 63 x 10-3 M-1.cm- 1 [literature value (Schonbaum & Lo, 1972) e403 = 102 x 10-3 M- 1.cm- 1 ] . 
5,6, 7 ,8-Tetrahydropteridin-4(3H)-one 
Unsubstituted (11) 
6-Methyl- (12) 
cis-6,7-Dimethyl- (13) 
4,5-Diaminopyrimidin-6(1H)-one (14) 
5,6, 7,8-Tetrahydropterin 
6-Methyl- (5) 
cis-6,7-Dimethyl- (6) 
* In 0.3 M-potassium phosphate buffer, pH 7.1. 
Vol. 234 
173 (±3) 
314 (±20) 
44.9 (±0.2) 
28.6 (±0.4)* 
203 (±8) 
45.7 (± 1.1) 
103 (±2) 
Vmax. (µmol / min per mg) 
143 (± 1) 
53.4 (±2) 
16.l (±0.03) 
11.6 ( ± 0.09)* 
149 (±3) 
27.9 (±0.4) 
50.9 (±0.8) 
Analytical 
kcat. (s- 1) wavelength (nm) 
58.6 ( ± 0.5) 289 
22.0 (±0.9) 290 
6.6 (±0.01) 292 
4.8 ( ± 0.04)* 292 
55.6 (± 1.4) 282 
11.5 (±0.1) 298 
21.0 (±0.3) 298 
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that the mechanisms of enzymic oxidation of the 
tetrahydropteridin-4(3H)-ones (11 ), (12) and (13) are 
probably similar to those of the tetrahydropterins (5) and 
(6), and that the initial products formed are the 
quinonoid species (8)-(10), (2) and (3) respectively. 
Kinetic parameters for dihydropteridine reductase 
In the first enzymic experiments we ventured to see if 
the peroxidase/H20 2 oxidation products of compounds 
(11)-(13) were inhibitors of dihydropteridine reductase. 
We found no inhibition at concentrations of 120-140 µM 
of the products when quinonoid 6-methyl-7,8-dihydro-
(6H)pterin (2) (at 49 µM) and NADH (at 58 µM) were 
used. Incubation of compounds (11 )-(13) in the presence 
of peroxidase/H20 2 for various times up to 6 half-lives 
(see Table 1) also showed no decrease in the initial rates 
with quinonoid pterin (2) and NADH. Preliminary 
studies, however, showed that one of the products of the 
peroxidase/H20 2 oxidation products of each of com-
pounds (11)-(14) was a substrate for dihydropteridine 
reductase. 
The kinetic properties of these substrates (shown in 
Table 1) made it difficult to use standard mixing 
procedures because the decomposition of the initial 
quinonoid species formed can proceed to quite an extent 
in one cuvette before addition of an ingredient in the other 
cuvette. It was imperative that addition of both the 
substrates (11)-(14) and the NADH solutions were 
respectively added simultaneously to both cuvettes. After 
experimenting also with the order of addition of reagents 
we selected the order that gave best reproducibility of 
initial rate traces for a particular series of runs. Because 
the initial products of peroxidase/ H 20 2 oxidation of the 
substrates (11)- (14) undergo decomposition readily, it 
was necessary to find out how the dihydropteridine 
reductase activity altered with time after allowing the 
decomposition to proceed before starting the assay for 
this enzyme. In this case the order of addition was stock 
solution (Tris/ HCl, peroxidase, H 20 2 ) , dihydropteridine 
reductase (in one cuvette only), substrate (11)-(14) 
(simultaneously to both cuvettes) and allowing a 
recorded time interval before initiation of the reductase 
W. L. F. Armarego, A. Ohnishi and H. Taguchi 
reaction by adding NADH (simultaneously to both 
cuvettes) and recording the spectral change at 340 nm. 
The curve for 6-methyl-5,6, 7,8-tetrahydropteridin-4(3H)-
one is shown in Fig. 3. Maximum activity was also 
observed at the shortest time with compounds (11), (13) 
and (14), and all subsequent assays were performed at 
the shortest possible time (approx. 1 min). The same 
procedure was used for the measurement of the kinetic 
parameters except that the order of simultaneous 
addition of compounds (11)-(14) and NADH was 
reversed, i.e. the reactions were initiated with compounds 
(11)-(14). In this order, the oxidation of the tetrahydro-
pteridines by peroxidase/H20 2 may appear to be 
inhibited by large concentrativns of NADH. This is 
because the quinonoid dihydropteridinc is reduced back 
300 
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Fig. 3. Dihydropteridine reductase (59 ng) activity at various 
time intervals after initiation of the peroxidase/H20 2 
oxidation of 6-methyl-5,6, 7 ,8-tetrahydropteridin-4(3H)-
one (988 µM) and starting the reaction with NADH 
(79 µM) in 0.1 M-Tris/ HCI buffer, pH 7.4 (total volume 
1 ml), at 25 °C 
Table 3. Kinetic parameters for compounds (8)-{10) with human brain dihydropteridine reductase at 25 °C 
Solutions were mixed in the order buffer (100 µl ; 10 times the concentration given below), peroxidase (100 µl; 40 µg) , H
2
0
2 (100 µ l; 11 µmol) and water to make 1.000 ml after all ingredients are added (these four are used as a stock solution), 
dihydropteridine reductase (7 µl of I/ IO-diluted enzyme, to 3 µl of stock enzyme injected, to one cuvette only), NADH (30 µl , 
simultaneously to the two cuvettes) and allowed to equilibrate. Reaction is initiated by addition of tetrahydropteridines (11)-(13) (30 µI) simultaneously to both cuvettes. 
Apparent Apparent 
Km vmax. Concn. of NADH Concn. of enzyme Substrate (µM) (µmol / min per mg) (µM) (µg/ml) 
0.1 M-Tris/ HCl buffer, pH 7.4 
(8) from (11) 669 (±2) 234 (±0.4) 117 0.39 (9) from (12) 366 (±20) 131 (± 3) 117 0.39 (10) from (13) 754 (±45) 76 (±4) 117 1.17* 
0.3 M-Potassium phosphate buffer, pH 7.1 
(8) from (11) 597 (±20) 318 (± 8) 117 0.39 (9) from ( 12) 276 (±8) 444 (±7) 80 0.27 (10) from (13) 640 (± 52) 489 (±27) 131 0.31 
* Close to , but not on, the linear part of the plot of rate versus enzyme concentration. 
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·ev. ub trate for dihydropteridine reducta e and peroxida e 
to the tarting tetrahydropteridine by ADH, the 
reduction being fa ter the higher the concentration of 
ADH and pteridine. We ha e tudied the rates of 
non-enz mic reduction of the quinonoid pecie (2), (3) 
and }--(10) with the u e of a ingle-beam spectrometer 
and found that at pH 7.4 the rate were 1.4--6.8 ° 0 of the 
enzymic rate . The rates of formation of quinonoid 
pecie are not rate-limiting. ote al o that the 
non-enz mic rate are compensated in the double-beam 
pectrometer and are neglected, and hence only the 
enzymic rate are ob erved. Belo pH 6.8, however, the 
non-enzymic rates increase harply because the quinonoid 
pecie become protonated (pKa approx. 5.4 for the 
pterin : ee below). The e compounds ere clearly 
oxidized to transient specie that exhibited Michaelis-
Menten kinetic with dihydropteridine reductase and the 
appropriate apparent Km and Vmax. alues that we 
mea ured are in Table 3. 
For meaningful kinetic parameters the concentrations 
of dih dropteridine reductase ere selected from plots of 
enzyme activity er u enzyme concentration. In all cases 
the plot were linear up to enzyme concentrations of 
0.4--0.6 mg/ml, i.e. the rate was doubled when the enzyme 
concentration as doubled, and then slo ly le elled off. 
Thi le elling off of enzyme acti ity does not appear to 
be cau ed b inefficient recycling of the pteridines by 
peroxida e/H 20 2 and may be due to lower effecti e 
concentration of enzyme caused by association or 
pol merization. but e ha e not in estigated this further. 
The enzyme concentration used ere selected from the 
linear portion of the plots . Although e found that the 
quinonoid pecie of the 4.5-diaminop rimidinone (14) 
had ub trate activit . the e decomposed too rapidly (see 
Table 1 • and the reproducibilit of the initial-rate plots 
wa ver poor. 
The parameter v ere mea ured in Tri and pho phate 
buffer becau e it v a found that the rate of oxidation 
were lower in the latter buffer. We do not kno precisely 
what i happening in thi reaction. but we kno that the 
quinonoid pecies are formed rapidl and then decompose. 
The plot in Fig. 3 confirm thi because the dih dro-
pteridine reducta e activit of the species formed 
from pero ida e H 20 2 oxidation i highest immediate! 
approx. 1 min after mixing and then decrea es . The rate 
con tant in Table 1 are therefore for the formation and 
degradation of the quinonoid pecies. Since e do not 
know the individual rate con tant of formation and 
degradation of the active pecie . we cannot take the 
concentration of the re pective quinonoid species in 
Table a being the ame a tho e of the tetrahydropteri-
dine 11 . l_ and 1 from which they were derived. 
Therefore the apparent Km Yalue are maximum alue 
for the e ub trate and the true value could be much 
maller. The reproducibility of the initial rate and the 
ati factory pre ad of error confirm thatthe proportional 
concentration of quinonoid pecie with re pect to 
tetrahydropteridine u ed. at variou concentration of 
the latter. are v,ithin experimental error in each et of 
expenment . 
The Km\ alue in pho phate buffer are lightly le than 
in Tri buffer and could reflect the higher proportion of 
quinonoid pecie lower decompo ition in the former 
buffer. Thi doe not affect the apparent J'max . value . 
which are higher in pho phate buffer. The concentration 
of. T ~ DH in Table are at or clo e to aturating value 
becau e when thev are doubled no ignificant increa e in 
- ~ 
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rates are obser ed. Some of the substrate contained 
small amounts of borate salts, and we were concerned 
that borate might inhibit the enzyme. o inhibition of 
dihydropteridine reductase was observed at borate con-
centrations up to 1 mM when 6-methyl-7 ,8-dihydro(6H)-
pterin (2) (at 55 pM) and ADH (100 pM) were used. The 
highest concentration of borate from the substrate in the 
assays was 0.9 mM, and most of the solutions contained 
considerably less than this concentration. 
In conclusion we have shown that the 5,6,7,8-
tetrahydropteridin-4(3H)-ones (11), (12) and (13) are 
effective substrates for horseradish peroxidase in the 
presence of H 20 2 , similarly to the related 2-amino 
derivati es, the 5,6,7,8-tetrahydropterins (5) and (6). The 
transient quinonoid species derived from the oxidation of 
the tetrahydropteridin-4(3H)-ones (11 }--(13) are found to 
be substrates for dihydropteridine reductase. A 2-amino 
group is not essential for substrate activity with the latter 
enzyme but mo t probably enhances the binding. The 
data show that the quinonoid structures (2) and (3), 
but not (7) are probably the reactive species in 
the dihydropteridine reductase-catalysed oxidation of 
ADH. The proposition that the quinonoid structures 
deri ed from compounds (l l}--(14) are different from 
those derived from the pterins (2) and (3) when the same 
oxidant (peroxidase/H 20 2 ) is used, and are also viable 
substrates for a second enzyme (dihydropteridine 
reductase), is ery unlikely. Such compounds howe er, 
could ha e the ortho-quinonoid structure (19) , a structure 
ith energy comparable with that of the tautomers (2 
and (3) (Gready, 1985), but this has been ruled out by 
other studies (Armarego & Waring, 1982; Lazarus et al .. 
1982: Benko ic et al., 1985). The u .. -spectral changes of 
2 5-diaminopyrimidin-4 3H)-one (20) on treatment with 
peroxidase/H20 2 are very similar to those of the 
pyrirnidinone (14) and the pteridines (l l}--(13) (see Fig. 
1 and ould exclude a quinonoid species with bond 
arrangements such as (19). Moreover, the pyrimidinone 
20 after peroxidase/ H 20 2 treatment exhibited some 
acti ity with dih droperidine reductase. Structure (19) 
for the pteridin-4(3H)-ones implies a remote possibility 
that dih dropteridine reductase can reduce two different 
tautomers of ery similar substrates. It is true that the 
cations of the t o tautomers are mesomeric. (21 ¢ (22 . 
and protonation of the quinonoid species will enhance 
h dride transfer to -5 considerably. HO\ e er. the 
enzyme will still need to transfer a proton to N-3 in one 
case the pterins) and to -8 in the other ca e (the 
pteridinones) after binding of the neutral pecies. if one 
po tulates different tautomeric tructures. If the pteridine 
binds as the cation. on the other hand. it does not matter 
v hich tautomer predominates in neutral solution. The 
pKa of the quinonoid dih dropterin 3) is 5.4 (W. L. F . 
Armarego. unpubli hed v ork: cf. al o Bailey & Ayling. 
1983) and at pH 7.4 it is almost entire! in the un-
protonated form. The absence of a 2-amino group from 
the corre ponding quinonoid dihydro 6H pteridin-4-one 
10 would be ba e-weakening and make it pKa lower 
than 5.4 by at lea t 1.6 pH units [compare the pKa 
value of 5.6.7. -tetrahydropteridin-4 3H)-ones appro . 
3. : Albert & ~at uura. 1962 and 5.6.7. -tetrahydrop-
terin approx. -.6: Ylat uura & Sugimoto. 19 0: 
Pfleiderer & YI en gel. 19 1 ] . The e pecie are even le 
likely to be protonated at pH approx. 7.4. Protonation of 
quinonoid pecie would mo t probably take place on the 
enzyme after or before hydride tran fer. but thi informa-
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tion is not known at present. Pulse-chase and stopped-
flow kinetic studies of the mechanism of the reactions at 
the active site of dihydropteridine reductase have revealed 
that NADH binds first and very tightly, followed by the 
quinonoid dihydropterin, and that the rate-determining 
step is a conformational change of the ternary complex, 
probably assisting in or associated with substrate 
protonation, immediately before the faster hydride 
transfer (no deuterium isotope effect) from NADH to the 
quinonoid dihydropterin, followed by release of products 
(Poddar & Henkin, 1984). A study of the profiles of the 
kinetic parameters plotted versus pH could tell us more 
about the details of the protonation process. Finally, we 
have examined 6-methyl-7,8-dihydro(6H)lumazine (23), 
which is relatively stable and whose structure has been 
established by n.m.r. spectroscopy (Lazarus et al., 1982), 
and found that at 41 µM it is neither a substrate nor an 
inhibitor of this enzyme. 
We thank Dr. D. J. Brown for gifts of several pyrimidine and 
pteridine intermediates, and Dr. D . Randles and Dr. P. Waring 
for stimulating discussions. 
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Reduced 2-Methyl-4-oxo, 2-Methylamino-4-oxo, 
2-Methylthio-4-oxo and 2-Amino-4-thioxo 
6, 7-Dimethylpteridines, and 6,8-Dimethylpterin 
as Substrates for Dihydropteridine Reductase 
Wilfred L. F. Armarego,A Akiko OhnishiA and Hiroyasu Taguchi8 
A John Curtin School of Medical Research, Australian National University, 
P.O. Box 334, Canberra, A.C.T. 2601. 
8 Department of Natural Science, Kyoto Women's University, 
Higashiyama-ku, Kyoto 605, Japan. 
Abstract 
The syntheses of unsubstituted (4), 6-methyl- (6), cis-6,7-dimethyl- (8), cis-2,6,7-trimethyl-
(10), cis-6,7-dimethyl-2-thioxo-(lH)- (12) and cis-6,7-dimethyl-2-methylthio- (13) 5,6,7,8-
tetrahydropteridin-4(3 H)-one and the deuterated derivatives (5), (7), (9) and (14), and a 
cis and trans mixture of 2-amino-6,7-dimethyl-5,6,7,8-tetrahydropteridin-4(3 H)-thione (11) are 
described. The existence of the transient quinonoid species (15)-( 17) had been previously 
demonstrated by showing that they are substrates for the enzyme dihydropteridine reductase 
from human brain. We report that the transient quinonoid species cis-2,6,7-trimethyl- (18), cis-2-
methylthio-6,7-dimethyl- (25), cis-2-methylamino-6,7-dimethyl- (26), and 2-amino-6,8-dimethyl-
(29) 7 ,8-dihydropteridin-4(6 H)-one, and 2-amino-6, 7-dimethyl-7 ,8-dihydropteridin-4(6 H)-thione 
(28), but not cis-6,7-dimethyl-2-thio-7,8-dihydropteridin-4(6H)-one (27) are substrates for this 
enzyme showing that a variety of substituents in position 2 of the pteridine ring can be tolerated, 
and confirming that the predominant tautomer (1) of the quinonoid species in aqueous solution 
is also the reactive tautomer at the active site of this enzyme. 
Introduction 
Several quinonoid dihydropterins are active substrates for the enzyme 
dihydropteridine reductase and can exit in three possible tautomeric forms ( 1 ), 
(2) and (3) in aqueous solution at near neutral pH. 1 15 N n.m.r. spectral studies of 15 N 
enriched 6,7-dimethylpterins have shown that species (1) are predominant in solution,2 
and tautomer (3) could not be detected in the 1 H n.m.r. spectra. 3 However, the 
predominant tautomer in solution is not necessarily the structure that is enzymically 
active. In an endeavour to deduce the tautomeric structure of pterin substrates at the 
active site we have synthesized the 5,6,7,8-tetrahydropteridin-4(3H)-ones (4)-(10), and 
the related thioxo and methylthio compounds (11)-(14) which we now report together 
with their spectral properties. The substrate activities of the transient quinonoid 
species ( 15)-( 17), derived by oxidation of the tetrahydropteridinones ( 4 ), ( 6) and (8), 
1 Armarego, W. L. F., Randles, D., and Waring, P., Med. Res. Rev., 1984, 4, 267. 
2 Benkovic, S. J., Sammons, D., Armarego, W. L. F., Waring, P., and Inners, R., J. Am. Chem. 
Soc., 1985, 107, 3706. 
3 Lazarus, R. A., DeBrosse, C. W., and Benkovic, S. J., J. Am. Chem. Soc., 1982, 104, 6871. 
0004-9425 I 86/010031 $02.00 
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towards dihydropteridine reductase have been reported, 4 and the activities of the 
quinonoid pteridinone (18), the thio compounds (25), (27) and (28), and the pterin (26) 
are briefly described here. The biological activities strongly support the tautomeric 
structure (I) as the enzymically active species, and show that the enzyme can tolerate 
quinonoid dihydropteridines with 2-methyl-4-oxo (18), 2-methylamino-4-oxo (26), 
2-methylthio-4-oxo (25), 2-amino-4-thioxo (28) and only 4-oxo (15)-(18) substituents 
in addition to the 2-amino-4-oxo substituents that are present in the natural substrate, 
quinonoid 7,8-dihydro(6H)biopterin and analogues such as (1). 1 
We have indicated in the Experimental section where our syntheses differed 
from published procedures and have included unpublished spectral data. Only new 
preparations and unusual features of the syntheses will be discussed here. 
Preparation of Pteridin-4(3 H)-ones 
Pteridin-4(3 H)-one could not be reduced catalytically with pre-reduced platinum 
oxide in trifluoroacetic acid or methanol, or with palladium on charcoal in ethanol. 
This was not due to poisoning of the catalyst by traces of sulfur from the intermediates 
because the reductions were unsuccessful with rigorously purified pteridinone, and 
when large excesses of catalyst were used. We have no satisfactory explanation for 
this failure. Reduction to the tetrahydro derivative (4) with sodium borohydride, 
however, was successful. 5 
6-Methylpteridin-4(3H)-one, on the other hand, gave the 5,6, 7,8-tetrahydro 
derivative (6) on hydrogenation with platinum oxide in methanol. When the 
reduction was carried out in trifluoroacetic acid and stopped after two equivalents 
of hydrogen were absorbed, a mixture of tetra- and hexahydro-pteridinone was 
formed. The pure hexahydro derivative (19) was obtained by allowing this reduction 
to proceed to completion. Alternative structures for the hexahydro product, such 
as the ring-opened cations of the N-methyltetrahydropyrazines (20) or (21), or 
of the N-hydroxymethyltetrahydropyrazines (22) or (23) derived from the bicyclic 
compound ( 19), were excluded on the grounds that the 1 H n.m.r. spectra in acidic 
solution had proton integrals consistent with two and not three H 2 protons for the 
singlet at 4 · 99 ppm [ compare with the singlets at 4. 30 and 4 · 33 ppm of the two 
H 2 protons in the spectra of the neutral species of cis- and trans-1,2,4a,5,6, 7,8,8a-
octahydroquinazolin-4(3 H)-one]. 6 Moreover, the 13C n.m.r. chemical shift of C 2 was 
at 52-1 ppm consistent with a -HNCH2NH- structure (19) rather than -HNCH
2
0H 
structures such as (22) and (23). This deduction was arrived at from the known 13 C 
chemical shifts of 6-aminohexan-1-o! where CI and C 6 are at 62. 9 and 43 · 2 ppm 
respectively. 
7 
The model shows that the oxygen adjacent to the methylene carbon 
atom deshields it much more strongly than an adjacent nitrogen atom. The value of 
52 · 1 ppm observed cannot be consistent with a -NHCH
2
0H structure. 
cis-6, 7-Dimethyl- (8) and cis-2,6, 7-trimethyl-5,6, 7,8-tetrahydropteridin-4(3H)-one 
( 10), unlike the above, were prepared as their hydrochloride salts by allowing the 
catalytic reduction of the respective pteridinone in acidic medium to proceed to 
4 
Armarego, W. L. F., Ohnishi, A., and Taguchi, H. , Biochem. J., 1986, 234, in press. 5 
Albert, A., and Matsuura, S., J. Chem. Soc., 1962, 2162. 6 
Armarego, W. L. F. , and Kobayashi, T., J. Chem. Soc. C, 1971, 238. 7 
Formacek, V., Desnoyer, L., Kellerhals, H. P., Keller, T., and Clerc, J. T., Bruker 13 C Data Bank, I 976, 1, 139. 
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completion. The cis stereochemistry at C 6 and C 7 was deduced from the small 
H 6-H 7 coupling constants (cf. 8). 
Preparation of Thiopteridines 
The successful reduction of pteridin-4(3 H)-ones to their 5,6, 7,8-tetrahydro 
derivatives with large excesses of sodium borohydride5 made us use this reagent to 
prepare 2-amino-6, 7-dimethyl-5,6, 7,8-tetrahydropteridin-4(3 H)-thione (11). Unlike 
previous reactions where the 6, 7-cis isomers were formed exclusively, this product 
was a 1 · 6 : 1 · 0 mixture of cis and trans isomers. As in previous reductions we were 
unable, however, to obtain the reduced pteridines completely free from small amounts 
of boric acid or sodium borate which did not interfere with enzyme activity. 4 The 
reduced pteridines were free from organic impurities other than solvent which adheres 
tenaciously. In an attempt to obtain preparations free from borate we reduced the 
2-amino-6, 7-dimethylpteridin-4(3 H)-thione by hydrogenation with platinum oxide in 
methanol. This gave only the cis-5,6, 7,8-tetrahydro derivative of (11) (by n.m.r.). 
Similar reduction in trifluoroacetic acid yielded a 2 · 3 : 1 · 0 mixture of cis and trans 
isomers. The sharp signals in the n.m.r. spectra of these products were an indication 
that they were free from platinum or platinum complexes. 
6, 7-Dimethyl-2-thioxo-2,3-dihydropteridin-4(1 H)-one was reduced to the cis-
hexahydro derivative (12) with excess sodium borohydride. However, when it 
was reduced catalytically with platinum oxide in methanol, 3M hydrochloric acid 
or trifluoroacetic acid, hydrogen uptake was not complete and the corresponding 
6, 7-dimethyl-2-thioxo-l,2, 7,8-tetrahydropteridin-4(3 H)-one only was formed. The 
7,8-dihydro structure of this compound was deduced by analogy with the incomplete 
catalytic reduction products of related pteridines which were known to be the more 
stable 7,8-dihydro derivatives (compared with the 5,6- or 5,8-dihydro derivatives). 
The structures of the 7,8-dihydropteridines were deduced by unambiguous synthesis. 8 
Catalytic reduction of 6, 7-dimethyl-2-methylthiopteridin-4(3 H)-one with platinum 
oxide in trifluoroacetic acid also gave the 7,8-dihydro derivative, but when the solvent 
was methanol or (D4) methanol (with deuterium gas) reduction was complete and 
the cis-derivatives (13) and (14) were obtained respectively. These were soluble in 
chloroform which is unusual for oxopteridines. 
Preparation of Substrates and Dihydropteridine Reductase Activity 
This enzyme has a strict requirement for quinonoid dihydropteridines, e.g. structure 
(1), as substrates. These substrates are reduced enzymically to the respective 
5,6, 7,8-tetrahydropteridines at the expense of NADH which in turn is oxidized to 
NAD + (see
1 
). The quinonoid species can be generated by specific oxidations (e.g. 
with peroxidase-hydrogen peroxide or air, potassium ferricyanide, bromine) of the 
corresponding 5,6, 7,8-tetrahydropteridines. Although many of them can be identified 
by their characteristic u. v. spectra, and by their reactions and n.m.r. spectra at 
low temperature, they are short lived. They either rearrange to the more stable 
tautomers, the 7,8-dihydropteridines (24), or undergo degradation depending on the 
nature and position of the substituents. 1 Neither the tetrahydro nor the 7,8-dihydro 
derivatives. nor the parent pteridines, are substrates for the enzyme. Consequently, 
8 
Armarego, W. L. F., and Schou, H. , J Chem. Soc., Perkin Trans. 1, 1977, 2529. 
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when a tetrahydropteridine is oxidized by the specific oxidants and the tran
sient 
species formed can be enzymically reduced back to the original tetrahydropte
ridine 
at the expense of NADH we can presume that the transient species have a quino
noid 
structure such as (1). 
In order to ascertain that the transient species were substrates we had to show th
at 
(i) maximum enzyme activity (i.e. initial rates of oxidation of NADH) was observed at 
least immediately after addition of enzyme, (ii) at a set concentration of substrate and 
NADH, enzyme activity increased linearly with increase in enzyme concentration,
 (iii) 
at a constant enzyme and NADH concentration but varying substrate concentrat
ion, 
the initial rates against substrate concentrations were hyperbolic, i.e. indicati
ve of 
saturation kinetics, and (iv) that Lineweaver-Burk plots of the data in (iii), i.e. 
reciprocal of initial velocity against reciprocal of concentration yielded the k
inetic 
parameters (apparent Michaelis constants Km and maximum velocities Vmax). We 
had shown that the tetrahydropteridin-4(3H)-ones (4), (6) and (8) were oxidized 
by peroxidase-hydrogen peroxide to the transient species ( 15)-( 17) respectively. 
Table 1. Kinetic parameters of human brain dihydropteridine reductase in
 O · 1 M Tris-HCl 
buffer pH 7 . 4 at 25° 
7, 8-Dihydropteridine-4(6 H)-one Km (µM) Vmax 
A VIK NADH (µM) 
2-Amino-6,7-dimethyl, (1) 24 · 7(+0.6) 199(+2.1) 8·06 95 
2,6, 7-Trimethyl, (18) 38 ·8(+o. 7) 10· l(+0.1) 0·26 111 
6,7-Dimethyl-2-methylthio, (25) 85. 5( +O ·04) 83· l(+0.3) 0.97 106 
6, 7-Dimethyl-2-methylamino, (26) 127( + 5) 150(+4) 1·18 117 
2-Amino-6,8-dimethyl,B (29) 349(+26) 24 · 3(+2 ·6) 0·06 108 
A Calculated on µM NADH oxidized per min per mg of protein. 
B Formed from 6,8-dimethyl-5,6,7,8-tetrahydropterin hydrochloride (Armarego, W. L. F., and
 
Milloy, B. A., Aust. J. Chem., 1977, 30, 2023), E270 14450 in 4 mM HCl (Pfleiderer, W., and
 
Mengel, R., Chem. Ber., 1971, 104, 2293), in the assay. 
These transient species were substrates for dihydropteridine reductase and w
e had 
determined their kinetic parameters.
4 We report an extension of these studies in 
which we have examined the viability of the derivatives (18), (25), (26) and (29) as 
substrates for dihydropteridine reductase. The results are summarized in the
 form 
of kinetic parameters in Table 1. The parameters of the known substrate 2-am
ino-
6, 7-dimethyl-7, 8-dihydropteridin-4(6 H)-one (1), were redetermined under identical 
conditions and were for comparison. The VIK values have been included in Ta
ble 1 
because they are a better index of the overall efficiency of the enzyme with a parti
cular 
substrate than the Km and Vmax values (see below). When we oxidized the related cis-
2,6, 7-trimethyl-5,6, 7,8-tetrahydropteridin-4(3 H)-one (10) with peroxidase-hydrogen 
peroxide we found that the quinonoid species (18) was formed at a relatively slow rate 
which was rate limiting. However, when the oxidant was replaced by three m
olar, 
or more, equivalents of potassium ferricyanide (with respect to the pteridine), the 
oxidation was complete within five seconds. By using the latter oxidant we sho
wed, 
by the above four criteria, that the transient quinonoid dihydropteridine ( 18) formed 
was a substrate (Table 1). Similarly we have shown that the quinonoid pteridines 
(25) and (26) derived from oxidation of 2-methylthio- (13) and 2-methylamino-
(kindly supplied by Dr P. Waring) 6, 7-dimethyl-5,6, 7,8-tetrahydropteridin-4(3 H)-one 
respectively are also substrates (Table 1). Kaufman9 had previously demonstrated 
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that the methylamino compound (26) was a substrate by measuring only one initial 
rate. This rate was 36% of the initial rate of the parent compound (1) measured 
under identical conditions (compare with Table 1; VIK values are a good index 
of substrate reactivity in these cases, the larger the value the better the substrate). 
The two quinonoid species (25) and (26) had typical u.v. spectra (cf. 1). We had 
previously shown that the latter rearranged to the 7,8-dihydro tautomer with a half 
life of 34 · 6 min (pH 7 · 6 Tris-HCI buffer, kobs 2 · Ox 10 - 2 min- 1) and when the rate 
was compared with that of the 6, 7-dideuterated derivative the k
8
/ kn value was 9 · 0. 10 
In the present study the 2-methylthio analogue (25) rearranged similarly, but with 
a half life of O · 9 min (pH 7 Tris-HCl buffer, kobs O · 75 min -I) and when compared 
with the rate of rearrangement of the deuterated quinonoid dihydropterin derived 
from (14) the k8 / kn value was 18. This further confirms the quinonoid structures 
(25) and (26) because these rearrangements are known to proceed with very large 
deuterium isotope effects.1 The 7,8-dihydro compounds formed were slowly further 
oxidized to the respective pteridines by air. 
The thioxopteridinone (12) was oxidized by peroxidase-hydrogen peroxide or 
potassium ferricyanide as observed by the u. v. spectral changes. However, no 
dihydropteridine reductase active species could be detected, and the t.l.c. and u. v. 
spectral properties of the final oxidation product were similar to those of the original 
6, 7-dimethyl-2-thioxo-2,3-dihydropteridin-4(1 H)-one. This experiment demonstrates 
that either the quinonoid species (27) were formed in very small (steady state) 
concentrations or were not formed at all. It should be pointed out that 6-methyl-
5,6, 7,8-tetrahydro-lumazine [the 2-oxygen analogue of (12)] has been oxidized to 
6-methyl-7,8-dihydropteridin-2(3 H),4(6H)-dione [related to the 2-oxygen analogue of 
(27)] which was not a substrate or inhibitor of the enzyme. We examined the oxidation 
of the tetrahydrothiopterin (11) with the above two oxidants, and the t.l.c. properties 
of the products after various intervals of time were similar. The intermediate (28) 
proved to be a substrate for the enzyme according to the first three criteria above. 
However, attempts to determine the kinetic parameters were unsatisfactory because 
it was not possible to reproduce the initial rate traces to within the accepted standard 
deviation. This is possibly due to the facile oxidation of the 4-thio group to give 
the respective disulfide which may or may not be enzyme active and/or dismutation 
between the species (28) and the unchanged 4-thioxo compound (11) in the early 
stages of oxidation. 
The ability of 6,8-dimethyl-7,8-dihydro(6H)pterin (29) to act as a substrate for 
dihydropteridine reductase was also examined in order to find out the effect of methyl 
substitution at N 8. This compound proved to be a substrate, albeit the poorest of 
the active pteridines that were studied, but satisfied the criteria for substrate activity 
stated above. 
We conclude that the enzyme can tolerate various substituents in the 2-position, 
as well as an 8-methyl group, in the quinonoid dihydropteridine substrates with 
a 4-oxo or 4-thioxo group. The results exclude the possibility that the tautomer 
with the exocyclic double bond at position 2 [e.g., structure (2)] is a substrate at 
the active site because such a tautomer cannot be formed when the 2-position is 
unsubstituted [cf. compounds (15)-(17)], and when it is substituted with a methyl 
9 
Kaufman, S., J Biol. Chem., 1964, 239, 332. 
IO Arrnarego, W. L. F. , and Waring, P., J Chem. Soc., Perkin Trans. 2, 1982, 1227. 
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(18) or a methylthio (25) group. The tautomer with a double bond between C 8a-N 8 
[e.g., structure (3)] is also excluded on the grounds that its presence cannot be 
detected in the 1 H n.m.r. spectra in neutral solution, 3 kinetic evidence
10 
and because 
the 8-methyl pterin (29) cannot form this tautomer at pH 7 · 3. The oxidation of 
6,8-dimethyl-5,6,7,8-tetrahydropterin to yield (29) should produce a cation with the 
positive charge on N 8 if it formed a tautomer such as (3); but at neutral pH this 
should deprotonate at N 3 to form the neutral species (29). The evidence that the 
pteridine substrates are not in the protonated states on the enzyme had been presented 
by us previously. 4 The above study also demonstrates that the predominant tautomer 
in aqueous solution at pH ~ 7 [structure (1), with the endocyclic C 2-N 3 double 
bond] is the active substrate for dihydropteridine reductase. 
Experimental 
Microanalyses were determined by the Australian National University Analytical Unit. 
Analytical specimens were dried at 25° and O. 3 mmHg in the presence of potassium hydroxide 
unless otherwise stated. 1 Hand 13c n.m.r. spectra were measured on a Jeol FX 90Q spectrometer 
operating at 34°. Sodium 3-(trimethylsilyl)propionate was used as internal standard for the 
1 
H 
n.m.r. spectra (o values are in ppm and J values in Hz). Kinetic measurements were performed on 
a Unicam SP1800 double-beam spectrometer and Rikadenki B-281H recorder with 5 mV across 
the slide wire to produce a maximum pen movement corresponding to O • 1 absorbance units. 
For higher sensitivity a Cary 219 spectrometer adjusted to produce maximum pen movement of 
0·01 absorbance units was used and accurate absorbance for concentration measurements were 
performed on a Perkin-Elmer Lambda 1 single-beam spectrometer. The cell holders were kept at 
constant temperature (25°) with recirculating water in a Coolnics thermostat. The mass spectra 
were measured at 16 eV on a Hitachi M-70 mass spectrometer. Thin-layer chromatography 
(t.1.c.) was run on Silica gel 60 F 254 (Merck) and eluted with BuOH/AcOH/H20 20: 3: 7. The 
spots were revealed by u.v. light (at 250 and 365 nm) and staining with iodine vapour. l.r. spectra 
(KBr disc) were measured on a Unicam SP 1050. 
Synthesis of Pteridin-4(3H)-ones 
5,6-Diaminopyrimidin-4(3H)-one, m.p. 238-243° (dee.), was prepared by desulfurizing the 
respective 2-thio derivative 11 and was recrystallized from water (Found: C, 33 · 9; H, 5 · 6; N, 
39-8. C
4
H6N40.0-8H20 requires C, 34-2; H, 5-5; N, 39-9%). The 
1
H n.m.r. spectrum 
had o (D
2
0): 7 · 76; and E278 8912 (pH 7). Pteridin-4(3 H)-one, prepared from the above 
pyrimidinone and glyoxalbis(sodium bisulfite), 11 was purified by alumina (Brockman II, B.D.H.) 
column chromatography and eluted with 18 mM aqueous ammonia. The main fraction (monitored 
by t.1.c.) was evaporated, the residue dissolved in hot water (charcoal), the pH was adjusted 
to 3-4 and cooled. The solid was collected, crystallized from a large volume of acetic acid 
and sublimed at 320°/0-9 mmHg (Found: C, 49-0; H, 2-7; N, 38-1. C6H 4N 40 requires C, 
48-7; H, 2-7; N, 37-8%). 1H n.m.r. (1 M DCl): 8-97, d, J 2-3, H6 or 7; 9-05, d, J 2-3, 
H7 or 6; 9-10, s, H2; (1 M NaOD): 8-46, s, H2; 8-74, d, J 2-2, H6 or 7; 8-85, d, J 2-2, 
H 7 or 6. ( 6,7-Di_)-Pteridin-4(3H)-one, m.p. 303-355° (dee.), was similarly prepared by using 
(1,2-D 2)-glyoxalbis(sodium bisulfite) 
12 and sublimed at 230° /0. 7 mmHg (Found: C, 48 · 2; H + D, 
4-2; N, 37-5; mle 149. C6H2D2N40 requires C, 48-0; H+D, 4-2; N, 37-3%; M+ 150). Vmax 
3090 (3030), 2925 (2885), 1724 (1724), 1615 (1617), 1545 (1550), 1434 (1468), 1378 (1398), 
1322 (1320), 1268 (1280), 1210 (1228), 1182 (1163), 1150 (1108) 1013 (1032), 1000, 990,925 
(923), 836 (827), 710 (720) and 652 (607) cm - 1, the values for the unlabelled 1 H-containing 
compound above being the ones in parentheses. The 1 H n.m.r. spectrum indicated c. 3. 7% 
contamination with the 1 H-containing compound. 5,6, 7 ,8-Tetrahydropteridin-4(3 H)-one5 ( 4), 
prepared by reduction of pteridin-4(3 H)-one with N aBH4, always contained small amounts of 
11 Albert, A., Brown, D. J., and Cheeseman, G., J. Chem. Soc., 1951, 474. 
12 Armarego, W. L. F., Randles, D., and Taguchi, H., Biochem. J., 1983, 211, 357. 
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borate (green-edged flame test with H 2S04 / EtOH) although it gave one spot on t.1.c. (Found: C, 
41-5; H, 5·7; N, 31 ·8. C6H 8N 40.0· 1NaH2B03.H20 requires C, 41,2; H, 5·6; N, 32,0%). The 
formula weight is consistent with the reported E2s9 value of 8511 (pH 7 ·O) for the anhydrous 
neutral species; 
1 
H n.m.r. (1 M DCl): 3. 69, m, H 6,6, 7, 7 and 8 · 59, s, H 2. Similar reduction 
of (6,7-D2)-pteridin-4(3H)-one with NaBD4 in D 20 gave (6,6,7,7-D4)-pteridin-4(3H)-one (5) (Found: C,41·4; H+D, 8·55; N, 31·5; m / e 156, base peak. C6H4D 4N 40.0·02NaH2B03
.H
2
0 
requires C, 41,0; H+D, 8· l; N, 31 ·9%; M+, 156]. The u.v. spectra and t.1.c. properties were 
identical with the above. The 1 H n.m.r. spectrum indicated that it was better than 95% deuterated 
on C6 and C7. 
6-Methylpteridin-4(3 H)-one 13 (150 mg) in methanol (300 ml) and platinum oxide (250 mg 
pre-reduced in 10 ml of methanol) were shaken with hydrogen (25° /720 mmHg) for 4. 2 h, 
a further quantity of platinum oxide (100 mg pre-reduced in 10 ml of methanol) was added 
and shaking was continued for a further 1 · 5 h. The solution was filtered and evaporated 
to dryness. The residue (144 mg) was recrystallized from water (10 parts) to give 6-methyl-
5,6, 7,8-tetrahydropteridin-4(3 H)-one (6), m.p. > 211 ° (dee.) (Found: C, 45. 9; H, 6. 3; N, 29. 9. 
C7H10N40.H20 requires C, 45·65; H, 6·6; N, 30·4%) which was pure by t.1.c. , and had u.v. 
spectra as reported. 
5 
Reduction with N aBH4 (instead of KBH4 as reported) 5 also gave the 6-methyl-5,6, 7,8-tetrahydropteridin-4(3 H)-one which could not be freed for small amounts of 
borate (flame test) (Found: C, 36,4; H, 5-4; N, 24·0. C7H 10N 40.0.76NaH2B03.0·lH2
0 
requires C, 36 · 3; H, 5 · 1; N, 24. 2%). The 1 H n.m.r. spectrum [1 M DCI): 1, 48 , d, J 6. 3, 
6-Me; 3·39, q, Jgem -14·4, J vic 9.4, H7 0 x; - 3.7, m, H6; 3,77, q, Jgem -14·5, Jvic 3·0, 
H 7 eq; 8 ·2, s, H 2] indicates a conformation similar to that of 6-methyl-5,6,7,8-tetrahydropterin, 
i.e. the methyl group is predominantly equatorial. 8 When 6-methylpteridin-4(3 H)-one (200 mg) 
in trifluoroacetic acid (5 ml) and platinum oxide (50 mg pre-reduced in 2. 5 ml of trifluoroacetic 
acid) was shaken with hydrogen (25° / 720 mmHg), the reduction was very rapid, and after 2 h the 
catalyst was filtered off, the filtrate was added to a cold solution of methanol (1 · 8 ml) and 7 M 
methanolic HCl (0 · 4 ml) followed by dry ether (60 ml) whereby the colourless hydrochloride 
separated. It was collected and washed with ether (3 x 15 ml) by centrifugation and dried under 
vacuum. 6-Methyl-2,3,5,6, 7,8-hexahydropteridin-4 (IH)-one (19) hydrochloride (242 mg) was 
recrystallized from methanol containing a few drops of methanolic HCI and ether, and had m.p. 
213-218°(effervescence) (Found: C, 35·5; H, 6·1; Cl, 21·6; N, 23,1. C7H 12N 40.1·45HCLH20 
requires C, 35·2; H, 6·5; CI, 21·5; N, 23·4%). E258 (inflex) 158 (pH O); E293 1054 (pH 7·3) and 
E286 1776 (pH 13 · 2). 1 H n.m.r. (1 M DCl): 1, 62, d, J 6 · 2, 6-Me; 3 · 61, q, Jg em -14 · 2, Jvic 
10.6, H7 ax; 3·95, q, Jge m -14·2, Jvic 4·4, H7 e q; -4·0, m, H6; 4-99, s, H2. 13 Cn.m.r. (proton 
coupled) (D20, dioxan internal standard 67. 6 ppm downfield from Me
4
Si): 16. 0, q, J 131, 
6-Me; 44·7, m, C7; 49·2, m, C6; 52,1. t, J 159, C2; 157.6, s, C8a; 162,9, s, C4. 6-Methyl-
(6,7-.Di)-5, 6, 7,8-tetrahydropteridin-4(3H)-one (7) was prepared as above but by using NaBD
4 
in 
D 20 and contained borate (flame test) , m.p. 213-215° (dee.) [Found: C, 44·5; H+D, 7•3; N, 
29·3; m / e 168 (100%), 153 (75%), 139.3 (metastable). C7H 8D 2N 40.0.1NaH2B03.0·9H20 requires C, 44·0; H+D, 7·3; N, 29·5%; M+ 168, M+ -15 (Me) 153]. The u.v. spectra and 
t.l.c. properties were identical with the above and the 1 H n.m.r. spectrum indicated better than 
95% deuteration. The concentration of aqueous solutions were determined from E
290 
9685 (pH 
7 ·O). 
6,7-Dimethylpteridin-4(3H)-one 13 [500 mg, 1H n.m.r. (1 MDCI): 2·78, s, 7-Me or 6-Me; 
2 · 81, s, 6-Me or 7-Me; 9 · 23, s, H 2] in 3M HCI (25 ml) and platinum oxide (100 mg pre-reduced in 
25 ml of 3 M HCl) were shaken with hydrogen as above (5. 25 h). The catalyst was filtered off and 
the filtrate evaporated to dryness. The colourless residue was dissolved in methanol (23 ml) and 
methanolic HCI (7 M, 18 ml) was added. The cis- 6, 7-Dimethyl-5,6, 7,8-tetrahydropteridin-4(3H)-
one (8) hydrochloride (500 mg) that separated on cooling, was collected and dried under vacuum, 
m.p. >219° (dee.) (Found: C, 36.7; H, 6·1 ; CI, 25,5; N, 21·3. C
8
H
12
N
4
0.1·87HCI.0.7H
2
0 
requires C, 36·7; H, 6·1 ; Cl, 25,5; N, 21,3%). U.v. spectrum had E262 6680 (pH O·O) and E292 9025 (pH 7 · 0). 1 H n.m.r. (0 · 5 M DCI): 1. 28, d, J 6 · 6, 6-Me or 7-Me; 1. 35, d, J 6. 6, 7-Me or 
6-Me; 3.35 and 3·93, m, J 6.6 and 3,3, H6 and 7; 8·09, s, H2. 6,7-Dimethyl-(6,7-J>i)-5,6,7,8-
rerrahydropteridin-4(3H)- one (9) hydrochloride, m.p. > 218° (dee.) was similarly obtained by 
using 3M DC! in D 20 and D 2 gas [Found: C, 34·3; H+D, 6-6; CI, 25·2; N , 19·7; m /e 182 
13 
Albert, A., Brown, D . J. , and Cheeseman, G. , J. Chem. Soc., 1952, 4219. 
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(87%) , 167 (100) , 152 (75), 138 (55). CgH 10D2N4 0.2 HCl.1 · 4H 20 requires C, 34 · 3; H + D, 
6-7; Cl, 25-3 ; N, 20-0%; M+ 182, M+ -15 (Me) 167, M+ -30 (2Me) 152, M+ -44 138] . 
Its 1 H n.m.r. spectrum indicated better than 95% deuterium incorporation at C 6 and C 7. 
5,6-Diamino-2-methylpyrimidin-4(3 H)-one sulfate 14 (0 · 5 g) and diacetyl (0. 5 ml) in water 
(10 ml) was boiled under reflux for 1 · 5 h, the pH was adjusted to 4 and cooled. The 2,6, 7-
trimethylpteridin-4(3H)-one (138 mg, 55%) that separated was washed with ethanol, dried and 
had m.p. >241° (dee.) (Found: C, 54-5; H, 5-3; N, 28-5. C9H10N 40 requires C, 54-8; H, 5-5; 
N , 28-4%). 1H n.m.r. (D 20): 2-54, s, 2-Me; 2-66, s, 6-Me or 7-Me; 2-68, s, 7-Me or 6-Me. 
Platinum oxide (50 mg) in 3 M hydrochloric acid (5 ml) was pre-reduced by shaking with hydrogen 
at 20° /720 mmHg, the trimethylpteridinone (50 mg) was added, and hydrogenation was continued 
until completion (9. 5 h). Filtration and evaporation of the filtrate to dryness gave a solid (70 mg) 
which was dissolved in 7 M methanolic hydrogen chloride and a small volume of ether was 
added to cause the separation of cis- 2, 6,7-trimethyl-5, 6,7, 8-tetrahydropteridin-4( 3H)- one ( 10) 
hydrochloride (30mg), m.p . 210-5- 211-5° (dee.) (Found: C, 37-2; H, 6-3; Cl, 23-7; N, 19-1. 
C
9
H
14
N
4
0 .2 HC1.1-4H20 requires C, 37-1; H, 6-5; Cl, 23-9; N, 19-2%). E263 8280 (4mM 
HCl). 1H n .m.r. (D 20): 1-26, d, J 6-6, 6-Me or 7-Me; 1-31, d, J 6-6, 7-Me or 6-Me; 2-34, s, 
2-Me; 3-81 , m, J 6-6 and 3-3, H6 and 7. 
cis-6,7-Dimethyl-2-methylamino-5 ,6,7 ,8-tetrahydropteridin-4 (3 H)-one hydrochloride supplied 
by Dr P. Waring had E270 13 800 (4 mM HCl). 
Syntheses of Thiotetrahydropteridines 
6,7-Dimethyl-2-thioxo-2,3-dihydropteridin-4(1 H)-one 15,16 [O. 5 g, 1 H n.m.r. (2 M DCl): 2 · 64, 
s, 6-Me or 7-Me; 2. 68; s, 7-Me or 6-Me (1 M NaOD): 2 · 47, s, 6-Me and 7-Me] in 1 M sodium 
carbonate (5 ml) was reduced by boiling under reflux with sodium borohydride (6 g, added in 
small portions) until the u.v. spectrum in 1 · 5 M hydrochloric acid indicated complete reduction 
(15 h), and cooled. The solid (0. 26 g) was collected, washed with water (centrifuge) and 
dried. The solid (0 · 15 g) was dissolved in methanol (15 ml), ethanol (15 ml) was added, the 
solution was filtered and cooled. The yellow solid was collected, washed with small volumes 
of methanol and dried to give colourless cis- 6, 7-dimethyl-2-thioxo-3,4,5, 6, 7,8-hexahydropteridin-
4( JH)-one (12) (28 mg), m.p. >259° (dee.) (Found: C, 41-7; H, 5-6; N, 23-3; S, 13-2. 
C
8
H
12
N
4
0S.0-5CH
3
0H.O-lH20.0·18NaH2B03 requires C, 41-6; H, 6-0; N, 22-8; S, 13-1 %) . 
1H n.m.r. (0-01 M NaOD): 1-07, d, J 6-7, 6-Me or 7-Me; 1-08 , d, J 6-7, 7-Me or 6-Me; 3-24, 
octet, J 6. 7 and 3. 2, H 6 or 7; 3 · 55 , octet, J 6 · 7 and 3 · 2, H 7 or 6. E2s2 5342 (pH 0). Reduction 
with platinum oxide in 3M hydrochloric acid, methanol or trifluoroacetic acid (5-11 h) gave 
the 6,7-dimethyl-2-thioxo-3,4,7,8-tetrahydropteridin-4(1 H)-one [1 H n.m.r. (5 M DCl) : 1 · 55 , d, 
J 7 -1, 7-Me; 2 · 53, s, 6-Me; 4. 94, q, J 7 -1 , H 7] which was oxidized by air in the solid state 
and in solution at room termperature to give the parent pteridinone. 
6,7-Dimethyl-2-methylthiopteridin-4(3H)-one, m.p. >255° (dee.) was prepared in 63% yield 
by boiling the preceding thioxo compound (5 g) in O · 5 M sodium hydroxide (50 ml) with methyl 
iodide ( 4. 42 ml) for 15 min, cooling, filtering and recrystallizing the product from propan-1-ol 
[lit.15,l7 m.p. 283° (dee.) prepared by condensation of 5,6-diamino-2-methylthiopyrimidin-4(3H)-
one and diacetyl] (Found: C, 49-0; H, 4-6; N , 25-4; S, 14-1. Cale. for C9H 10N 40S: C, 48-6; H, 
4. 5; N , 25. 2; S, 14. 4%). 1 H n.m.r. (0 -1 M NaOD): 2. 54, s, MeS; 2. 60, s(br), 6-Me and 7-Me and 
(2 M DCl) : 2 · 70; s, 6-Me and 7-Me; 2. 83, s, MeS. Attempts to prepare the tetrahydro derivative 
as above required very large amounts of sodium borohydride and gave a very impure product that 
released methanethiol readily on attempted purification. Smaller amounts of borohydride were 
required when propan-1-ol was used but purification was difficult. cis- 6, 7-Dimethyl-2-methylthio-
5,6,7,8-tetrahydropteridin-4(3H)-one (13) (67 mg) , m.p. > 115° (dee.) , was obtained when the 
methylthiopteridinone (50 mg) in methanol (5 ml) was hydrogenated with pre-reduced platinum 
oxide ( 45 mg in 5 ml methanol) at 20° /720 mmHg (7. 5 h) . The catalyst was filtered off and 
the filtrate was evaporated (Found: N, 17-0; S, 9-5 . C9H 14 N 40S.5-6H20 requires N , 17-1 , 
S, 9-8%). 1H n.m.r. (CDC13): 1-18, d , J 6-6, 6-Me or 7-Me; 1 -22, d , J 6-6, 7-Me or 6-Me; 
14 Albert, A., Brown, D . J., Wood, H. C. S., J. Chem. Soc., 1954, 3832. 
15 Schneider, H .-J., and Pfleiderer, W ., Chem. Ber., 1974, 107, 3377. 
16 Gal, E. M ., J. Am. Chem. Soc., 1950, 72, 3532. 
17 Angier, R. B., and Curran, W. V., J. Am. Chem. Soc., 1959, 81 , 5650. 
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2-49, s. MeS; 3-49, octet, J 6-6 and 3-0, H6 or 7; 3-74, octet, J 6-6 and 3-0, H7 or 6. E
274 6710 (1,5 M HCl). Similar reduction in CD 30D and D 2 gas gave the 6,7-dideutero derivative 
(14) which had > 96% deuterium incorporation (by n.m.r.). Reduction with platinum oxide 
in trifluoroacetic acid gave 6, 7-dimethyf-2-methyfthio-7,8-dihydropteridin-4(3H)- one which was 
isolated as the hydrochloride: 1 H n.m.r. (5 M DCI): 1- 57, d, J 7 · l, 7-Me; 2 · 58, s, MeS; 2. 95, 
s, 6-Me; 4-99, q, J 7-1, H7. 
2,5,6-Triaminopyrimidin-4(3 H)-thione, prepared by direct thiation of the respective pyrimidin-
4(3 H)-one sulfate as before, 18 was very impure and was purified by placing it (2 g, in 150 ml 
water) on a Dowex 50W x 4 (400 ml, 20-50 mesh, H + form) column, washing it with water 
(1 . 5 I.), 0. 5 M hydrochloric acid (0. 5 I.) and 1 . 5 M hydrochloric acid (8 I.), and was eluted 
with 2 M hydrochloric acid (10 I. , followed by the u.v. spectral band at 310 nm). Evaporation 
gave a residue which was triturated with the latter solvent (c. 4 ml), filtered off and dried at 
100° for 2 h to give the colourless rlzione hydrochloride (l · 32 g), m.p. > 300° (dee.) (Found: 
C, 21-1 ; H, 3-9; CI, 30-6; N, 30-6; S, 13-8. C4H 3N 5S.2HC1 requires C, 20,9; H , 3-9; 
CI, 30. 8%; N , 30. 4; S, 13. 9; Iit. 18 reported the free base). This hydrochloride (200 mg) 
was dissolved in water (5 ml), the pH was adjusted to 4 and diacetyl (0. 2 ml) was added 
and boiled under reflux (70 min). The solid (150 mg) that separated on cooling was collected 
and recrystallized from water to give 2-amino-6, 7-dimerlzyfpteridin-4(3H)- thione (140 mg), m.p. 
>290° (dee.) (Found: C, 45-9; H, 4-4; N, 33-3; S, 14-5. C7H 9N 5S.0-15H20 requires C, 45-8; H, 4-5 ; N, 33-4; S, 15-3%). 1H n.m.r. (1 M DCI) : 2-66, s, 6-Me or 7-Me; 2-68, s, 7-Me or 
6-Me. The thione (50 mg) was reduced with sodium borohydride in sodium carbonate as above 
except that at the end of the reaction (12 h, under nitrogen) 7 M methanolic hydrogen chloride 
was added (ice bath) and evaporated to dryness. The residue (2. 33 g) was passed through 
a Dowex SOW x 8 (2 ml, 100- 200 mesh) column, washed with O. 5 M to 1 . 5 M hydrochloric 
acid, and eluted with 2 M hydrochloric acid. Evaporation of the last eluate gave a mixture of 
cis- and trans- 2-amin o-6, 7-dimerlzyf-5, 6, 7, 8-rerralzydropteridin-4( 3H)- rhione (11) hydrochloride 
(1 · 6 : 1 · 0 by n.m.r.) (60 mg), m.p. > 211 ° (dee.) (Found: C, 26. 3; H, 4. 7; Cl, 23. 4; S, 9. 5. 
C8H 13 N 5 S. l-6HCI.0-8 NaCI.0-8 H 3 B03 requires C, 26-3; H, 4-7; CI, 23-3; S, 8-8%); 1H 
n.m .r. (2 l\l DCI at 270 MHz): cis isomer 1- 33, d, J 6. 8, 6-Me or 7-Me; 1- 41, d, J 6. 8, 7-Me 
or 6-Me; 3 · 98, m, J 6 · 8 and 3 · 3, H 6 or 7; 4. 05, m, J 6. 8 and 3. 3, H 7 or 6; trans isomer 
1- 42, d, J 6 · 6, 6-Me or 7-Me; 1- 53, d, J 6. 6, 7-Me or 6-Me; 3. 56, m, J 6. 6 and 8. 3, H 6 or 
7; 3. 74, m, J 6, 6 and 8. 3, H 7 or 6, assigned by proton decoupling. Catalytic reduction with 
platinum oxide in trifluoroacetic acid (11 h) also gave the cis and rrans mixture (2 · 3 : 1 · 0 by 
n.m.r.) of the tetrahydro-pteridinthione hydrochloride, whereas catalytic reduction in methanol 
gave exclusively the cis isomer (by n.m.r.). 
D ihydropreridine R eductase Assay 
The assays were performed in cuvettes in the thermostated cell holders of a double-beam 
spectrometer set at 340 nm. Stock solutions containing 1 M Tris-HCI (100 µI), 2 mM potassium 
ferricyanide (100 µl) and water (670 µI) were placed in each cuvette. The substrate in 4 mM 
hydrochloric acid (100 µI, final concentration O. 1 to - 1. 5 Km) was added to each cuvette 
and allowed to equilibrate ( c. l min). N ADH (30 µl, with final concentrations listed in Table 
1) was added simultaneously to the cuvettes by using two platinum buckets which were then 
moved up and down (10 times) into the assay solution to ensure complete mixing. One of 
the buckets also contained human brain dihydropteridine reductase 19 (3-8 µI, 0-118-0-314 µg). 
Soon after mixing the pen recorder was activated. The initial rates of the reaction from at 
least five different concentrations of pteridine substrates were calculated from the rate traces 
and using E3~0 6200 for the extinction coefficient of NADH. The Km and Vmax values (see 
Table 1) were computed from the initial rates and concentrations of substrates by means of the 
Cornish- Bowden program. 20 In preliminary runs we showed that at the highest concentrations 
of potassium ferricyanide and NADH the rate of oxidation of the latter was neligible compared 
ith the enzymic rate. Also the largest non-enzymic rate of oxidation of NADH by the highest 
concentration of quinonoid dihydropteridine was small ( < 5%) compared with the enzymic rate, 
18 
McCormack, J. J ., and Mautner, H. G. , J Org. Chem., 1964, 29, 3370. 19 
Armarego, W . L. F. , and Waring, P., Biochem. Biophys. Res. Commun., 1983, 113, 895 . 
~° Cornish-Bowden, A., and Endrenyi , L. , B iochem. J., 1981, 193, 1005. 
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and both these non-enzymic rates are compensated in the double beam of the spectrometer, i.e. 
the loss in NADH concentration was small and the concentration of NADH was still at or near 
saturating levels. The rate of rearrangement of quinonoid dihydropteridines to the 7 ,8-dihydropteridines were 
determined by generating the quinonoid species from the respective 5,6,7 ,8-tetrahydropteridines 
with ferricyanide as above and observing the rate of change of absorbance at 340 nm, a wavelength 
at which the difference in E values between K3Fe(CN)6 and K4 Fe(CN)6 is very small compared 
with the total change in absorbance during the rearrangement. 
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